cluster O
##ing O
of O
miss O
##ense O
mutations O
in O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
gene O
in O
a O
s B-Disease
##poradic I-Disease
t I-Disease
- I-Disease
cell I-Disease
le I-Disease
##uka I-Disease
##emia I-Disease
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
is O
a O
re B-Disease
##cess I-Disease
##ive I-Disease
multi I-Disease
- I-Disease
system I-Disease
disorder I-Disease
caused O
by O
mutations O
in O
the O
at O
##m O
gene O
at O
11 O
##q O
##22 O
- O
q O
##23 O
( O
re O
##f O
. O
3 O
) O
. O

the O
risk O
of O
cancer B-Disease
, O
especially O
l B-Disease
##ymph I-Disease
##oid I-Disease
neo I-Disease
##p I-Disease
##lasia I-Disease
##s I-Disease
, O
is O
substantially O
elevated O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
and O
has O
long O
been O
associated O
with O
ch O
##rom O
##oso O
##mal O
instability O
. O

by O
anal O
##ys O
##ing O
t B-Disease
##umour I-Disease
d O
##na O
from O
patients O
with O
s B-Disease
##poradic I-Disease
t I-Disease
- I-Disease
cell I-Disease
pro I-Disease
##ly I-Disease
##mp I-Disease
##ho I-Disease
##cy I-Disease
##tic I-Disease
le I-Disease
##uka I-Disease
##emia I-Disease
( O
t B-Disease
- I-Disease
p I-Disease
##ll I-Disease
) O
, O
a O
rare O
c B-Disease
##lon I-Disease
##al I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncy I-Disease
with O
similarities O
to O
a O
mature B-Disease
t I-Disease
- I-Disease
cell I-Disease
le I-Disease
##uka I-Disease
##emia I-Disease
seen O
in O
a B-Disease
- I-Disease
t I-Disease
, O
we O
demonstrate O
a O
high O
frequency O
of O
at O
##m O
mutations O
in O
t B-Disease
- I-Disease
p I-Disease
##ll I-Disease
. O

in O
marked O
contrast O
to O
the O
at O
##m O
mutation O
pattern O
in O
a B-Disease
- I-Disease
t I-Disease
, O
the O
most O
frequent O
n O
##uc O
##leo O
##tide O
changes O
in O
this O
le B-Disease
##uka I-Disease
##emia I-Disease
were O
miss O
##ense O
mutations O
. O

these O
cluster O
##ed O
in O
the O
region O
corresponding O
to O
the O
kinase O
domain O
, O
which O
is O
highly O
conserved O
in O
at O
##m O
- O
related O
proteins O
in O
mouse O
, O
yeast O
and O
d O
##ros O
##op O
##hil O
##a O
. O

the O
resulting O
amino O
- O
acid O
substitution O
##s O
are O
predicted O
to O
interfere O
with O
at O
##p O
binding O
or O
substrate O
recognition O
. O

two O
of O
seventeen O
m O
##uta O
##ted O
t B-Disease
- I-Disease
p I-Disease
##ll I-Disease
samples O
had O
a O
previously O
reported O
a B-Disease
- I-Disease
t I-Disease
all O
##ele O
. O

in O
contrast O
, O
no O
mutations O
were O
detected O
in O
the O
p O
##53 O
gene O
, O
suggesting O
that O
this O
t B-Disease
##umour I-Disease
suppress O
##or O
is O
not O
frequently O
altered O
in O
this O
le B-Disease
##uka I-Disease
##emia I-Disease
. O

occasional O
miss O
##ense O
mutations O
in O
at O
##m O
were O
also O
found O
in O
t B-Disease
##umour I-Disease
d O
##na O
from O
patients O
with O
b B-Disease
- I-Disease
cell I-Disease
non I-Disease
- I-Disease
ho I-Disease
##d I-Disease
##g I-Disease
##kins I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
##s I-Disease
( O
b B-Disease
- I-Disease
n I-Disease
##hl I-Disease
) O
and O
a O
b B-Disease
- I-Disease
n I-Disease
##hl I-Disease
cell O
line O
. O

the O
evidence O
of O
a O
significant O
proportion O
of O
loss O
- O
of O
- O
function O
mutations O
and O
a O
complete O
absence O
of O
the O
normal O
copy O
of O
at O
##m O
in O
the O
majority O
of O
m O
##uta O
##ted O
t B-Disease
##umour I-Disease
##s I-Disease
establishes O
so O
##matic O
in O
##act O
##ivation O
of O
this O
gene O
in O
the O
path O
##ogen O
##esis O
of O
s B-Disease
##poradic I-Disease
t I-Disease
- I-Disease
p I-Disease
##ll I-Disease
and O
suggests O
that O
at O
##m O
acts O
as O
a O
t B-Disease
##umour I-Disease
suppress O
##or O
. O

as O
constitutional O
d O
##na O
was O
not O
available O
, O
a O
put O
##ative O
hereditary O
pre O
##dis O
##position O
to O
t B-Disease
- I-Disease
p I-Disease
##ll I-Disease
will O
require O
further O
investigation O
. O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
protein O
kinase O
is O
involved O
in O
the O
m O
##od O
##ulation O
of O
the O
ca O
##2 O
+ O
home O
##ost O
##asis O
in O
skeletal O
muscle O
cells O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
, O
the O
most O
prevalent O
muscular B-Disease
disorder I-Disease
in O
adults O
, O
is O
caused O
by O
( O
c O
##t O
##g O
) O
n O
- O
repeat O
expansion O
in O
a O
gene O
encoding O
a O
protein O
kinase O
( O
d B-Disease
##m I-Disease
protein O
kinase O
; O
d O
##mp O
##k O
) O
and O
involves O
changes O
in O
c O
##yt O
##oar O
##chi O
##tec O
##ture O
and O
ion O
home O
##ost O
##asis O
. O

to O
obtain O
clues O
to O
the O
normal O
biological O
role O
of O
d O
##mp O
##k O
in O
cellular O
ion O
home O
##ost O
##asis O
, O
we O
have O
compared O
the O
resting O
[ O
ca O
##2 O
+ O
] O
i O
, O
the O
amplitude O
and O
shape O
of O
de O
##pol O
##ari O
##zation O
- O
induced O
ca O
##2 O
+ O
trans O
##ients O
, O
and O
the O
content O
of O
at O
##p O
- O
driven O
ion O
pumps O
in O
culture O
##d O
skeletal O
muscle O
cells O
of O
wild O
- O
type O
and O
d O
##mp O
##k O
[ O
- O
/ O
- O
] O
knockout O
mice O
. O

in O
v O
##it O
##ro O
- O
differentiated O
d O
##mp O
##k O
[ O
- O
/ O
- O
] O
my O
##ot O
##ube O
##s O
exhibit O
a O
higher O
resting O
[ O
ca O
##2 O
+ O
] O
i O
than O
do O
wild O
- O
type O
my O
##ot O
##ube O
##s O
because O
of O
an O
altered O
open O
probability O
of O
voltage O
- O
dependent O
l O
- O
type O
ca O
##2 O
+ O
and O
na O
+ O
channels O
. O

the O
mutant O
my O
##ot O
##ube O
##s O
exhibit O
smaller O
and O
slower O
ca O
##2 O
+ O
responses O
upon O
trigger O
##ing O
by O
ace O
##ty O
##l O
##cho O
##line O
or O
high O
external O
k O
+ O
. O

in O
addition O
, O
we O
observed O
that O
these O
ca O
##2 O
+ O
trans O
##ients O
partially O
result O
from O
an O
influx O
of O
extra O
##cellular O
ca O
##2 O
+ O
through O
the O
l O
- O
type O
ca O
##2 O
+ O
channel O
. O

neither O
the O
content O
nor O
the O
activity O
of O
na O
+ O
/ O
k O
+ O
at O
##pas O
##e O
and O
sa O
##rc O
##op O
##las O
##mic O
re O
##tic O
##ulum O
ca O
##2 O
+ O
- O
at O
##pas O
##e O
are O
affected O
by O
d O
##mp O
##k O
absence O
. O

in O
conclusion O
, O
our O
data O
suggest O
that O
d O
##mp O
##k O
is O
involved O
in O
m O
##od O
##ulating O
the O
initial O
events O
of O
ex O
##citation O
- O
contraction O
coupling O
in O
skeletal O
muscle O
. O
. O

constitutional O
r O
##b O
##1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
un B-Disease
##ila I-Disease
##teral I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

in O
most O
patients O
with O
isolated O
un B-Disease
##ila I-Disease
##teral I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
, O
tumor B-Disease
development O
is O
initiated O
by O
so O
##matic O
in O
##act O
##ivation O
of O
both O
all O
##ele O
##s O
of O
the O
r O
##b O
##1 O
gene O
. O

however O
, O
some O
of O
these O
patients O
can O
transmit O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
pre O
##dis O
##position O
to O
their O
offspring O
. O

to O
determine O
the O
frequency O
and O
nature O
of O
constitutional O
r O
##b O
##1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
un B-Disease
##ila I-Disease
##teral I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
, O
we O
analyzed O
d O
##na O
from O
peripheral O
blood O
and O
from O
tumor B-Disease
tissue O
. O

the O
analysis O
of O
tumors B-Disease
from O
54 O
( O
71 O
% O
) O
of O
76 O
inform O
##ative O
patients O
showed O
loss O
of O
constitutional O
he O
##tero O
##zy O
##gos O
##ity O
( O
lo O
##h O
) O
at O
in O
##tra O
##genic O
lo O
##ci O
. O

three O
of O
13 O
un O
##in O
##form O
##ative O
patients O
had O
constitutional O
del O
##eti O
##ons O
. O

for O
39 O
randomly O
selected O
tumors B-Disease
, O
s O
##s O
##c O
##p O
, O
he O
##tero O
- O
du O
##plex O
analysis O
, O
se O
##quencing O
, O
and O
southern O
b O
##lot O
analysis O
were O
used O
to O
identify O
mutations O
. O

mutations O
were O
detected O
in O
21 O
( O
91 O
% O
) O
of O
23 O
tumors B-Disease
with O
lo O
##h O
. O

in O
6 O
( O
38 O
% O
) O
of O
16 O
tumors B-Disease
without O
lo O
##h O
, O
one O
mutation O
was O
detected O
, O
and O
in O
9 O
( O
56 O
% O
) O
of O
the O
tumors B-Disease
without O
lo O
##h O
, O
both O
mutations O
were O
found O
. O

thus O
, O
a O
total O
of O
45 O
mutations O
were O
identified O
in O
tumors B-Disease
of O
36 O
patients O
. O

thirty O
- O
nine O
of O
the O
mutations O
- O
including O
34 O
small O
mutations O
, O
2 O
large O
structural O
alterations O
, O
and O
h O
##yper O
##met O
##hyl O
##ation O
in O
3 O
tumors O
- O
were O
not O
detected O
in O
the O
corresponding O
peripheral O
blood O
d O
##na O
. O

in O
6 O
( O
17 O
% O
) O
of O
the O
36 O
patients O
, O
a O
mutation O
was O
detected O
in O
constitutional O
d O
##na O
, O
and O
1 O
of O
these O
mutations O
is O
known O
to O
be O
associated O
with O
reduced O
express O
##ivity O
. O

the O
presence O
of O
a O
constitutional O
mutation O
was O
not O
associated O
with O
an O
early O
age O
at O
treatment O
. O

in O
1 O
patient O
, O
so O
##matic O
mosaic O
##ism O
was O
demonstrated O
by O
molecular O
analysis O
of O
d O
##na O
and O
r O
##na O
from O
peripheral O
blood O
. O

in O
2 O
patients O
without O
a O
detect O
##able O
mutation O
in O
peripheral O
blood O
, O
mosaic O
##ism O
was O
suggested O
because O
1 O
of O
the O
patients O
showed O
multi O
##fo O
##cal O
tumors B-Disease
and O
the O
other O
later O
developed O
bilateral B-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

in O
conclusion O
, O
our O
results O
emphasize O
that O
the O
manifest O
##ation O
and O
trans O
##mis O
##si O
##bility O
of O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
depend O
on O
the O
nature O
of O
the O
first O
mutation O
, O
its O
time O
in O
development O
, O
and O
the O
number O
and O
types O
of O
cells O
that O
are O
affected O
. O
. O

hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
man O
. O

i O
. O

clinical O
, O
im O
##mu O
##no O
##chemical O
, O
and O
family O
studies O
. O

the O
first O
recognized O
human O
kind O
##red O
with O
hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##5 O
) O
is O
described O
. O

the O
pro O
##band O
, O
a O
20 O
- O
year O
- O
old O
black O
female O
with O
systemic B-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
since O
age O
11 O
, O
lacked O
serum O
hem O
##oly O
##tic O
complement O
activity O
, O
even O
during O
re O
##mission O
. O

c O
##5 O
was O
und O
##ete O
##ct O
##able O
in O
her O
serum O
by O
both O
im O
##mu O
##no O
##di O
##ff O
##usion O
and O
hem O
##oly O
##tic O
ass O
##ays O
. O

other O
complement O
components O
were O
normal O
during O
re O
##mission O
of O
l O
##up O
##us O
, O
but O
c O
##1 O
, O
c O
##4 O
, O
c O
##2 O
, O
and O
c O
##3 O
levels O
fell O
during O
ex O
##ace O
##rb O
##ations O
. O

a O
younger O
half O
- O
sister O
, O
who O
had O
no O
underlying O
disease O
, O
was O
also O
found O
to O
lack O
im O
##mu O
##no O
##chemical O
##ly O
detect O
##able O
c O
##5 O
. O

by O
hem O
##oly O
##tic O
ass O
##ay O
, O
she O
exhibited O
1 O
- O
2 O
% O
of O
the O
normal O
serum O
c O
##5 O
level O
and O
normal O
concentrations O
of O
other O
complement O
components O
. O

c O
##5 O
levels O
of O
other O
family O
members O
were O
either O
normal O
or O
approximately O
half O
- O
normal O
, O
consistent O
with O
auto O
##so O
##mal O
co O
##dom O
##ina O
##nt O
inheritance O
of O
the O
gene O
determining O
c B-Disease
##5 I-Disease
deficiency I-Disease
. O

normal O
hem O
##oly O
##tic O
t O
##iter O
##s O
were O
restored O
to O
both O
ho O
##mo O
##zy O
##go O
##us O
c B-Disease
##5 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
( O
c B-Disease
##5 I-Disease
##d I-Disease
) O
se O
##ra O
by O
addition O
of O
highly O
pu O
##rified O
human O
c O
##5 O
. O

in O
specific O
c O
##5 O
t O
##it O
##rations O
, O
however O
, O
it O
was O
noted O
that O
when O
limited O
amounts O
of O
c O
##5 O
were O
ass O
##ay O
##ed O
in O
the O
presence O
of O
low O
di O
##lution O
##s O
of O
either O
c B-Disease
##5 I-Disease
##d I-Disease
serum O
, O
curving O
rather O
than O
linear O
dose O
- O
response O
plots O
were O
consistently O
obtained O
, O
suggesting O
some O
inhibitor O
##y O
effect O
. O

further O
studies O
suggested O
that O
low O
di O
##lution O
##s O
of O
c B-Disease
##5 I-Disease
##d I-Disease
serum O
contain O
a O
factor O
( O
or O
factors O
) O
interfering O
at O
some O
step O
in O
the O
hem O
##oly O
##tic O
ass O
##ay O
of O
c O
##5 O
, O
rather O
than O
a O
true O
c O
##5 O
inhibitor O
or O
in O
##act O
##iva O
##tor O
. O

of O
clinical O
interest O
are O
( O
a O
) O
the O
documentation O
of O
me O
##mb O
##rano O
##us O
g B-Disease
##lo I-Disease
##mer I-Disease
##ulon I-Disease
##ep I-Disease
##hr I-Disease
##itis I-Disease
, O
v B-Disease
##as I-Disease
##cu I-Disease
##lit I-Disease
##is I-Disease
, O
and O
art B-Disease
##hr I-Disease
##itis I-Disease
in O
an O
individual O
lacking O
c O
##5 O
( O
and O
its O
bio O
##log O
##ic O
functions O
) O
, O
and O
( O
b O
) O
a O
remarkable O
prop O
##ens O
##ity O
to O
bacterial B-Disease
infections I-Disease
in O
the O
pro O
##band O
, O
even O
during O
periods O
of O
low O
- O
dose O
or O
alternate O
- O
day O
co O
##rt O
##ico O
##ster O
##oid O
therapy O
. O

other O
observations O
indicate O
that O
the O
c B-Disease
##5 I-Disease
##d I-Disease
state O
is O
compatible O
with O
normal O
co O
##agu O
##lation O
function O
and O
the O
capacity O
to O
mount O
a O
ne O
##ut O
##rop O
##hil O
##ic O
le O
##uk O
##oc O
##yt O
##osis O
during O
p B-Disease
##yo I-Disease
##genic I-Disease
infection I-Disease
. O
. O

su O
##s O
##ce O
##pt O
##ibility O
to O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
in O
twins O
: O
the O
role O
of O
genes O
, O
h O
##la O
, O
and O
the O
environment O
. O

objective O
to O
determine O
the O
relative O
effects O
of O
genetic O
and O
environmental O
factors O
in O
su O
##s O
##ce O
##pt O
##ibility O
to O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
( O
as B-Disease
) O
. O

methods O
twins O
with O
as B-Disease
were O
identified O
from O
the O
royal O
national O
hospital O
for O
r B-Disease
##he I-Disease
##umatic I-Disease
diseases I-Disease
database O
. O

clinical O
and O
radio O
##graphic O
examinations O
were O
performed O
to O
establish O
di O
##ag O
##nose O
##s O
, O
and O
disease O
severity O
was O
assessed O
using O
a O
combination O
of O
valid O
##ated O
scoring O
systems O
. O

h O
##la O
typing O
for O
h O
##la O
- O
b O
##27 O
, O
h O
##la O
- O
b O
##60 O
, O
and O
h O
##la O
- O
d O
##r O
##1 O
was O
performed O
by O
polymer O
##ase O
chain O
reaction O
with O
sequence O
- O
specific O
prime O
##rs O
, O
and O
z O
##y O
##gos O
##ity O
was O
assessed O
using O
micro O
##sat O
##elli O
##te O
markers O
. O

genetic O
and O
environmental O
variance O
components O
were O
assessed O
with O
the O
program O
m O
##x O
, O
using O
data O
from O
this O
and O
previous O
studies O
of O
twins O
with O
as B-Disease
. O

results O
six O
of O
8 O
mon O
##oz O
##y O
##got O
##ic O
( O
m O
##z O
) O
twin O
pairs O
were O
disease O
con O
##cor O
##dant O
, O
compared O
with O
4 O
of O
15 O
b O
##27 O
- O
positive O
di O
##zy O
##got O
##ic O
( O
d O
##z O
) O
twin O
pairs O
( O
27 O
% O
) O
and O
4 O
of O
32 O
d O
##z O
twin O
pairs O
overall O
( O
12 O
. O
5 O
% O
) O
. O

non O
##sign O
##ificant O
increases O
in O
similarity O
with O
regard O
to O
age O
at O
disease O
onset O
and O
all O
of O
the O
disease O
severity O
scores O
assessed O
were O
noted O
in O
disease O
- O
con O
##cor O
##dant O
m O
##z O
twins O
compared O
with O
con O
##cor O
##dant O
d O
##z O
twins O
. O

h O
##la O
- O
b O
##27 O
and O
b O
##60 O
were O
associated O
with O
the O
disease O
in O
pro O
##band O
##s O
, O
and O
the O
rate O
of O
disease O
con O
##cor O
##dance O
was O
significantly O
increased O
among O
d O
##z O
twin O
pairs O
in O
which O
the O
co O
- O
twin O
was O
positive O
for O
both O
b O
##27 O
and O
d O
##r O
##1 O
. O

add O
##itive O
genetic O
effects O
were O
estimated O
to O
contribute O
97 O
% O
of O
the O
population O
variance O
. O

conclusion O
su O
##s O
##ce O
##pt O
##ibility O
to O
as B-Disease
is O
largely O
genetically O
determined O
, O
and O
the O
environmental O
trigger O
for O
the O
disease O
is O
probably O
u O
##bi O
##quito O
##us O
. O

h O
##la O
- O
b O
##27 O
accounts O
for O
a O
minority O
of O
the O
overall O
genetic O
su O
##s O
##ce O
##pt O
##ibility O
to O
as B-Disease
. O

cell O
cycle O
- O
dependent O
co O
##loc O
##ali O
##zation O
of O
bar O
##d O
##1 O
and O
br O
##ca O
##1 O
proteins O
in O
discrete O
nuclear O
domains O
. O

g O
##er O
##m O
- O
line O
mutations O
of O
the O
br O
##ca O
##1 O
gene O
pre O
##dis O
##pose O
women O
to O
early O
- O
onset O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
by O
com O
##p O
##rom O
##ising O
the O
genes O
pre O
##su O
##mpt O
##ive O
function O
as O
a O
tumor B-Disease
suppress O
##or O
. O

although O
the O
bio O
##chemical O
properties O
of O
br O
##ca O
##1 O
p O
##oly O
##pe O
##pt O
##ides O
are O
not O
understood O
, O
their O
expression O
pattern O
and O
sub O
##cellular O
local O
##ization O
suggest O
a O
role O
in O
cell O
- O
cycle O
regulation O
. O

when O
resting O
cells O
are O
induced O
to O
pro O
##life O
##rate O
, O
the O
steady O
- O
state O
levels O
of O
br O
##ca O
##1 O
increase O
in O
late O
g O
##1 O
and O
reach O
a O
maximum O
during O
s O
phase O
. O

more O
##over O
, O
in O
s O
phase O
cells O
, O
br O
##ca O
##1 O
p O
##oly O
##pe O
##pt O
##ides O
are O
h O
##yper O
##ph O
##os O
##ph O
##ory O
##lated O
and O
a O
##cc O
##um O
##ulate O
into O
discrete O
sub O
##nu O
##cle O
##ar O
f O
##oc O
##i O
termed O
" O
br O
##ca O
##1 O
nuclear O
dots O
. O

" O
br O
##ca O
##1 O
associates O
in O
v O
##ivo O
with O
a O
structural O
##ly O
related O
protein O
termed O
bar O
##d O
##1 O
. O

here O
we O
show O
that O
the O
steady O
- O
state O
levels O
of O
bar O
##d O
##1 O
, O
unlike O
those O
of O
br O
##ca O
##1 O
, O
remain O
relatively O
constant O
during O
cell O
cycle O
progression O
. O

however O
, O
im O
##mu O
##nos O
##taining O
revealed O
that O
bar O
##d O
##1 O
resides O
within O
br O
##ca O
##1 O
nuclear O
dots O
during O
s O
phase O
of O
the O
cell O
cycle O
, O
but O
not O
during O
the O
g O
##1 O
phase O
. O

nevertheless O
, O
bar O
##d O
##1 O
p O
##oly O
##pe O
##pt O
##ides O
are O
found O
exclusively O
in O
the O
nuclear O
fraction O
##s O
of O
both O
g O
##1 O
- O
and O
s O
- O
phase O
cells O
. O

therefore O
, O
progression O
to O
s O
phase O
is O
accompanied O
by O
the O
a O
##gg O
##regation O
of O
nuclear O
bar O
##d O
##1 O
p O
##oly O
##pe O
##pt O
##ides O
into O
br O
##ca O
##1 O
nuclear O
dots O
. O

this O
cell O
cycle O
- O
dependent O
co O
##loc O
##ali O
##zation O
of O
bar O
##d O
##1 O
and O
br O
##ca O
##1 O
indicates O
a O
role O
for O
bar O
##d O
##1 O
in O
br O
##ca O
##1 O
- O
mediated O
tumor B-Disease
suppression O
. O

ethnic O
differences O
in O
the O
h O
##fe O
co O
##don O
28 O
##2 O
( O
c O
##ys O
/ O
t O
##yr O
) O
p O
##oly O
##mor O
##phism O
. O

recent O
studies O
have O
shown O
that O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
( O
h B-Disease
##h I-Disease
) O
is O
likely O
to O
be O
caused O
by O
ho O
##mo O
##zy O
##gos O
##ity O
for O
a O
c O
##ys O
##28 O
##2 O
##ty O
##r O
mutation O
in O
the O
h O
##fe O
gene O
located O
4 O
. O

5 O
m O
##b O
te O
##lo O
##mer O
##ic O
to O
h O
##la O
- O
a O
. O

population O
studies O
of O
this O
p O
##oly O
##mor O
##phism O
are O
facilitated O
by O
the O
fact O
that O
the O
c O
##ys O
##28 O
##2 O
##ty O
##r O
mutation O
creates O
a O
r O
##sal O
restriction O
site O
. O

we O
have O
studied O
the O
co O
##don O
28 O
##2 O
( O
c O
##ys O
/ O
t O
##yr O
) O
p O
##oly O
##mor O
##phism O
in O
different O
ethnic O
groups O
. O

in O
agreement O
with O
previous O
observations O
the O
t O
##yr O
all O
##ele O
appeared O
to O
be O
rare O
or O
absent O
in O
as O
##ia O
##tic O
( O
in O
##dian O
, O
chin O
##ese O
) O
populations O
. O

the O
highest O
all O
##ele O
frequency O
( O
7 O
. O
5 O
% O
) O
was O
found O
in O
s O
##wed O
##es O
. O

sa O
##ami O
##s O
( O
2 O
% O
) O
and O
m O
##ord O
##vin O
##ians O
( O
1 O
. O
8 O
% O
) O
had O
significantly O
lower O
frequencies O
of O
the O
t O
##yr O
all O
##ele O
. O

comparisons O
with O
all O
##ele O
frequencies O
based O
on O
prevalence O
estimates O
of O
h B-Disease
##h I-Disease
showed O
some O
disagreements O
with O
the O
r O
##f O
##l O
##p O
data O
, O
particularly O
in O
fin O
##ns O
. O

the O
newly O
described O
h O
##fe O
marker O
provides O
a O
new O
approach O
to O
the O
screening O
of O
h B-Disease
##h I-Disease
as O
well O
as O
studies O
of O
the O
relationship O
between O
the O
h O
##fe O
t O
##yr O
all O
##ele O
and O
different O
disorders O
including O
cancer B-Disease

auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
associated O
with O
a O
miss O
##ense O
mutation O
encoding O
g O
##ly O
##23 O
- O
- O
[UNK] O
v O
##al O
in O
ne O
##uro O
##phy O
##sin O
ii O
. O

auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
( O
ad B-Disease
##ndi I-Disease
) O
is O
an O
inherited B-Disease
disease I-Disease
caused O
by O
progressive O
de O
##gene O
##ration O
of O
the O
ma O
##gno O
##cellular O
neurons O
of O
the O
h O
##y O
##pot O
##hala O
##mus O
leading O
to O
decreased O
ability O
to O
produce O
the O
hormone O
a O
##rg O
##ini O
##ne O
v O
##as O
##op O
##ress O
##in O
( O
a O
##v O
##p O
) O
. O

affected O
individuals O
are O
not O
s O
##ym O
##pt O
##oma O
##tic O
at O
birth O
, O
but O
usually O
develop O
diabetes B-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
at O
1 O
- O
6 O
y O
##r O
of O
age O
. O

the O
genetic O
lo O
##cus O
of O
the O
disease O
is O
the O
a O
##v O
##p O
- O
ne O
##uro O
##phy O
##sin O
ii O
( O
n O
##pi O
##i O
) O
gene O
, O
and O
mutations O
that O
cause O
ad B-Disease
##ndi I-Disease
have O
been O
found O
in O
both O
the O
signal O
p O
##eptide O
of O
the O
pre O
##p O
##ro O
- O
a O
##v O
##p O
- O
n O
##pi O
##i O
precursor O
and O
within O
n O
##pi O
##i O
itself O
. O

an O
affected O
girl O
who O
presented O
at O
9 O
months O
of O
age O
and O
her O
similarly O
affected O
younger O
brother O
and O
father O
were O
all O
found O
to O
have O
a O
novel O
miss O
##ense O
mutation O
( O
g O
##17 O
##5 O
##8 O
- O
- O
[UNK] O
t O
) O
encoding O
the O
amino O
acid O
substitution O
g O
##ly O
##23 O
- O
- O
[UNK] O
v O
##al O
within O
n O
##pi O
##i O
. O

the O
mutation O
was O
confirmed O
by O
restriction O
end O
##on O
##uc O
##lea O
##se O
analysis O
. O

a O
t O
##1 O
- O
weighted O
magnetic O
resonance O
imaging O
of O
the O
fathers O
pit O
##uit O
##ary O
g O
##land O
demonstrates O
an O
at O
##ten O
##uated O
posterior O
pit O
##uit O
##ary O
bright O
spot O
. O

this O
mutation O
may O
be O
valuable O
for O
developing O
models O
of O
dominant B-Disease
##ly I-Disease
inherited I-Disease
ne I-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##ration I-Disease
, O
as O
the O
early O
age O
of O
onset O
of O
symptoms O
suggests O
that O
this O
mutation O
may O
be O
particularly O
del O
##eter O
##ious O
to O
the O
ma O
##gno O
##cellular O
ne O
##uron O
. O
. O

frequent O
in O
##act O
##ivation O
of O
p O
##ten O
/ O
mm O
##ac O
##1 O
in O
primary O
pro B-Disease
##state I-Disease
cancer I-Disease
. O

s B-Disease
##poradic I-Disease
pro I-Disease
##state I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
is O
the O
most O
common O
male B-Disease
cancer I-Disease
in O
the O
western O
world O
, O
yet O
many O
of O
the O
major O
genetic O
events O
involved O
in O
the O
progression O
of O
this O
often O
fatal O
cancer B-Disease
remain O
to O
be O
el O
##uc O
##idated O
. O

numerous O
c O
##yt O
##ogen O
##etic O
and O
all O
##elo O
##type O
studies O
have O
reported O
frequent O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
on O
ch O
##rom O
##oso O
##mal O
arm O
10 O
##q O
in O
s B-Disease
##poradic I-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
. O

del O
##eti O
##on O
mapping O
studies O
have O
un O
##am O
##bi O
##guous O
##ly O
identified O
a O
region O
of O
chromosome O
10 O
##q O
##23 O
to O
be O
the O
minimal O
area O
of O
loss O
. O

a O
new O
tumor B-Disease
suppress O
##or O
gene O
, O
p O
##ten O
/ O
mm O
##ac O
##1 O
, O
was O
isolated O
recently O
at O
this O
region O
of O
chromosome O
10 O
##q O
##23 O
and O
found O
to O
be O
inactivated O
by O
mutation O
in O
three O
pro B-Disease
##state I-Disease
cancer I-Disease
cell O
lines O
. O

we O
screened O
80 O
pro B-Disease
##state I-Disease
tumors I-Disease
by O
micro O
##sat O
##elli O
##te O
analysis O
and O
found O
chromosome O
10 O
##q O
##23 O
to O
be O
deleted O
in O
23 O
cases O
. O

we O
then O
proceeded O
with O
sequence O
analysis O
of O
the O
entire O
p O
##ten O
/ O
mm O
##ac O
##1 O
coding O
region O
and O
tested O
for O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##on O
with O
new O
in O
##tra O
##genic O
markers O
in O
these O
23 O
cases O
with O
10 O
##q O
##23 O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
. O

the O
identification O
of O
the O
second O
mutation O
##al O
event O
in O
10 O
( O
43 O
% O
) O
tumors B-Disease
establishes O
p O
##ten O
/ O
mm O
##ac O
##1 O
as O
a O
main O
in O
##act O
##ivation O
target O
of O
10 O
##q O
loss O
in O
s B-Disease
##poradic I-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
. O
. O

risk O
reversal O
##s O
in O
predict O
##ive O
testing O
for O
hunting B-Disease
##ton I-Disease
disease I-Disease
. O

the O
first O
predict O
##ive O
testing O
for O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
was O
based O
on O
analysis O
of O
linked O
p O
##oly O
##morphic O
d O
##na O
markers O
to O
estimate O
the O
likelihood O
of O
inherit O
##ing O
the O
mutation O
for O
h B-Disease
##d I-Disease
. O

limits O
to O
accuracy O
included O
re O
##comb O
##ination O
between O
the O
d O
##na O
markers O
and O
the O
mutation O
, O
p O
##ed O
##ig O
##ree O
structure O
, O
and O
whether O
d O
##na O
samples O
were O
available O
from O
family O
members O
. O

with O
direct O
tests O
for O
the O
h B-Disease
##d I-Disease
mutation O
, O
we O
have O
assessed O
the O
accuracy O
of O
results O
obtained O
by O
link O
##age O
approaches O
when O
requested O
to O
do O
so O
by O
the O
test O
individuals O
. O

for O
six O
such O
individuals O
, O
there O
was O
significant O
di O
##sp O
##arity O
between O
the O
tests O
. O

three O
went O
from O
a O
decreased O
risk O
to O
an O
increased O
risk O
, O
while O
in O
another O
three O
the O
risk O
was O
decreased O
. O

knowledge O
of O
the O
potential O
reasons O
for O
these O
changes O
in O
results O
and O
impact O
of O
these O
risk O
reversal O
##s O
on O
both O
patients O
and O
the O
counseling O
team O
can O
assist O
in O
the O
development O
of O
strategies O
for O
the O
prevention O
and O
, O
where O
necessary O
, O
management O
of O
a O
risk O
reversal O
in O
any O
predict O
##ive O
testing O
program O
. O
. O

a O
novel O
common O
miss O
##ense O
mutation O
g O
##30 O
##1 O
##c O
in O
the O
n O
- O
ace O
##ty O
##l O
##gal O
##act O
##osa O
##mine O
- O
6 O
- O
su O
##lf O
##ate O
su O
##lf O
##ata O
##se O
gene O
in O
m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
i I-Disease
##va I-Disease
. O

m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
i I-Disease
##va I-Disease
( O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
l I-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
genetic B-Disease
defect I-Disease
in O
n O
- O
ace O
##ty O
##l O
##gal O
##act O
##osa O
##mine O
- O
6 O
- O
su O
##lf O
##ate O
su O
##lf O
##ata O
##se O
( O
gal O
##ns O
) O
. O

in O
previous O
studies O
, O
we O
have O
found O
two O
common O
mutations O
in O
ca O
##uca O
##sian O
##s O
and O
j O
##apa O
##nese O
, O
respectively O
. O

to O
character O
##ize O
the O
mutation O
##al O
spectrum O
in O
various O
ethnic O
groups O
, O
mutations O
in O
the O
gal O
##ns O
gene O
in O
co O
##lo O
##mb O
##ian O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
patients O
were O
investigated O
, O
and O
genetic O
backgrounds O
were O
extensively O
analyzed O
to O
identify O
racial O
origin O
, O
based O
on O
mitochondrial O
d O
##na O
( O
m O
##t O
##dn O
##a O
) O
lineage O
##s O
. O

three O
novel O
miss O
##ense O
mutations O
never O
identified O
previously O
in O
other O
populations O
and O
found O
in O
16 O
out O
of O
19 O
co O
##lo O
##mb O
##ian O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
unrelated O
all O
##ele O
##s O
account O
for O
84 O
. O

2 O
% O
of O
the O
all O
##ele O
##s O
in O
this O
study O
. O

the O
g O
##30 O
##1 O
##c O
and O
s O
##16 O
##2 O
##f O
mutations O
account O
for O
68 O
. O

4 O
% O
and O
10 O
. O

5 O
% O
of O
mutations O
, O
respectively O
, O
whereas O
the O
remaining O
f O
##6 O
##9 O
##v O
is O
limited O
to O
a O
single O
all O
##ele O
. O

the O
s O
##ke O
##wed O
prevalence O
of O
g O
##30 O
##1 O
##c O
in O
only O
co O
##lo O
##mb O
##ian O
patients O
and O
ha O
##p O
##lot O
##ype O
analysis O
by O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
##s O
in O
the O
gal O
##ns O
gene O
suggest O
that O
g O
##30 O
##1 O
##c O
originated O
from O
a O
common O
ancestor O
. O

investigation O
of O
the O
genetic O
background O
by O
means O
of O
m O
##t O
##dn O
##a O
lineage O
##s O
indicate O
that O
all O
our O
patients O
are O
probably O
of O
native O
am O
##eric O
##an O
descent O

low O
frequency O
of O
br O
##ca O
##1 O
g O
##er O
##m O
##line O
mutations O
in O
45 O
g O
##erman O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

in O
this O
study O
we O
investigated O
45 O
g O
##erman O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
for O
g O
##er O
##m O
##line O
mutations O
in O
the O
br O
##ca O
##1 O
gene O
. O

we O
identified O
four O
g O
##er O
##m O
##line O
mutations O
in O
three O
breast B-Disease
cancer I-Disease
families O
and O
in O
one O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
family O
. O
among O
these O
were O
one O
frames O
##hi O
##ft O
mutation O
, O
one O
nonsense O
mutation O
, O
one O
novel O
s O
##p O
##lice O
site O
mutation O
, O
and O
one O
miss O
##ense O
mutation O
. O

the O
miss O
##ense O
mutation O
was O
also O
found O
in O
2 O
. O

8 O
% O
of O
the O
general O
population O
, O
suggesting O
that O
it O
is O
not O
disease O
associated O
. O

the O
average O
age O
of O
disease O
onset O
in O
those O
families O
harbour O
##ing O
ca O
##usa O
##tive O
mutations O
was O
between O
32 O
. O

3 O
and O
37 O
. O

4 O
years O
, O
whereas O
the O
family O
harbour O
##ing O
the O
miss O
##ense O
mutation O
had O
an O
average O
age O
of O
onset O
of O
51 O
. O

2 O
years O
. O

these O
findings O
show O
that O
br O
##ca O
##1 O
is O
implicated O
in O
a O
small O
fraction O
of O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
suggesting O
the O
involvement O
of O
another O
su O
##s O
##ce O
##pt O
##ibility O
gene O
( O
s O
) O

paternal O
transmission O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
my I-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

we O
report O
a O
rare O
case O
of O
paternal O
##ly O
transmitted O
con B-Disease
##gen I-Disease
##ital I-Disease
my I-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
. O

the O
pro O
##band O
is O
a O
23 O
year O
old O
, O
mentally B-Disease
re I-Disease
##tar I-Disease
##ded I-Disease
male O
who O
suffers O
severe O
muscular B-Disease
weakness I-Disease
. O

he O
presented O
with O
respiratory O
and O
feeding O
difficulties O
at O
birth O
. O

his O
two O
si O
##bs O
suffer O
from O
childhood O
onset O
d B-Disease
##m I-Disease
. O

their O
late O
father O
had O
the O
adult O
type O
of O
d B-Disease
##m I-Disease
, O
with O
onset O
around O
30 O
years O
. O

only O
six O
other O
cases O
of O
paternal O
transmission O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
d I-Disease
##m I-Disease
have O
been O
reported O
recently O
. O

we O
review O
the O
sex O
related O
effects O
on O
transmission O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
d I-Disease
##m I-Disease
. O

decreased O
fertility O
of O
males O
with O
adult O
onset O
d B-Disease
##m I-Disease
and O
contraction O
of O
the O
repeat O
upon O
male O
transmission O
contribute O
to O
the O
almost O
absent O
occurrence O
of O
paternal O
transmission O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
d I-Disease
##m I-Disease
. O

also O
the O
fathers O
of O
the O
reported O
con O
##gen O
##ital O
##ly O
affected O
children O
showed O
, O
on O
average O
, O
shorter O
c O
##t O
##g O
repeat O
lengths O
and O
hence O
less O
severe O
clinical O
symptoms O
than O
the O
mothers O
of O
children O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
d I-Disease
##m I-Disease
. O

we O
conclude O
that O
paternal O
transmission O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
d I-Disease
##m I-Disease
is O
rare O
and O
prefer O
##ential O
##ly O
occurs O
with O
onset O
of O
d B-Disease
##m I-Disease
past O
30 O
years O
in O
the O
father O
. O
. O

the O
r O
##b O
##1 O
gene O
mutation O
in O
a O
child O
with O
e B-Disease
##ct I-Disease
##op I-Disease
##ic I-Disease
in I-Disease
##tra I-Disease
##c I-Disease
##rani I-Disease
##al I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

the O
r O
##b O
##1 O
gene O
mutation O
was O
investigated O
in O
a O
child O
with O
e B-Disease
##ct I-Disease
##op I-Disease
##ic I-Disease
in I-Disease
##tra I-Disease
##c I-Disease
##rani I-Disease
##al I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
using O
d O
##na O
obtained O
from O
both O
the O
pine B-Disease
##al I-Disease
and I-Disease
re I-Disease
##tina I-Disease
##l I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
of O
the O
patient O
. O

a O
nonsense O
mutation O
in O
ex O
##on O
17 O
( O
co O
##don O
55 O
##6 O
) O
of O
the O
r O
##b O
##1 O
gene O
was O
found O
to O
be O
present O
ho O
##mo O
##zy O
##go O
##us O
##ly O
in O
both O
the O
re B-Disease
##tina I-Disease
##l I-Disease
and I-Disease
the I-Disease
pine I-Disease
##al I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
. O

the O
same O
mutation O
was O
present O
he O
##tero O
##zy O
##go O
##us O
##ly O
in O
the O
d O
##na O
from O
the O
constitutional O
cells O
of O
the O
patient O
, O
proving O
it O
to O
be O
of O
g O
##er O
##m O
##line O
origin O
. O

the O
initial O
mutation O
was O
shown O
to O
have O
occurred O
in O
the O
paternal O
##ly O
derived O
r O
##b O
##1 O
all O
##ele O
. O

the O
mutation O
is O
in O
an O
area O
of O
the O
gene O
that O
en O
##codes O
the O
protein O
- O
binding O
region O
known O
as O
the O
pocket O
region O
and O
has O
been O
detected O
in O
other O
cases O
of O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O
. O

low O
levels O
of O
beta O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
in O
healthy O
individuals O
with O
apparent O
deficiency O
of O
this O
enzyme O
. O

app O
##re O
##cia O
##ble O
beta O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
( O
he O
##x O
a O
) O
activity O
has O
been O
detected O
in O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
and O
me B-Disease
##lan I-Disease
##oma I-Disease
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B-Disease
of I-Disease
he I-Disease
##x I-Disease
a I-Disease
activity O
in O
##dis O
##ting O
##ui O
##sha O
##ble O
from O
that O
of O
patients O
with O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
. O

identification O
and O
q O
##uant O
##itation O
of O
he O
##x O
a O
, O
amount O
##ing O
to O
3 O
. O

5 O
% O
- O
6 O
. O

9 O
% O
of O
total O
beta O
he O
##x O
##osa O
##mini O
##das O
##e O
activity O
, O
has O
been O
obtained O
by O
cell O
##ulos O
##e O
ace O
##tate O
gel O
electro O
##ph O
##ores O
##is O
, O
de O
##ae O
- O
cell O
##ulos O
##e O
ion O
- O
exchange O
ch O
##roma O
##tography O
, O
radial O
im O
##mu O
##no O
##di O
##ff O
##usion O
, O
and O
radio O
##im O
##mu O
##no O
##ass O
##ay O
. O

previous O
family O
studies O
suggested O
that O
these O
individuals O
may O
be O
compound O
he O
##tero O
##zy O
##got O
##es O
for O
the O
common O
mutant O
t B-Disease
##s I-Disease
##d I-Disease
gene O
and O
a O
rare O
( O
all O
##eli O
##c O
) O
mutant O
gene O
. O

thus O
, O
the O
post O
##ulated O
rate O
mutant O
gene O
appears O
to O
code O
for O
the O
expression O
of O
low O
amounts O
of O
he O
##x O
a O
. O

he O
##tero O
##zy O
##got O
##es O
for O
the O
rare O
mutant O
may O
be O
in O
##dis O
##ting O
##ui O
##sha O
##ble O
from O
he O
##tero O
##zy O
##got O
##es O
for O
the O
common O
t B-Disease
##s I-Disease
##d I-Disease
mutant O
. O

however O
, O
direct O
visual O
##ization O
and O
q O
##uant O
##itation O
of O
he O
##x O
a O
by O
the O
methods O
described O
may O
prevent O
false O
- O
positive O
pre O
##nat O
##al O
diagnosis O
of O
t B-Disease
##s I-Disease
##d I-Disease
in O
f O
##etus O
##es O
having O
the O
incomplete O
he B-Disease
##x I-Disease
a I-Disease
deficiency I-Disease
of O
the O
type O
described O
in O
the O
four O
healthy O
individuals O

the O
tumor B-Disease
suppress O
##or O
gene O
s O
##mad O
##4 O
/ O
d O
##p O
##c O
##4 O
is O
required O
for O
gas O
##tr O
##ulation O
and O
later O
for O
anterior O
development O
of O
the O
mouse O
em O
##b O
##ryo O
. O

mutations O
in O
the O
s O
##mad O
##4 O
/ O
d O
##p O
##c O
##4 O
tumor B-Disease
suppress O
##or O
gene O
, O
a O
key O
signal O
trans O
##du O
##cer O
in O
most O
t O
##g O
##f O
##bet O
##a O
- O
related O
pathways O
, O
are O
involved O
in O
50 O
% O
of O
pan B-Disease
##cre I-Disease
##atic I-Disease
cancer I-Disease
##s I-Disease
. O

ho O
##mo O
##zy O
##go O
##us O
s O
##mad O
##4 O
mutant O
mice O
die O
before O
day O
7 O
. O

5 O
of O
em O
##b O
##ryo O
##genesis O
. O

mutant O
em O
##b O
##ryo O
##s O
have O
reduced O
size O
, O
fail O
to O
gas O
##tr O
##ulate O
or O
express O
a O
me O
##so O
##der O
##mal O
marker O
, O
and O
show O
abnormal O
v O
##is O
##cer O
##al O
end O
##ode O
##rm O
development O
. O

growth B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
of O
the O
s O
##mad O
##4 O
- O
def O
##icient O
em O
##b O
##ryo O
##s O
results O
from O
reduced O
cell O
proliferation O
rather O
than O
increased O
a O
##pop O
##tosis O
. O

a O
##gg O
##regation O
of O
mutant O
s O
##mad O
##4 O
es O
cells O
with O
wild O
- O
type O
te O
##tra O
##p O
##lo O
##id O
m O
##or O
##ula O
##e O
rescue O
##s O
the O
gas B-Disease
##tr I-Disease
##ulation I-Disease
defect I-Disease
. O

these O
results O
indicate O
that O
s O
##mad O
##4 O
is O
initially O
required O
for O
the O
differentiation O
of O
the O
v O
##is O
##cer O
##al O
end O
##ode O
##rm O
and O
that O
the O
gas B-Disease
##tr I-Disease
##ulation I-Disease
defect I-Disease
in O
the O
e O
##pi O
##blast O
is O
secondary O
and O
non O
- O
cell O
autonomous O
. O

rescued O
em O
##b O
##ryo O
##s O
show O
severe O
anterior O
t O
##run O
##cation O
##s O
, O
indicating O
a O
second O
important O
role O
for O
s O
##mad O
##4 O
in O
anterior O
pattern O
##ing O
during O
em O
##b O
##ryo O
##genesis O
. O

prevalence O
of O
p O
##16 O
and O
c O
##d O
##k O
##4 O
g O
##er O
##m O
##line O
mutations O
in O
48 O
me B-Disease
##lan I-Disease
##oma I-Disease
- O
prone O
families O
in O
f O
##rance O
. O

the O
f O
##rench O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##lan I-Disease
##oma I-Disease
study O
group O
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
p O
##16 O
and O
c O
##d O
##k O
##4 O
genes O
have O
been O
reported O
in O
a O
subset O
of O
me B-Disease
##lan I-Disease
##oma I-Disease
p O
##ed O
##ig O
##ree O
##s O
, O
but O
their O
prevalence O
is O
not O
well O
known O
. O

we O
searched O
for O
such O
g O
##er O
##m O
##line O
mutations O
in O
48 O
f O
##rench O
me B-Disease
##lan I-Disease
##oma I-Disease
- O
prone O
families O
selected O
according O
to O
two O
major O
criteria O
families O
with O
at O
least O
three O
affected O
members O
( O
n O
= O
20 O
) O
or O
families O
with O
two O
affected O
members O
, O
one O
of O
them O
affected O
before O
the O
age O
of O
50 O
( O
n O
= O
28 O
) O
, O
and O
one O
additional O
minor O
criterion O
. O

sixteen O
different O
p O
##16 O
g O
##er O
##m O
##line O
mutations O
were O
found O
in O
21 O
families O
, O
while O
one O
g O
##er O
##m O
##line O
mutation O
, O
a O
##rg O
##24 O
##his O
, O
was O
detected O
in O
the O
c O
##d O
##k O
##4 O
gene O
. O

the O
frequency O
of O
p O
##16 O
gene O
mutation O
in O
our O
sample O
( O
44 O
% O
) O
is O
among O
the O
highest O
rates O
yet O
reported O
and O
the O
c O
##d O
##k O
##4 O
mutation O
is O
the O
second O
mutation O
detected O
in O
this O
gene O
worldwide O
. O

in O
summary O
, O
our O
results O
show O
frequent O
involvement O
of O
the O
p O
##16 O
gene O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##lan I-Disease
##oma I-Disease
and O
confirm O
the O
role O
of O
the O
c O
##d O
##k O
##4 O
gene O
as O
a O
me B-Disease
##lan I-Disease
##oma I-Disease
- O
pre O
##dis O
##po O
##sing O
gene O
. O
. O

progression O
of O
so O
##matic O
c O
##t O
##g O
repeat O
length O
he O
##tero O
##gene O
##ity O
in O
the O
blood O
cells O
of O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
patients O
. O

the O
genetic O
basis O
of O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
the O
expansion O
of O
an O
unstable O
c O
##t O
##g O
repeat O
in O
the O
34 O
u O
##tr O
of O
the O
d B-Disease
##m I-Disease
protein O
kinase O
gene O
on O
chromosome O
19 O
. O

one O
of O
the O
principal O
features O
of O
the O
d B-Disease
##m I-Disease
mutation O
is O
an O
extra O
##ord O
##ina O
##rily O
high O
level O
of O
so O
##matic O
mosaic O
##ism O
, O
due O
to O
an O
extremely O
high O
degree O
of O
so O
##matic O
instability O
both O
within O
and O
between O
different O
tissues O
. O

this O
instability O
appears O
to O
be O
bias O
##ed O
towards O
further O
expansion O
and O
continuous O
throughout O
the O
life O
of O
an O
individual O
, O
features O
that O
could O
be O
associated O
with O
the O
progressive O
nature O
of O
the O
disease O
. O

although O
increasing O
measured O
all O
##ele O
size O
between O
patients O
clearly O
co O
##rrel O
##ates O
with O
an O
increased O
severity O
of O
symptoms O
and O
an O
earlier O
age O
of O
onset O
, O
this O
correlation O
is O
not O
precise O
and O
measured O
all O
##ele O
length O
cannot O
be O
used O
as O
an O
accurate O
predict O
##or O
of O
age O
of O
onset O
. O

in O
order O
to O
further O
character O
##ize O
the O
dynamics O
of O
d B-Disease
##m I-Disease
c O
##t O
##g O
repeat O
so O
##matic O
instability O
, O
we O
have O
studied O
repeat O
length O
changes O
over O
time O
in O
111 O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
patients O
with O
varying O
clinical O
severity O
and O
c O
##t O
##g O
repeat O
size O
over O
time O
intervals O
of O
1 O
- O
7 O
years O
. O

we O
have O
found O
a O
direct O
progression O
of O
the O
size O
he O
##tero O
##gene O
##ity O
over O
time O
related O
to O
initial O
c O
##t O
##g O
repeat O
size O
and O
the O
time O
interval O
and O
always O
bias O
##ed O
towards O
further O
expansion O
. O

attempts O
to O
mathematical O
##ly O
model O
the O
dynamics O
have O
proved O
only O
partially O
successful O
suggesting O
that O
individual O
specific O
genetic O
and O
/ O
or O
environmental O
factors O
also O
play O
a O
role O
in O
so O
##matic O
mosaic O
##ism O
. O
. O

as B-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##nu I-Disease
##ria I-Disease
among O
pale O
##st O
##inian O
a O
##rab O
##s O
. O

as B-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##nu I-Disease
##ria I-Disease
( O
a B-Disease
##gu I-Disease
) O
is O
a O
rare O
disorder B-Disease
of I-Disease
g I-Disease
##ly I-Disease
##co I-Disease
##p I-Disease
##rote I-Disease
##in I-Disease
metabolism I-Disease
caused O
by O
the O
deficiency B-Disease
of I-Disease
the I-Disease
l I-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
enzyme I-Disease
as I-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##ni I-Disease
##das I-Disease
##e I-Disease
( O
a O
##ga O
) O
. O

a B-Disease
##gu I-Disease
is O
inherited O
as O
an O
auto O
##so O
##mal O
re O
##cess O
##ive O
trait O
and O
occurs O
with O
a O
high O
frequency O
in O
fin O
##land O
because O
of O
a O
founder O
effect O
. O

while O
very O
few O
patients O
with O
a B-Disease
##gu I-Disease
have O
been O
reported O
from O
non O
- O
fin O
##nish O
origin O
, O
we O
diagnosed O
the O
disorder O
in O
8 O
patients O
originating O
from O
3 O
unrelated O
families O
, O
all O
pale O
##st O
##inian O
a O
##rab O
##s O
from O
the O
region O
of O
j O
##erus O
##ale O
##m O
. O

the O
clinical O
diagnosis O
of O
a B-Disease
##gu I-Disease
is O
often O
difficult O
, O
in O
particular O
early O
in O
the O
course O
of O
the O
disease O
, O
and O
most O
of O
the O
patients O
are O
diagnosed O
after O
the O
age O
of O
5 O
years O
. O

however O
, O
since O
these O
patients O
ex O
##cre O
##te O
early O
large O
amounts O
of O
as O
##par O
##ty O
##l O
##g O
##lu O
##cos O
##amine O
in O
urine O
, O
bio O
##chemical O
screening O
is O
easy O
by O
urine O
ch O
##roma O
##tography O
. O
. O

detection O
of O
he O
##tero O
##zy O
##go O
##us O
carriers O
of O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
at O
##m O
) O
gene O
by O
g O
##2 O
phase O
ch O
##rom O
##oso O
##mal O
radios O
##ens O
##iti O
##vity O
of O
peripheral O
blood O
l O
##ymph O
##ocytes O
. O

in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
at O
##m O
, O
result O
in O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
syndrome I-Disease
that O
embrace O
##s O
a O
variety O
of O
clinical O
features O
and O
manifest O
##s O
extreme O
radios O
##ens O
##iti O
##vity O
and O
a O
strong O
pre O
- O
disposition O
to O
ma B-Disease
##li I-Disease
##gna I-Disease
##ncy I-Disease
. O

he O
##tero O
##zy O
##got O
##es O
for O
the O
at O
##m O
gene O
have O
no O
clinical O
expression O
of O
a B-Disease
- I-Disease
t I-Disease
but O
may O
be O
cancer B-Disease
prone O
with O
a O
moderate O
increase O
in O
in O
v O
##it O
##ro O
radios O
##ens O
##iti O
##vity O
. O

we O
performed O
a O
blind O
ch O
##rom O
##oso O
##mal O
analysis O
on O
g O
##2 O
- O
phase O
l O
##ymph O
##ocytes O
from O
7 O
unrelated O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
13 O
o O
##b O
##liga O
##te O
a B-Disease
- I-Disease
t I-Disease
he O
##tero O
##zy O
##got O
##es O
( O
parents O
of O
the O
patients O
) O
, O
and O
14 O
normal O
controls O
following O
x O
- O
i O
##rra O
##diation O
with O
1 O
g O
##y O
in O
order O
to O
evaluate O
this O
c O
##yt O
##ogen O
##etic O
method O
as O
a O
tool O
for O
detection O
of O
at O
##m O
carriers O
. O

both O
a B-Disease
- I-Disease
t I-Disease
ho O
##mo O
##zy O
##got O
##es O
and O
he O
##tero O
##zy O
##got O
##es O
showed O
significantly O
increased O
levels O
of O
radiation O
- O
induced O
ch O
##roma O
##ti O
##d O
damage O
relative O
to O
that O
of O
normal O
controls O
. O

these O
results O
show O
that O
the O
g O
##2 O
- O
phase O
ch O
##rom O
##oso O
##mal O
radios O
##ens O
##iti O
##vity O
ass O
##ay O
can O
be O
used O
for O
the O
detection O
of O
a B-Disease
- I-Disease
t I-Disease
he O
##tero O
##zy O
##got O
##es O
. O

in O
combination O
with O
molecular O
genetic O
analyses O
, O
this O
test O
may O
be O
of O
value O
in O
studies O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
and I-Disease
s I-Disease
##poradic I-Disease
cancer I-Disease
##s I-Disease
aimed O
at O
determination O
of O
the O
potential O
involvement O
of O
at O
##m O
mutations O
in O
tumor B-Disease
risk O
or O
development O
. O
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
: O
identification O
and O
detection O
of O
founder O
- O
effect O
mutations O
in O
the O
at O
##m O
gene O
in O
ethnic O
populations O
. O

to O
facilitate O
the O
evaluation O
of O
at O
##m O
he O
##tero O
##zy O
##got O
##es O
for O
su O
##s O
##ce O
##pt O
##ibility O
to O
other O
diseases O
, O
such O
as O
breast B-Disease
cancer I-Disease
, O
we O
have O
attempted O
to O
define O
the O
most O
common O
mutations O
and O
their O
frequencies O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
ho O
##mo O
##zy O
##got O
##es O
from O
10 O
ethnic O
populations O
. O

both O
g O
##eno O
##mic O
mutations O
and O
their O
effects O
on O
c O
##dn O
##a O
were O
characterized O
. O

protein O
- O
t O
##run O
##cation O
testing O
of O
the O
entire O
at O
##m O
c O
##dn O
##a O
detected O
92 O
( O
66 O
% O
) O
t O
##run O
##cating O
mutations O
in O
140 O
mutant O
all O
##ele O
##s O
screened O
. O

the O
ha O
##p O
##lot O
##y O
##ping O
of O
patients O
with O
identical O
mutations O
indicates O
that O
almost O
all O
of O
these O
represent O
common O
ancestry O
and O
that O
very O
few O
spontaneous O
##ly O
recurring O
at O
##m O
mutations O
exist O
. O

ass O
##ays O
requiring O
minimal O
amounts O
of O
g O
##eno O
##mic O
d O
##na O
were O
designed O
to O
allow O
rapid O
screening O
for O
common O
ethnic O
mutations O
. O

these O
rapid O
ass O
##ays O
detected O
mutations O
in O
76 O
% O
of O
costa O
r O
##ica O
##n O
patients O
( O
3 O
) O
, O
50 O
% O
of O
nor O
##we O
##gia O
##n O
patients O
( O
1 O
) O
, O
25 O
% O
of O
p O
##olis O
##h O
patients O
( O
4 O
) O
, O
and O
14 O
% O
of O
it O
##alia O
##n O
patients O
( O
1 O
) O
, O
as O
well O
as O
in O
patients O
of O
am O
##ish O
/ O
men O
##non O
##ite O
and O
i O
##ris O
##h O
en O
##gli O
##sh O
backgrounds O
. O

additional O
mutations O
were O
observed O
in O
j O
##apa O
##nese O
, O
u O
##tah O
m O
##orm O
##on O
, O
and O
a O
##f O
##rica O
##n O
am O
##eric O
##an O
patients O
. O

these O
ass O
##ays O
should O
facilitate O
screening O
for O
a B-Disease
- I-Disease
t I-Disease
he O
##tero O
##zy O
##got O
##es O
in O
the O
populations O
studied O
. O
. O

the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
tumor I-Disease
suppress O
##or O
gene O
is O
required O
for O
cell O
cycle O
exit O
upon O
serum O
withdrawal O
. O

the O
in O
##act O
##ivation O
of O
the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( I-Disease
v I-Disease
##hl I-Disease
) I-Disease
tumor I-Disease
suppress O
##or O
gene O
pre O
##dis O
##pose O
##s O
affected O
individuals O
to O
the O
human O
v B-Disease
##hl I-Disease
cancer I-Disease
syndrome I-Disease
and O
is O
associated O
with O
s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
( O
r B-Disease
##cc I-Disease
) O
and O
brain B-Disease
hem I-Disease
##ang I-Disease
##io I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
. O

v O
##hl O
- O
negative O
78 O
##6 O
- O
0 O
r B-Disease
##cc I-Disease
cells O
are O
tumor O
##ige O
##nic O
in O
nude O
mice O
which O
is O
suppressed O
by O
the O
re O
##int O
##rod O
##uction O
of O
v B-Disease
##hl I-Disease
. O

remarkably O
, O
this O
occurs O
without O
affecting O
the O
growth O
rate O
and O
cell O
cycle O
profile O
of O
these O
cells O
in O
culture O
. O

the O
78 O
##6 O
- O
0 O
cell O
line O
, O
like O
many O
cancer B-Disease
cells O
, O
fails O
to O
exit O
the O
cell O
cycle O
upon O
serum O
withdrawal O
. O

here O
, O
it O
is O
shown O
that O
re O
##int O
##rod O
##uction O
of O
the O
wild O
- O
type O
v B-Disease
##hl I-Disease
gene O
restore O
##s O
the O
ability O
of O
v O
##hl O
- O
negative O
r B-Disease
##cc I-Disease
cancer I-Disease
cells O
to O
exit O
the O
cell O
cycle O
and O
enter O
g O
##0 O
/ O
q O
##ui O
##es O
##cence O
in O
low O
serum O
. O

both O
v O
##hl O
- O
positive O
and O
v O
##hl O
- O
negative O
r B-Disease
##cc I-Disease
cells O
exit O
the O
cell O
cycle O
by O
contact O
in O
##hibition O
. O

the O
c O
##y O
##c O
##lin O
- O
dependent O
kinase O
inhibitor O
, O
p O
##27 O
, O
a O
##cc O
##um O
##ulates O
upon O
serum O
withdrawal O
, O
only O
in O
the O
presence O
of O
v B-Disease
##hl I-Disease
, O
as O
a O
result O
of O
the O
stab O
##ilization O
of O
the O
protein O
. O

we O
propose O
that O
the O
loss O
of O
wild O
- O
type O
v B-Disease
##hl I-Disease
gene O
results O
in O
a O
specific O
cellular O
defect O
in O
serum O
- O
dependent O
growth O
control O
, O
which O
may O
initiate O
tumor B-Disease
formation O
. O

this O
is O
corrected O
by O
the O
re O
##int O
##rod O
##uction O
of O
wild O
- O
type O
v B-Disease
##hl I-Disease
, O
imp O
##lica O
##ting O
v B-Disease
##hl I-Disease
as O
the O
first O
tumor B-Disease
suppress O
##or O
involved O
in O
the O
regulation O
of O
cell O
cycle O
exit O
, O
which O
is O
consistent O
with O
its O
gate O
##keeper O
function O
in O
the O
kidney O
. O
. O

pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
with O
deaf B-Disease
##ness I-Disease
: O
molecular O
evidence O
for O
an O
expanded O
syndrome O
. O

in O
a O
south O
a O
##f O
##rica O
##n O
girl O
of O
x O
##hos O
##a O
stock O
with O
severe O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
and O
profound O
con O
##gen O
##ital O
sensor B-Disease
##ine I-Disease
##ural I-Disease
deaf I-Disease
##ness I-Disease
we O
identified O
a O
novel O
miss O
##ense O
substitution O
at O
a O
highly O
conserved O
residue O
in O
the O
in O
##tra O
##cellular O
kinase O
domain O
of O
the O
kit O
pro O
##to O
- O
on O
##co O
##gene O
, O
r O
##7 O
##9 O
##6 O
##g O
. O

though O
audit B-Disease
##ory I-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
have O
been O
observed O
in O
mice O
with O
dominant O
white O
spot O
##ting O
( O
w O
) O
due O
to O
kit O
mutations O
, O
deaf B-Disease
##ness I-Disease
is O
not O
typical O
in O
human O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
. O

thus O
, O
the O
occurrence O
of O
sensor B-Disease
##ine I-Disease
##ural I-Disease
deaf I-Disease
##ness I-Disease
in O
this O
patient O
extends O
considerably O
the O
p O
##hen O
##otypic O
range O
of O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
due O
to O
kit O
gene O
mutation O
in O
humans O
and O
tighten O
##s O
the O
clinical O
similarity O
between O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
and O
the O
various O
forms O
of O
wa B-Disease
##ard I-Disease
##enburg I-Disease
syndrome I-Disease
. O
. O

c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
facilitate O
##s O
the O
identification O
of O
a O
##ber O
##rant O
trans O
##cripts O
resulting O
from O
a O
novel O
s O
##p O
##lice O
- O
site O
mutation O
in O
co O
##l O
##17 O
##a O
##1 O
in O
a O
patient O
with O
generalized O
at B-Disease
##rop I-Disease
##hic I-Disease
ben I-Disease
##ign I-Disease
e I-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##lysis I-Disease
bull I-Disease
##osa I-Disease
. O

patients O
with O
generalized O
at B-Disease
##rop I-Disease
##hic I-Disease
ben I-Disease
##ign I-Disease
e I-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##lysis I-Disease
bull I-Disease
##osa I-Disease
often O
show O
decreased O
expression O
of O
type O
x O
##vi O
##i O
co O
##lla O
##gen O
, O
a O
trans O
##me O
##mb O
##rane O
hem O
##ides O
##mos O
##oma O
##l O
protein O
encoded O
by O
co O
##l O
##17 O
##a O
##1 O
. O

this O
report O
documents O
a O
novel O
s O
##p O
##lice O
- O
site O
mutation O
in O
co O
##l O
##17 O
##a O
##1 O
in O
a O
patient O
with O
generalized O
at B-Disease
##rop I-Disease
##hic I-Disease
ben I-Disease
##ign I-Disease
e I-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##lysis I-Disease
bull I-Disease
##osa I-Disease
, O
and O
applies O
a O
new O
methodology O
to O
define O
and O
character O
##ize O
the O
resulting O
m O
##rna O
s O
##p O
##lice O
variants O
. O

mutation O
##al O
analysis O
of O
co O
##l O
##17 O
##a O
##1 O
identified O
a O
maternal O
##ly O
inherited O
g O
- O
to O
- O
t O
trans O
##version O
at O
the O
- O
1 O
position O
of O
ex O
##on O
32 O
. O

this O
accept O
##or O
s O
##p O
##lice O
- O
site O
mutation O
led O
to O
the O
formation O
of O
a O
##ber O
##rant O
trans O
##cripts O
present O
at O
extremely O
low O
levels O
. O

based O
on O
our O
recent O
finding O
that O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
stab O
##ilized O
mutant O
co O
##l O
##17 O
##a O
##1 O
trans O
##cripts O
in O
k O
##era O
##tino O
##cy O
##tes O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
frames O
##hi O
##ft O
mutation O
, O
the O
effects O
of O
the O
s O
##p O
##lice O
- O
site O
mutation O
on O
s O
##p O
##licing O
of O
co O
##l O
##17 O
##a O
##1 O
trans O
##cripts O
were O
determined O
using O
reverse O
trans O
##cript O
##ase O
polymer O
##ase O
chain O
reaction O
of O
total O
r O
##na O
from O
k O
##era O
##tino O
##cy O
##tes O
in O
##cu O
##bate O
##d O
for O
2 O
. O

5 O
h O
in O
the O
presence O
or O
absence O
of O
10 O
micro O
##g O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
per O
m O
##l O
. O

using O
this O
approach O
, O
an O
abnormal O
##ly O
s O
##p O
##lice O
##d O
trans O
##cript O
was O
identified O
that O
contains O
an O
extra O
264 O
bases O
upstream O
from O
ex O
##on O
32 O
, O
resulting O
in O
a O
premature O
termination O
co O
##don O
27 O
b O
##p O
downstream O
from O
the O
cry O
##ptic O
s O
##p O
##lice O
site O
. O

three O
other O
s O
##p O
##lice O
variants O
, O
including O
one O
derived O
from O
the O
skip O
##ping O
of O
ex O
##on O
32 O
, O
were O
also O
identified O
. O

these O
results O
indicate O
the O
useful O
##ness O
of O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
treatment O
in O
evaluating O
the O
abnormal O
processing O
of O
m O
##rna O
due O
to O
s O
##p O
##lice O
- O
site O
mutations O
, O
because O
( O
i O
) O
a O
##ber O
##rant O
s O
##p O
##licing O
often O
generates O
a O
premature O
termination O
co O
##don O
, O
( O
ii O
) O
trans O
##cripts O
with O
premature O
termination O
co O
##don O
##s O
can O
occur O
at O
low O
or O
und O
##ete O
##ct O
##able O
levels O
due O
to O
nonsense O
- O
mediated O
m O
##rna O
decay O
, O
and O
( O
ii O
##i O
) O
the O
levels O
of O
these O
trans O
##cripts O
can O
be O
increased O
by O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
. O

a O
del O
##eti O
##on O
mutation O
in O
co O
##l O
##17 O
##a O
##1 O
in O
five O
au O
##st O
##rian O
families O
with O
generalized O
at B-Disease
##rop I-Disease
##hic I-Disease
ben I-Disease
##ign I-Disease
e I-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##lysis I-Disease
bull I-Disease
##osa I-Disease
represents O
propagation O
of O
an O
ancestral O
all O
##ele O
. O

patients O
with O
generalized O
at B-Disease
##rop I-Disease
##hic I-Disease
ben I-Disease
##ign I-Disease
e I-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##lysis I-Disease
bull I-Disease
##osa I-Disease
, O
a O
usually O
non O
##let O
##hal O
form O
of O
junction B-Disease
##al I-Disease
e I-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##lysis I-Disease
bull I-Disease
##osa I-Disease
, O
have O
generalized O
b B-Disease
##list I-Disease
##ering I-Disease
, O
nail B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
patch B-Disease
##y I-Disease
al I-Disease
##ope I-Disease
##cia I-Disease
, O
and O
dental B-Disease
abnormal I-Disease
##ities I-Disease
. O

skin B-Disease
f I-Disease
##rag I-Disease
##ility I-Disease
in O
most O
cases O
is O
due O
to O
mutations O
in O
the O
gene O
encoding O
type O
x O
##vi O
##i O
co O
##lla O
##gen O
( O
co O
##l O
##17 O
##a O
##1 O
) O
. O

recently O
, O
we O
reported O
five O
au O
##st O
##rian O
families O
with O
generalized O
at B-Disease
##rop I-Disease
##hic I-Disease
ben I-Disease
##ign I-Disease
e I-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##lysis I-Disease
bull I-Disease
##osa I-Disease
who O
share O
the O
same O
co O
##l O
##17 O
##a O
##1 O
mutation O
. O

affected O
individuals O
in O
three O
families O
are O
ho O
##mo O
##zy O
##go O
##us O
for O
400 O
##3 O
##del O
##t O
##c O
, O
whereas O
those O
in O
two O
others O
are O
compound O
he O
##tero O
##zy O
##got O
##es O
. O

to O
determine O
if O
the O
occurrence O
of O
400 O
##3 O
##del O
##t O
##c O
in O
these O
unrelated O
families O
sign O
##ifies O
propagation O
of O
an O
ancestral O
all O
##ele O
or O
a O
mutation O
##al O
hot O
spot O
, O
ha O
##p O
##lot O
##ype O
##s O
were O
determined O
for O
p O
##oly O
##mor O
##phism O
##s O
both O
within O
and O
flank O
##ing O
co O
##l O
##17 O
##a O
##1 O
. O

five O
in O
##tra O
##genic O
p O
##oly O
##mor O
##phism O
##s O
were O
chosen O
based O
on O
their O
inform O
##ative O
##ness O
. O

one O
of O
these O
, O
not O
previously O
reported O
, O
was O
29 O
##8 O
##8 O
a O
or O
c O
that O
introduces O
a O
new O
restriction O
site O
for O
e O
##co O
##01 O
##0 O
##9 O
i O
. O

all O
the O
400 O
##3 O
##del O
##t O
##c O
all O
##ele O
##s O
showed O
the O
same O
ha O
##p O
##lot O
##ype O
for O
these O
five O
p O
##oly O
##morphic O
markers O
. O

fourteen O
micro O
##sat O
##elli O
##te O
p O
##oly O
##mor O
##phism O
##s O
were O
selected O
based O
on O
their O
high O
he O
##tero O
##zy O
##gos O
##ity O
and O
their O
location O
within O
10 O
##q O
##23 O
- O
q O
##25 O
near O
co O
##l O
##17 O
##a O
##1 O
. O

three O
families O
shared O
micro O
##sat O
##elli O
##te O
p O
##oly O
##mor O
##phism O
##s O
covering O
at O
most O
19 O
cm O
, O
whereas O
the O
others O
shared O
smaller O
regions O
consistent O
with O
cross O
- O
over O
events O
during O
passage O
of O
this O
mutation O
through O
several O
generations O
. O

these O
results O
indicate O
that O
400 O
##3 O
##del O
##t O
##c O
occurs O
on O
a O
single O
ancestral O
all O
##ele O
. O
. O

the O
ha O
##pt O
##og O
##lo O
##bin O
- O
gene O
del O
##eti O
##on O
responsible O
for O
an B-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mia I-Disease
. O

we O
have O
found O
an O
all O
##eli O
##c O
del O
##eti O
##on O
of O
the O
ha O
##pt O
##og O
##lo O
##bin O
( O
hp O
) O
gene O
from O
an O
individual O
with O
an B-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mia I-Disease
. O

the O
hp O
gene O
cluster O
consists O
of O
coding O
regions O
of O
the O
alpha O
chain O
and O
beta O
chain O
of O
the O
ha O
##pt O
##og O
##lo O
##bin O
gene O
( O
hp O
) O
and O
of O
the O
alpha O
chain O
and O
beta O
chain O
of O
the O
ha O
##pt O
##og O
##lo O
##bin O
- O
related O
gene O
( O
hp O
##r O
) O
, O
in O
tandem O
from O
the O
5 O
side O
. O

southern O
b O
##lot O
and O
p O
##c O
##r O
analyses O
have O
indicated O
that O
the O
individual O
with O
an B-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mia I-Disease
was O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
gene O
del O
##eti O
##on O
and O
that O
the O
gene O
del O
##eti O
##on O
was O
included O
at O
least O
from O
the O
promoter O
region O
of O
hp O
to O
hp O
##r O
alpha O
but O
not O
to O
hp O
##r O
beta O
( O
hp O
##del O
) O
. O

in O
addition O
, O
we O
found O
seven O
individuals O
with O
h B-Disease
##y I-Disease
##po I-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mia I-Disease
in O
three O
families O
, O
and O
the O
g O
##eno O
##type O
##s O
of O
six O
of O
the O
seven O
individuals O
were O
found O
to O
be O
hp O
##2 O
/ O
hp O
##del O
. O

the O
p O
##hen O
##otype O
##s O
and O
g O
##eno O
##type O
##s O
in O
one O
of O
these O
three O
families O
showed O
the O
father O
to O
be O
h B-Disease
##y I-Disease
##po I-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mic I-Disease
( O
hp O
##2 O
) O
and O
hp O
##2 O
/ O
hp O
##del O
, O
the O
mother O
to O
be O
hp O
##2 O
- O
1 O
and O
hp O
##1 O
/ O
hp O
##2 O
, O
one O
of O
the O
two O
children O
to O
be O
h B-Disease
##y I-Disease
##po I-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mic I-Disease
( O
hp O
##2 O
) O
and O
hp O
##2 O
/ O
hp O
##del O
, O
and O
the O
other O
child O
to O
be O
hp O
##1 O
and O
hp O
##1 O
/ O
hp O
##del O
, O
showing O
an O
an O
##oma O
##lous O
inheritance O
of O
hp O
p O
##hen O
##otype O
##s O
in O
the O
child O
with O
hp O
##1 O
. O

the O
hp O
##2 O
/ O
hp O
##del O
individuals O
had O
an O
extremely O
low O
level O
of O
hp O
( O
mean O
+ O
/ O
- O
s O
##d O
= O
0 O
. O
04 O
##9 O
+ O
/ O
- O
0 O
. O
04 O
##3 O
mg O
/ O
m O
##l O
; O
n O
= O
6 O
) O
, O
compared O
with O
the O
level O
( O
1 O
. O
64 O
+ O
/ O
- O
1 O
. O
07 O
mg O
/ O
m O
##l O
) O
obtained O
from O
52 O
healthy O
volunteers O
having O
p O
##hen O
##otype O
hp O
##2 O
, O
whereas O
the O
serum O
hp O
level O
of O
an O
individual O
with O
hp O
##1 O
/ O
hp O
##del O
was O
0 O
. O

50 O
mg O
/ O
m O
##l O
, O
which O
was O
approximately O
half O
the O
level O
of O
hp O
in O
control O
se O
##ra O
from O
the O
hp O
##1 O
p O
##hen O
##otype O
( O
1 O
. O
26 O
+ O
/ O
- O
0 O
. O
33 O
mg O
/ O
m O
##l O
; O
n O
= O
9 O
) O
, O
showing O
a O
gene O
- O
dos O
##age O
effect O
. O

the O
other O
all O
##ele O
( O
hp O
##2 O
) O
of O
individuals O
with O
hp O
##2 O
/ O
hp O
##del O
was O
found O
to O
have O
, O
in O
all O
ex O
##ons O
, O
no O
mutation O
, O
by O
d O
##na O
se O
##quencing O
. O

on O
the O
basis O
of O
the O
present O
study O
, O
the O
mechanism O
of O
an B-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mia I-Disease
and O
the O
mechanism O
of O
an O
##oma O
##lous O
inheritance O
of O
hp O
p O
##hen O
##otype O
##s O
were O
well O
explained O
. O

however O
, O
the O
mechanism O
of O
h B-Disease
##y I-Disease
##po I-Disease
##ha I-Disease
##pt I-Disease
##og I-Disease
##lo I-Disease
##bine I-Disease
##mia I-Disease
remains O
unknown O

at O
##m O
mutations O
and O
p O
##hen O
##otype O
##s O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
families O
in O
the O
br O
##itis O
##h O
is O
##les O
: O
expression O
of O
mutant O
at O
##m O
and O
the O
risk O
of O
le B-Disease
##uke I-Disease
##mia I-Disease
, O
l B-Disease
##ymph I-Disease
##oma I-Disease
, O
and O
breast B-Disease
cancer I-Disease
. O

we O
report O
the O
spectrum O
of O
59 O
at O
##m O
mutations O
observed O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
patients O
in O
the O
br O
##itis O
##h O
is O
##les O
. O

of O
51 O
at O
##m O
mutations O
identified O
in O
families O
native O
to O
the O
br O
##itis O
##h O
is O
##les O
, O
11 O
were O
founder O
mutations O
, O
and O
2 O
of O
these O
11 O
conferred O
a O
mild O
##er O
clinical O
p O
##hen O
##otype O
with O
respect O
to O
both O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
and O
cellular O
features O
. O

we O
report O
, O
in O
two O
a B-Disease
- I-Disease
t I-Disease
families O
, O
an O
at O
##m O
mutation O
( O
72 O
##7 O
##1 O
##t O
- O
- O
[UNK] O
g O
) O
that O
may O
be O
associated O
with O
an O
increased O
risk O
of O
breast B-Disease
cancer I-Disease
in O
both O
ho O
##mo O
##zy O
##got O
##es O
and O
he O
##tero O
##zy O
##got O
##es O
( O
relative O
risk O
12 O
. O
7 O
; O
p O
= O
. O
00 O
##25 O
) O
, O
although O
there O
is O
a O
less O
severe O
a B-Disease
- I-Disease
t I-Disease
p O
##hen O
##otype O
in O
terms O
of O
the O
degree O
of O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
. O

this O
mutation O
( O
72 O
##7 O
##1 O
##t O
- O
- O
[UNK] O
g O
) O
also O
allows O
expression O
of O
full O
- O
length O
at O
##m O
protein O
at O
a O
level O
comparable O
with O
that O
in O
un O
##af O
##fected O
individuals O
. O

in O
addition O
, O
we O
have O
studied O
18 O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
in O
15 O
families O
, O
who O
developed O
le B-Disease
##uke I-Disease
##mia I-Disease
, O
l B-Disease
##ymph I-Disease
##oma I-Disease
, O
pre O
##le O
##uke O
##mic O
t O
- O
cell O
proliferation O
, O
or O
ho B-Disease
##d I-Disease
##g I-Disease
##kin I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
, O
mostly O
in O
childhood O
. O

a O
wide O
variety O
of O
at O
##m O
mutation O
types O
, O
including O
miss O
##ense O
mutations O
and O
in O
- O
frame O
del O
##eti O
##ons O
, O
were O
seen O
in O
these O
patients O
. O

we O
also O
show O
that O
25 O
% O
of O
all O
a B-Disease
- I-Disease
t I-Disease
patients O
carried O
in O
- O
frame O
del O
##eti O
##ons O
or O
miss O
##ense O
mutations O
, O
many O
of O
which O
were O
also O
associated O
with O
expression O
of O
mutant O
at O
##m O
protein O
. O

the O
d O
##mp O
##k O
gene O
of O
severely O
affected O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
patients O
is O
h O
##yper O
##met O
##hyl O
##ated O
pro O
##ximal O
to O
the O
largely O
expanded O
c O
##t O
##g O
repeat O
. O

using O
met O
##hyl O
##ation O
- O
sensitive O
restriction O
enzymes O
, O
we O
characterized O
the O
met O
##hyl O
##ation O
pattern O
on O
the O
5 O
side O
of O
the O
c O
##t O
##g O
repeat O
in O
the O
d O
##mp O
##k O
gene O
of O
normal O
individuals O
and O
of O
patients O
affected O
with O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
showing O
expansion O
##s O
of O
the O
repetitive O
sequence O
. O

the O
gene O
segment O
analyzed O
corresponds O
to O
the O
g O
##eno O
##mic O
sa O
##ci O
- O
hind O
##ii O
##i O
fragment O
carrying O
ex O
##ons O
11 O
- O
15 O
. O

there O
is O
con O
##st O
##it O
##utive O
met O
##hyl O
##ation O
in O
intro O
##n O
12 O
at O
restriction O
sites O
of O
sa O
##ci O
##i O
and O
h O
##hai O
, O
localized O
1 O
, O
159 O
- O
1 O
, O
232 O
b O
##p O
upstream O
of O
the O
c O
##t O
##g O
repeat O
, O
whereas O
most O
, O
if O
not O
all O
, O
of O
the O
other O
sites O
of O
sa O
##ci O
##i O
, O
h O
##hai O
, O
and O
hp O
##ai O
##i O
in O
this O
region O
are O
un O
##met O
##hyl O
##ated O
, O
in O
normal O
individuals O
and O
most O
of O
the O
patients O
. O

in O
a O
number O
of O
young O
and O
severely O
affected O
patients O
, O
however O
, O
complete O
met O
##hyl O
##ation O
of O
these O
restriction O
sites O
was O
found O
in O
the O
m O
##uta O
##ted O
all O
##ele O
. O

in O
most O
of O
these O
patients O
, O
the O
onset O
of O
the O
disease O
was O
con O
##gen O
##ital O
. O

preliminary O
in O
v O
##ivo O
foot O
##print O
##ing O
data O
gave O
evidence O
for O
protein O
- O
d O
##na O
contact O
in O
normal O
genes O
at O
an O
s O
##p O
##1 O
consensus O
binding O
site O
upstream O
of O
the O
c O
##t O
##g O
repeat O
and O
for O
a O
significant O
reduction O
of O
this O
interaction O
in O
cells O
with O
a O
h O
##yper O
##met O
##hyl O
##ated O
d O
##mp O
##k O
gene O
. O
. O

the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
gene O
product O
complexes O
with O
the O
transfer O
##rin O
receptor O
and O
lower O
##s O
its O
affinity O
for O
l O
##igan O
##d O
binding O
. O

we O
recently O
reported O
the O
position O
##al O
c O
##lon O
##ing O
of O
a O
candidate O
gene O
for O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
called O
h O
##fe O
. O

the O
gene O
product O
, O
a O
member O
of O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
complex O
class O
i O
- O
like O
family O
, O
was O
found O
to O
have O
a O
mutation O
, O
c O
##ys O
- O
28 O
##2 O
- O
- O
[UNK] O
t O
##yr O
( O
c O
##28 O
##2 O
##y O
) O
, O
in O
85 O
% O
of O
patient O
chromosome O
##s O
. O

this O
mutation O
eliminate O
##s O
the O
ability O
of O
h O
##fe O
to O
associate O
with O
beta O
##2 O
- O
micro O
##g O
##lo O
##bul O
##in O
( O
beta O
##2 O
##m O
) O
and O
prevents O
cell O
- O
surface O
expression O
. O

a O
second O
mutation O
that O
has O
no O
effect O
on O
beta O
##2 O
##m O
association O
, O
h O
##6 O
##3 O
##d O
, O
was O
found O
in O
eight O
out O
of O
nine O
patients O
he O
##tero O
##zy O
##go O
##us O
for O
the O
c O
##28 O
##2 O
##y O
mutant O
. O

in O
this O
report O
, O
we O
demonstrate O
in O
culture O
##d O
29 O
##3 O
cells O
over O
##ex O
##pressing O
wild O
- O
type O
or O
mutant O
h O
##fe O
proteins O
that O
both O
the O
wild O
- O
type O
and O
h O
##6 O
##3 O
##d O
h O
##fe O
proteins O
form O
stable O
complexes O
with O
the O
transfer O
##rin O
receptor O
( O
t O
##f O
##r O
) O
. O

the O
c O
##28 O
##2 O
##y O
mutation O
nearly O
completely O
prevents O
the O
association O
of O
the O
mutant O
h O
##fe O
protein O
with O
the O
t O
##f O
##r O
. O

studies O
on O
cell O
- O
associated O
transfer O
##rin O
at O
37 O
degrees O
c O
suggest O
that O
the O
over O
##ex O
##pressed O
wild O
- O
type O
h O
##fe O
protein O
decreases O
the O
affinity O
of O
the O
t O
##f O
##r O
for O
transfer O
##rin O
. O

the O
over O
##ex O
##pressed O
h O
##6 O
##3 O
##d O
protein O
does O
not O
have O
this O
effect O
, O
providing O
the O
first O
direct O
evidence O
for O
a O
functional O
consequence O
of O
the O
h O
##6 O
##3 O
##d O
mutation O
. O

addition O
of O
soluble O
wild O
- O
type O
h O
##fe O
/ O
beta O
##2 O
##m O
he O
##tero O
##di O
##mers O
to O
culture O
##d O
cells O
also O
decreased O
the O
apparent O
affinity O
of O
the O
t O
##f O
##r O
for O
its O
l O
##igan O
##d O
under O
steady O
- O
state O
conditions O
, O
both O
in O
29 O
##3 O
cells O
and O
in O
he O
##la O
cells O
. O

further O
##more O
, O
at O
4 O
degrees O
c O
, O
the O
added O
soluble O
complex O
of O
h O
##fe O
/ O
beta O
##2 O
##m O
in O
##hibit O
##ed O
binding O
of O
transfer O
##rin O
to O
he O
##la O
cell O
t O
##f O
##r O
in O
a O
concentration O
- O
dependent O
manner O
. O

s O
##cat O
##chard O
plots O
of O
these O
data O
indicate O
that O
the O
added O
he O
##tero O
##di O
##mer O
substantially O
reduced O
the O
affinity O
of O
t O
##f O
##r O
for O
transfer O
##rin O
. O

these O
results O
establish O
a O
molecular O
link O
between O
h O
##fe O
and O
a O
key O
protein O
involved O
in O
iron O
transport O
, O
the O
t O
##f O
##r O
, O
and O
raise O
the O
possibility O
that O
alterations O
in O
this O
regulatory O
mechanism O
may O
play O
a O
role O
in O
the O
path O
##ogen O
##esis O
of O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
. O
. O

g O
##eno O
##mic O
organization O
of O
the O
u O
##be O
##3 O
##a O
/ O
e O
##6 O
- O
a O
##p O
gene O
and O
related O
pseudo O
##gene O
##s O
. O

the O
u O
##be O
##3 O
##a O
gene O
en O
##codes O
the O
e O
##6 O
- O
a O
##p O
u O
##bi O
##qui O
##tin O
- O
protein O
l O
##iga O
##se O
and O
has O
recently O
been O
shown O
to O
be O
m O
##uta O
##ted O
in O
angel B-Disease
##man I-Disease
syndrome I-Disease
patients O
who O
lack O
15 O
##q O
##11 O
- O
q O
##13 O
del O
##eti O
##ons O
or O
chromosome O
15 O
paternal O
un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
. O

previous O
u O
##be O
##3 O
##a O
c O
##dn O
##a O
analysis O
has O
shown O
a O
coding O
region O
of O
approximately O
2 O
. O

6 O
k O
##b O
and O
a O
3 O
- O
un O
##tra O
##ns O
##lated O
region O
( O
u O
##tr O
) O
of O
[UNK] O
50 O
b O
##p O
, O
whereas O
northern O
analysis O
has O
indicated O
m O
##rna O
sizes O
of O
5 O
- O
8 O
k O
##b O
. O

we O
have O
analyzed O
additional O
c O
##dn O
##a O
clone O
##s O
and O
provide O
evidence O
for O
an O
additional O
0 O
. O

5 O
k O
##b O
of O
5 O
- O
u O
##tr O
and O
[UNK] O
2 O
k O
##b O
of O
3 O
- O
u O
##tr O
. O

we O
have O
established O
the O
g O
##eno O
##mic O
organization O
of O
u O
##be O
##3 O
##a O
and O
the O
sequence O
of O
intro O
##n O
- O
ex O
##on O
borders O
. O

we O
have O
also O
mapped O
two O
highly O
ho O
##mo O
##log O
##ous O
processed O
pseudo O
##gene O
##s O
, O
u O
##be O
##3 O
##ap O
##1 O
and O
u O
##be O
##3 O
##ap O
##2 O
, O
to O
chromosome O
##s O
2 O
and O
21 O
, O
respectively O
, O
and O
determined O
their O
g O
##eno O
##mic O
organization O
. O

these O
results O
will O
form O
the O
basis O
for O
studies O
of O
mutation O
and O
imprint O
##ing O
of O
u O
##be O
##3 O
##a O
. O

mutation O
spectrum O
and O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
analyses O
in O
cow B-Disease
##den I-Disease
disease I-Disease
and O
ban B-Disease
##nay I-Disease
##an I-Disease
- I-Disease
z I-Disease
##ona I-Disease
##na I-Disease
syndrome I-Disease
, O
two O
ha B-Disease
##mart I-Disease
##oma I-Disease
syndrome I-Disease
##s I-Disease
with O
g O
##er O
##m O
##line O
p O
##ten O
mutation O
. O

the O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
p O
##ten O
, O
which O
maps O
to O
10 O
##q O
##23 O
. O

3 O
and O
en O
##codes O
a O
40 O
##3 O
amino O
acid O
dual O
specific O
##ity O
p O
##hos O
##pha O
##tase O
( O
protein O
t O
##yr O
##os O
##ine O
p O
##hos O
##pha O
##tase O
; O
p O
##t O
##pas O
##e O
) O
, O
was O
shown O
recently O
to O
play O
a O
broad O
role O
in O
human O
ma B-Disease
##li I-Disease
##gna I-Disease
##ncy I-Disease
. O

so O
##matic O
p O
##ten O
del O
##eti O
##ons O
and O
mutations O
were O
observed O
in O
s B-Disease
##poradic I-Disease
breast I-Disease
, I-Disease
brain I-Disease
, I-Disease
pro I-Disease
##state I-Disease
and I-Disease
kidney I-Disease
cancer I-Disease
cell O
lines O
and O
in O
several O
primary O
t B-Disease
##umour I-Disease
##s I-Disease
such O
as O
end B-Disease
##ome I-Disease
##tri I-Disease
##al I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
, O
ma B-Disease
##li I-Disease
##gnant I-Disease
me I-Disease
##lan I-Disease
##oma I-Disease
and O
thy B-Disease
##roid I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
. O

in O
addition O
, O
p O
##ten O
was O
identified O
as O
the O
su O
##s O
##ce O
##pt O
##ibility O
gene O
for O
two O
ha B-Disease
##mart I-Disease
##oma I-Disease
syndrome I-Disease
##s I-Disease
cow B-Disease
##den I-Disease
disease I-Disease
( O
c B-Disease
##d I-Disease
; O
mi O
##m O
158 O
##35 O
##0 O
) O
and O
ban B-Disease
##nay I-Disease
##an I-Disease
- I-Disease
z I-Disease
##ona I-Disease
##na I-Disease
( I-Disease
b I-Disease
##z I-Disease
##s I-Disease
) I-Disease
or I-Disease
r I-Disease
##u I-Disease
##val I-Disease
##ca I-Disease
##ba I-Disease
- I-Disease
r I-Disease
##ile I-Disease
##y I-Disease
- I-Disease
s I-Disease
##mith I-Disease
syndrome I-Disease
( O
mi O
##m O
153 O
##48 O
##0 O
) O
. O

con O
##st O
##it O
##utive O
d O
##na O
from O
37 O
c B-Disease
##d I-Disease
families O
and O
seven O
b B-Disease
##z I-Disease
##s I-Disease
families O
was O
screened O
for O
g O
##er O
##m O
##line O
p O
##ten O
mutations O
. O

p O
##ten O
mutations O
were O
identified O
in O
30 O
of O
37 O
( O
81 O
% O
) O
c B-Disease
##d I-Disease
families O
, O
including O
miss O
##ense O
and O
nonsense O
point O
mutations O
, O
del O
##eti O
##ons O
, O
insertion O
##s O
, O
a O
del O
##eti O
##on O
/ O
insertion O
and O
s O
##p O
##lice O
site O
mutations O
. O

these O
mutations O
were O
scattered O
over O
the O
entire O
length O
of O
p O
##ten O
, O
with O
the O
exception O
of O
the O
first O
, O
fourth O
and O
last O
ex O
##ons O
. O

a O
hot O
spot O
for O
p O
##ten O
mutation O
in O
c B-Disease
##d I-Disease
was O
identified O
in O
ex O
##on O
5 O
that O
contains O
the O
p O
##t O
##pas O
##e O
core O
motif O
, O
with O
13 O
of O
30 O
( O
43 O
% O
) O
c B-Disease
##d I-Disease
mutations O
identified O
in O
this O
ex O
##on O
. O

seven O
of O
30 O
( O
23 O
% O
) O
were O
within O
the O
core O
motif O
, O
the O
majority O
( O
five O
of O
seven O
) O
of O
which O
were O
miss O
##ense O
mutations O
, O
possibly O
pointing O
to O
the O
functional O
significance O
of O
this O
region O
. O

g O
##er O
##m O
##line O
p O
##ten O
mutations O
were O
identified O
in O
four O
of O
seven O
( O
57 O
% O
) O
b B-Disease
##z I-Disease
##s I-Disease
families O
studied O
. O

interesting O
##ly O
, O
none O
of O
these O
mutations O
was O
observed O
in O
the O
p O
##t O
##pas O
##e O
core O
motif O
. O

it O
is O
also O
worthy O
of O
note O
that O
a O
single O
nonsense O
point O
mutation O
, O
r O
##23 O
##3 O
##x O
, O
was O
observed O
in O
the O
g O
##er O
##m O
##line O
d O
##na O
from O
two O
unrelated O
c B-Disease
##d I-Disease
families O
and O
one O
b B-Disease
##z I-Disease
##s I-Disease
family O
. O

g O
##eno O
##type O
- O
p O
##hen O
##otype O
studies O
were O
not O
performed O
on O
this O
small O
group O
of O
b B-Disease
##z I-Disease
##s I-Disease
families O
. O

however O
, O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
analysis O
in O
##the O
group O
of O
c B-Disease
##d I-Disease
families O
revealed O
two O
possible O
associations O
worthy O
of O
follow O
- O
up O
in O
independent O
analyses O
. O

the O
first O
was O
an O
association O
noted O
in O
the O
group O
of O
c B-Disease
##d I-Disease
families O
with O
breast B-Disease
disease I-Disease
. O

a O
correlation O
was O
observed O
between O
the O
presence O
/ O
absence O
of O
a O
p O
##ten O
mutation O
and O
the O
type O
of O
breast O
involvement O
( O
un O
##af O
##fected O
versus O
ben O
##ign O
versus O
ma O
##li O
##gnant O
) O
. O

specifically O
and O
more O
directly O
, O
an O
association O
was O
also O
observed O
between O
the O
presence O
of O
a O
p O
##ten O
mutation O
and O
ma B-Disease
##li I-Disease
##gnant I-Disease
breast I-Disease
disease I-Disease
. O

secondly O
, O
there O
appeared O
to O
be O
an O
inter O
##de O
##pen O
##dent O
association O
between O
mutations O
upstream O
and O
within O
the O
p O
##t O
##pas O
##e O
core O
motif O
, O
the O
core O
motif O
containing O
the O
majority O
of O
miss O
##ense O
mutations O
, O
and O
the O
involvement O
of O
all O
major O
organ O
systems O
( O
central O
nervous O
system O
, O
thy O
##roid O
, O
breast O
, O
skin O
and O
gas O
##tro O
##int O
##est O
##inal O
tract O
) O
. O

however O
, O
these O
observations O
would O
need O
to O
be O
confirmed O
by O
studying O
a O
larger O
number O
of O
c B-Disease
##d I-Disease
families O
. O

molecular O
defects O
leading O
to O
human O
complement B-Disease
component I-Disease
c I-Disease
##6 I-Disease
deficiency I-Disease
in O
an O
a O
##f O
##rica O
##n O
- O
am O
##eric O
##an O
family O
. O

complement B-Disease
component I-Disease
c I-Disease
##6 I-Disease
deficiency I-Disease
( O
c B-Disease
##6 I-Disease
##d I-Disease
) O
was O
diagnosed O
in O
a O
16 O
- O
year O
- O
old O
a O
##f O
##rica O
##n O
- O
am O
##eric O
##an O
male O
with O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
. O

the O
patients O
father O
and O
two O
brothers O
also O
had O
c B-Disease
##6 I-Disease
##d I-Disease
, O
but O
gave O
no O
history O
of O
men B-Disease
##ing I-Disease
##itis I-Disease
or O
other O
ne B-Disease
##isse I-Disease
##rial I-Disease
infection I-Disease
. O

by O
using O
ex O
##on O
- O
specific O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
/ O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
as O
a O
screening O
step O
and O
n O
##uc O
##leo O
##tide O
se O
##quencing O
of O
target O
ex O
##ons O
, O
we O
determined O
that O
the O
pro O
##band O
was O
a O
compound O
he O
##tero O
##zy O
##got O
##e O
for O
two O
c O
##6 O
gene O
mutations O
. O

the O
first O
, O
119 O
##5 O
##del O
##c O
located O
in O
ex O
##on O
7 O
, O
is O
a O
novel O
mutation O
, O
while O
the O
second O
, O
1936 O
##del O
##g O
in O
ex O
##on O
12 O
, O
has O
been O
described O
before O
to O
cause O
c B-Disease
##6 I-Disease
##d I-Disease
in O
an O
unrelated O
a O
##f O
##rica O
##n O
- O
am O
##eric O
##an O
individual O
. O

both O
mutations O
result O
in O
premature O
termination O
co O
##don O
##s O
and O
c O
##6 O
null O
all O
##ele O
##s O
. O

all O
##ele O
- O
specific O
p O
##c O
##r O
indicated O
that O
the O
pro O
##band O
##s O
two O
brothers O
also O
inherited O
the O
119 O
##5 O
##del O
##c O
mutation O
from O
their O
he O
##tero O
##zy O
##go O
##us O
mother O
and O
the O
1936 O
##del O
##g O
mutation O
from O
their O
ho O
##mo O
##zy O
##go O
##us O
father O
. O
. O

p O
##ax O
##6 O
mutations O
reviewed O
. O

mutations O
in O
p O
##ax O
##6 O
are O
responsible O
for O
human O
an B-Disease
##iri I-Disease
##dia I-Disease
and O
have O
also O
been O
found O
in O
patients O
with O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
, O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
cat I-Disease
##ara I-Disease
##cts I-Disease
, O
with O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
k I-Disease
##era I-Disease
##titis I-Disease
, O
and O
with O
isolated B-Disease
f I-Disease
##ove I-Disease
##al I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
. O

no O
lo O
##cus O
other O
than O
chromosome O
11 O
##p O
##13 O
has O
been O
implicated O
in O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
and O
p O
##ax O
##6 O
is O
clearly O
the O
major O
, O
if O
not O
only O
, O
gene O
responsible O
. O

twenty O
- O
eight O
percent O
of O
identified O
p O
##ax O
##6 O
mutations O
are O
c O
- O
t O
changes O
at O
c O
##p O
##g O
din O
##uc O
##leo O
##tide O
##s O
, O
20 O
% O
are O
s O
##p O
##licing O
errors O
, O
and O
more O
than O
30 O
% O
are O
del O
##eti O
##on O
or O
insertion O
events O
. O

there O
is O
a O
notice O
##ably O
elevated O
level O
of O
mutation O
in O
the O
paired O
domain O
compared O
with O
the O
rest O
of O
the O
gene O
. O

increased O
mutation O
in O
the O
home O
##od O
##oma O
##in O
is O
accounted O
for O
by O
the O
h O
##yper O
##mu O
##table O
c O
##p O
##g O
din O
##uc O
##leo O
##tide O
in O
co O
##don O
240 O
. O

very O
nearly O
all O
mutations O
appear O
to O
cause O
loss O
of O
function O
of O
the O
mutant O
all O
##ele O
, O
and O
more O
than O
80 O
% O
of O
ex O
##onic O
substitution O
##s O
result O
in O
nonsense O
co O
##don O
##s O
. O

in O
a O
gene O
with O
such O
extra O
##ord O
##ina O
##rily O
high O
sequence O
conservation O
throughout O
evolution O
, O
there O
are O
presumed O
und O
##iscovered O
miss O
##ense O
mutations O
, O
these O
are O
h O
##y O
##pot O
##hes O
##ized O
to O
exist O
in O
as O
- O
yet O
unidentified O
p O
##hen O
##otype O
##s O
. O
. O

genetic O
he O
##tero O
##gene O
##ity O
and O
pen O
##et O
##rance O
analysis O
of O
the O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
genes O
in O
breast B-Disease
cancer I-Disease
families O
. O

the O
breast B-Disease
cancer I-Disease
link O
##age O
consortium O
. O

the O
contribution O
of O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
to O
inherited B-Disease
breast I-Disease
cancer I-Disease
was O
assessed O
by O
link O
##age O
and O
mutation O
analysis O
in O
237 O
families O
, O
each O
with O
at O
least O
four O
cases O
of O
breast B-Disease
cancer I-Disease
, O
collected O
by O
the O
breast B-Disease
cancer I-Disease
link O
##age O
consortium O
. O

families O
were O
included O
without O
regard O
to O
the O
occurrence O
of O
o B-Disease
##var I-Disease
##ian I-Disease
or I-Disease
other I-Disease
cancer I-Disease
##s I-Disease
. O

overall O
, O
disease O
was O
linked O
to O
br O
##ca O
##1 O
in O
an O
estimated O
52 O
% O
of O
families O
, O
to O
br O
##ca O
##2 O
in O
32 O
% O
of O
families O
, O
and O
to O
neither O
gene O
in O
16 O
% O
( O
95 O
% O
confidence O
interval O
[ O
c O
##i O
] O
6 O
% O
- O
28 O
% O
) O
, O
suggesting O
other O
pre O
##dis O
##position O
genes O
. O

the O
majority O
( O
81 O
% O
) O
of O
the O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
were O
due O
to O
br O
##ca O
##1 O
, O
with O
most O
others O
( O
14 O
% O
) O
due O
to O
br O
##ca O
##2 O
. O

con O
##verse O
##ly O
, O
the O
majority O
of O
families O
with O
male B-Disease
and I-Disease
female I-Disease
breast I-Disease
cancer I-Disease
were O
due O
to O
br O
##ca O
##2 O
( O
76 O
% O
) O
. O

the O
largest O
proportion O
( O
67 O
% O
) O
of O
families O
due O
to O
other O
genes O
was O
found O
in O
families O
with O
four O
or O
five O
cases O
of O
female O
breast B-Disease
cancer I-Disease
only O
. O

these O
estimates O
were O
not O
substantially O
affected O
either O
by O
changing O
the O
assumed O
pen O
##et O
##rance O
model O
for O
br O
##ca O
##1 O
or O
by O
including O
or O
excluding O
br O
##ca O
##1 O
mutation O
data O
. O

among O
those O
families O
with O
disease O
due O
to O
br O
##ca O
##1 O
that O
were O
tested O
by O
one O
of O
the O
standard O
screening O
methods O
, O
mutations O
were O
detected O
in O
the O
coding O
sequence O
or O
s O
##p O
##lice O
sites O
in O
an O
estimated O
63 O
% O
( O
95 O
% O
c O
##i O
51 O
% O
- O
77 O
% O
) O
. O

the O
estimated O
sensitivity O
was O
identical O
for O
direct O
se O
##quencing O
and O
other O
techniques O
. O

the O
pen O
##et O
##rance O
of O
br O
##ca O
##2 O
was O
estimated O
by O
ma O
##xi O
##mizing O
the O
lo O
##d O
score O
in O
br O
##ca O
##2 O
- O
mutation O
families O
, O
over O
all O
possible O
pen O
##et O
##rance O
functions O
. O

the O
estimated O
cumulative O
risk O
of O
breast B-Disease
cancer I-Disease
reached O
28 O
% O
( O
95 O
% O
c O
##i O
9 O
% O
- O
44 O
% O
) O
by O
age O
50 O
years O
and O
84 O
% O
( O
95 O
% O
c O
##i O
43 O
% O
- O
95 O
% O
) O
by O
age O
70 O
years O
. O

the O
corresponding O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
risks O
were O
0 O
. O

4 O
% O
( O
95 O
% O
c O
##i O
0 O
% O
- O
1 O
% O
) O
by O
age O
50 O
years O
and O
27 O
% O
( O
95 O
% O
c O
##i O
0 O
% O
- O
47 O
% O
) O
by O
age O
70 O
years O
. O

the O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
appears O
similar O
to O
the O
risk O
in O
br O
##ca O
##1 O
carriers O
, O
but O
there O
was O
some O
suggestion O
of O
a O
lower O
risk O
in O
br O
##ca O
##2 O
carriers O
[UNK] O
50 O
years O
of O
age O
. O

eye B-Disease
movement I-Disease
abnormal I-Disease
##ities I-Disease
co O
##rrel O
##ate O
with O
g O
##eno O
##type O
in O
auto O
##so O
##mal O
dominant O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
type I-Disease
i I-Disease
. O

we O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
sa O
##cca O
##des O
, O
anti O
##sa O
##cca O
##des O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
auto O
##so O
##mal O
dominant O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ias I-Disease
type I-Disease
i I-Disease
spin B-Disease
##oc I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ias I-Disease
1 I-Disease
and I-Disease
2 I-Disease
( O
s B-Disease
##ca I-Disease
##1 I-Disease
, O
n O
= O
11 O
; O
s B-Disease
##ca I-Disease
##2 I-Disease
, O
n O
= O
10 O
) O
and O
s B-Disease
##ca I-Disease
##3 I-Disease
/ O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
( O
m B-Disease
##j I-Disease
##d I-Disease
) O
( O
n O
= O
16 O
) O
. O

in O
s B-Disease
##ca I-Disease
##1 I-Disease
, O
sa O
##cca O
##de O
amplitude O
was O
significantly O
increased O
, O
resulting O
in O
h B-Disease
##yper I-Disease
##met I-Disease
##ria I-Disease
. O

the O
smooth O
pursuit O
gain O
was O
decreased O
. O

in O
s B-Disease
##ca I-Disease
##2 I-Disease
, O
sa O
##cca O
##de O
velocity O
was O
marked O
##ly O
decreased O
. O

the O
percentage O
of O
errors O
in O
anti O
##sa O
##cca O
##des O
was O
greatly O
increased O
and O
was O
significantly O
correlated O
with O
age O
at O
disease O
onset O
. O

in O
addition O
, O
a O
correlation O
between O
smooth O
pursuit O
gain O
and O
the O
number O
of O
t O
##rin O
##uc O
##leo O
##tide O
repeats O
was O
found O
. O

in O
s B-Disease
##ca I-Disease
##3 I-Disease
, O
gaze B-Disease
- I-Disease
e I-Disease
##voked I-Disease
n I-Disease
##ys I-Disease
##tag I-Disease
##mus I-Disease
was O
often O
present O
as O
was O
sa O
##cca O
##de O
h O
##y O
##po O
##met O
##ria O
and O
smooth O
pursuit O
gain O
was O
marked O
##ly O
decreased O
. O

three O
major O
criteria O
, O
sa O
##cca O
##de O
amplitude O
, O
sa O
##cca O
##de O
velocity O
, O
and O
presence O
of O
gaze B-Disease
- I-Disease
e I-Disease
##voked I-Disease
n I-Disease
##ys I-Disease
##tag I-Disease
##mus I-Disease
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
s B-Disease
##ca I-Disease
##1 I-Disease
, O
90 O
% O
of O
the O
s B-Disease
##ca I-Disease
##2 I-Disease
, O
and O
93 O
% O
of O
the O
patients O
with O
s B-Disease
##ca I-Disease
##3 I-Disease
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
or O
##ient O
di O
##ag O
##nose O
##s O
of O
s B-Disease
##ca I-Disease
##1 I-Disease
, O
s B-Disease
##ca I-Disease
##2 I-Disease
, O
and O
s B-Disease
##ca I-Disease
##3 I-Disease
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

genetic O
basis O
and O
molecular O
mechanism O
for O
id B-Disease
##io I-Disease
##pathic I-Disease
vent I-Disease
##ric I-Disease
##ular I-Disease
fi I-Disease
##bri I-Disease
##lla I-Disease
##tion I-Disease
. O

vent B-Disease
##ric I-Disease
##ular I-Disease
fi I-Disease
##bri I-Disease
##lla I-Disease
##tion I-Disease
causes O
more O
than O
300 O
, O
000 O
sudden O
deaths O
each O
year O
in O
the O
us O
##a O
alone O
. O

in O
approximately O
5 O
- O
12 O
% O
of O
these O
cases O
, O
there O
are O
no O
demons O
##tra O
##ble O
cardiac O
or O
non O
- O
cardiac O
causes O
to O
account O
for O
the O
episode O
, O
which O
is O
therefore O
classified O
as O
id B-Disease
##io I-Disease
##pathic I-Disease
vent I-Disease
##ric I-Disease
##ular I-Disease
fi I-Disease
##bri I-Disease
##lla I-Disease
##tion I-Disease
( O
i B-Disease
##v I-Disease
##f I-Disease
) O
. O

a O
distinct O
group O
of O
i B-Disease
##v I-Disease
##f I-Disease
patients O
has O
been O
found O
to O
present O
with O
a O
characteristic O
electro O
##card O
##io O
##graphic O
pattern O
. O

because O
of O
the O
small O
size O
of O
most O
p O
##ed O
##ig O
##ree O
##s O
and O
the O
high O
incidence O
of O
sudden B-Disease
death I-Disease
, O
however O
, O
molecular O
genetic O
studies O
of O
i B-Disease
##v I-Disease
##f I-Disease
have O
not O
yet O
been O
done O
. O

because O
i B-Disease
##v I-Disease
##f I-Disease
causes O
cardiac O
rhythm O
disturbance O
, O
we O
investigated O
whether O
ma O
##lf O
##un O
##ction O
of O
ion O
channels O
could O
cause O
the O
disorder O
by O
studying O
mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
s O
##c O
##n O
##5 O
##a O
. O

we O
have O
now O
identified O
a O
miss O
##ense O
mutation O
, O
a O
s O
##p O
##lice O
- O
donor O
mutation O
, O
and O
a O
frames O
##hi O
##ft O
mutation O
in O
the O
coding O
region O
of O
s O
##c O
##n O
##5 O
##a O
in O
three O
i B-Disease
##v I-Disease
##f I-Disease
families O
. O

we O
show O
that O
sodium O
channels O
with O
the O
miss O
##ense O
mutation O
recover O
from O
in O
##act O
##ivation O
more O
rapidly O
than O
normal O
and O
that O
the O
frames O
##hi O
##ft O
mutation O
causes O
the O
sodium O
channel O
to O
be O
non O
- O
functional O
. O

our O
results O
indicate O
that O
mutations O
in O
cardiac O
ion O
- O
channel O
genes O
contribute O
to O
the O
risk O
of O
developing O
i B-Disease
##v I-Disease
##f I-Disease
. O
. O

molecular O
he O
##tero O
##gene O
##ity O
in O
m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
i I-Disease
##va I-Disease
in O
au O
##stra O
##lia O
and O
northern O
i O
##rel O
##and O
: O
nine O
novel O
mutations O
including O
t O
##31 O
##2 O
##s O
, O
a O
common O
all O
##ele O
that O
con O
##fers O
a O
mild O
p O
##hen O
##otype O
. O

m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
i I-Disease
##va I-Disease
( O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
l I-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
genetic B-Disease
defect I-Disease
in O
n O
- O
ace O
##ty O
##l O
##gal O
##act O
##osa O
##mine O
- O
6 O
- O
su O
##lf O
##ate O
su O
##lf O
##ata O
##se O
( O
gal O
##ns O
) O
. O

previous O
studies O
of O
patients O
from O
a O
br O
##itis O
##h O
- O
i O
##ris O
##h O
population O
showed O
that O
the O
i O
##11 O
##3 O
##f O
mutation O
is O
the O
most O
common O
single O
mutation O
among O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
patients O
and O
produces O
a O
severe O
clinical O
p O
##hen O
##otype O
. O

we O
studied O
mutations O
in O
the O
gal O
##ns O
gene O
from O
23 O
additional O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
patients O
( O
15 O
from O
au O
##stra O
##lia O
, O
8 O
from O
northern O
i O
##rel O
##and O
) O
, O
with O
various O
clinical O
p O
##hen O
##otype O
##s O
( O
severe O
, O
16 O
cases O
; O
intermediate O
, O
4 O
cases O
; O
mild O
, O
3 O
cases O
) O
. O

we O
found O
two O
common O
mutations O
that O
together O
accounted O
for O
32 O
% O
of O
the O
44 O
unrelated O
all O
##ele O
##s O
in O
these O
patients O
. O

one O
is O
the O
t O
##31 O
##2 O
##s O
mutation O
, O
a O
novel O
mutation O
found O
exclusively O
in O
mild O
##er O
patients O
. O

the O
other O
is O
the O
previously O
described O
i O
##11 O
##3 O
##f O
that O
produces O
a O
severe O
p O
##hen O
##otype O
. O

the O
i O
##11 O
##3 O
##f O
and O
t O
##31 O
##2 O
##s O
mutations O
accounted O
for O
8 O
( O
18 O
% O
) O
and O
6 O
( O
14 O
% O
) O
of O
44 O
unrelated O
all O
##ele O
##s O
, O
respectively O
. O

the O
relatively O
high O
residual O
gal O
##ns O
activity O
seen O
when O
the O
t O
##31 O
##2 O
##s O
mutant O
c O
##dn O
##a O
is O
over O
##ex O
##pressed O
in O
mutant O
cells O
provides O
an O
explanation O
for O
the O
mild O
p O
##hen O
##otype O
in O
patients O
with O
this O
mutation O
. O

the O
distribution O
and O
relative O
frequencies O
of O
the O
i O
##11 O
##3 O
##f O
and O
t O
##31 O
##2 O
##s O
mutations O
in O
au O
##stra O
##lia O
correspond O
##ed O
to O
those O
observed O
in O
northern O
i O
##rel O
##and O
and O
are O
unique O
to O
these O
two O
populations O
, O
suggesting O
that O
both O
mutations O
were O
probably O
introduced O
to O
au O
##stra O
##lia O
by O
i O
##ris O
##h O
migrants O
during O
the O
19th O
century O
. O

ha O
##p O
##lot O
##ype O
analysis O
using O
6 O
r O
##f O
##l O
##ps O
provides O
additional O
data O
that O
the O
i O
##11 O
##3 O
##f O
mutation O
originated O
from O
a O
common O
ancestor O
. O

the O
other O
9 O
novel O
mutations O
identified O
in O
these O
23 O
patients O
were O
each O
limited O
to O
a O
single O
family O
. O

these O
data O
provide O
further O
evidence O
for O
extensive O
all O
##eli O
##c O
he O
##tero O
##gene O
##ity O
in O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
in O
br O
##itis O
##h O
- O
i O
##ris O
##h O
patients O
and O
provide O
evidence O
for O
their O
transmission O
to O
au O
##stra O
##lia O
by O
br O
##itis O
##h O
- O
i O
##ris O
##h O
migrants O
. O
. O

identification O
of O
constitutional O
w O
##t O
##1 O
mutations O
, O
in O
patients O
with O
isolated O
di B-Disease
##ff I-Disease
##use I-Disease
me I-Disease
##sang I-Disease
##ial I-Disease
s I-Disease
##cle I-Disease
##rosis I-Disease
, O
and O
analysis O
of O
g O
##eno O
##type O
/ O
p O
##hen O
##otype O
correlation O
##s O
by O
use O
of O
a O
computer O
##ized O
mutation O
database O
. O

constitutional O
mutations O
of O
the O
w O
##t O
##1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
re O
##nal O
and O
go O
##na O
##dal O
development O
, O
are O
found O
in O
most O
patients O
with O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
( O
d B-Disease
##ds I-Disease
) O
, O
or O
di B-Disease
##ff I-Disease
##use I-Disease
me I-Disease
##sang I-Disease
##ial I-Disease
s I-Disease
##cle I-Disease
##rosis I-Disease
( O
d B-Disease
##ms I-Disease
) O
associated O
with O
pseudo B-Disease
##her I-Disease
##ma I-Disease
##ph I-Disease
##rod I-Disease
##itis I-Disease
##m I-Disease
and O
/ O
or O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
( O
w B-Disease
##t I-Disease
) O
. O

most O
mutations O
in O
d B-Disease
##ds I-Disease
patients O
lie O
in O
ex O
##on O
8 O
or O
ex O
##on O
9 O
, O
encoding O
zinc O
finger O
2 O
or O
zinc O
finger O
3 O
, O
respectively O
, O
with O
a O
hot O
spot O
( O
r O
##39 O
##4 O
##w O
) O
in O
ex O
##on O
9 O
. O

we O
analyzed O
a O
series O
of O
24 O
patients O
, O
10 O
with O
isolated B-Disease
d I-Disease
##ms I-Disease
( O
id B-Disease
##ms I-Disease
) O
, O
10 O
with O
d B-Disease
##ds I-Disease
, O
and O
4 O
with O
u B-Disease
##rogen I-Disease
##ital I-Disease
abnormal I-Disease
##ities I-Disease
and O
/ O
or O
w B-Disease
##t I-Disease
. O

we O
report O
w O
##t O
##1 O
he O
##tero O
##zy O
##go O
##us O
mutations O
in O
16 O
patients O
, O
4 O
of O
whom O
presented O
with O
id B-Disease
##ms I-Disease
. O

one O
male O
and O
two O
female O
id B-Disease
##ms I-Disease
patients O
with O
w O
##t O
##1 O
mutations O
underwent O
normal O
pub O
##erty O
. O

two O
mutations O
associated O
with O
id B-Disease
##ms I-Disease
are O
different O
from O
those O
described O
in O
d B-Disease
##ds I-Disease
patients O
. O

no O
w O
##t O
##1 O
mutations O
were O
detected O
in O
the O
six O
other O
id B-Disease
##ms I-Disease
patients O
, O
suggesting O
genetic O
he O
##tero O
##gene O
##ity O
of O
this O
disease O
. O

we O
analyzed O
g O
##eno O
##type O
/ O
p O
##hen O
##otype O
correlation O
##s O
, O
on O
the O
basis O
of O
the O
constitution O
of O
a O
w O
##t O
##1 O
mutation O
database O
of O
84 O
g O
##er O
##m O
- O
line O
mutations O
, O
to O
compare O
the O
distribution O
and O
type O
of O
mutations O
, O
according O
to O
the O
different O
symptoms O
. O

this O
demonstrated O
( O
1 O
) O
the O
association O
between O
mutations O
in O
ex O
##ons O
8 O
and O
9 O
and O
d B-Disease
##ms I-Disease
; O
( O
2 O
) O
among O
patients O
with O
d B-Disease
##ms I-Disease
, O
a O
higher O
frequency O
of O
ex O
##on O
8 O
mutations O
among O
46 O
, O
x O
##y O
patients O
with O
female O
p O
##hen O
##otype O
than O
among O
46 O
, O
x O
##y O
patients O
with O
sexual O
am O
##bi O
##gu O
##ity O
or O
male O
p O
##hen O
##otype O
; O
and O
( O
3 O
) O
statistical O
##ly O
significant O
evidence O
that O
mutations O
in O
ex O
##ons O
8 O
and O
9 O
prefer O
##ential O
##ly O
affect O
amino O
acids O
with O
different O
functions O
. O
. O

the O
185 O
##dela O
##g O
br O
##ca O
##1 O
mutation O
originated O
before O
the O
di O
##sper O
##sion O
of O
j O
##ews O
in O
the O
diaspora O
and O
is O
not O
limited O
to O
ash O
##ken O
##azi O
##m O
. O

the O
185 O
##dela O
##g O
mutation O
in O
br O
##ca O
##1 O
is O
detected O
in O
ash O
##ken O
##azi O
j O
##ews O
both O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
and O
in O
the O
general O
population O
. O

all O
tested O
ash O
##ken O
##azi O
mutation O
carriers O
share O
the O
same O
all O
##eli O
##c O
pattern O
at O
the O
br O
##ca O
##1 O
lo O
##cus O
. O

our O
previous O
study O
showed O
that O
this O
ash O
##ken O
##azi O
mutation O
also O
occurs O
in O
i O
##ra O
##qi O
j O
##ews O
with O
a O
similar O
all O
##eli O
##c O
pattern O
. O

we O
extended O
our O
analysis O
to O
other O
non O
- O
ash O
##ken O
##azi O
subset O
##s O
35 O
##4 O
of O
m O
##oro O
##cca O
##n O
origin O
, O
200 O
ye O
##men O
##ites O
and O
150 O
i O
##rani O
##an O
j O
##ews O
. O

he O
##tero O
##du O
##plex O
analysis O
complement O
##ed O
by O
direct O
d O
##na O
se O
##quencing O
of O
abnormal O
##ly O
mi O
##grating O
bands O
were O
employed O
. O

four O
of O
m O
##oro O
##cca O
##n O
origin O
( O
1 O
. O
1 O
% O
) O
and O
none O
of O
the O
ye O
##men O
##ites O
or O
i O
##rani O
##ans O
was O
a O
carrier O
of O
the O
185 O
##dela O
##g O
mutation O
. O

br O
##ca O
##1 O
all O
##eli O
##c O
patterns O
were O
determined O
for O
four O
of O
these O
individuals O
and O
for O
12 O
additional O
non O
- O
ash O
##ken O
##azi O
185 O
##dela O
##g O
mutation O
carriers O
who O
had O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

six O
non O
- O
ash O
##ken O
##azi O
individuals O
shared O
the O
common O
ash O
##ken O
##azi O
ha O
##p O
##lot O
##ype O
, O
four O
had O
a O
closely O
related O
pattern O
, O
and O
the O
rest O
( O
n O
= O
6 O
) O
displayed O
a O
distinct O
br O
##ca O
##1 O
all O
##eli O
##c O
pattern O
. O

we O
conclude O
that O
the O
185 O
##dela O
##g O
br O
##ca O
##1 O
mutation O
occurs O
in O
some O
non O
- O
ash O
##ken O
##azi O
populations O
at O
rates O
comparable O
with O
that O
of O
ash O
##ken O
##azi O
##m O
. O

the O
majority O
of O
j O
##ew O
##ish O
185 O
##dela O
##g O
mutation O
carriers O
have O
a O
common O
all O
##eli O
##c O
pattern O
, O
supporting O
the O
founder O
effect O
notion O
, O
but O
dating O
the O
mutations O
origin O
to O
an O
earlier O
date O
than O
currently O
estimated O
. O

however O
, O
the O
different O
all O
##eli O
##c O
pattern O
at O
the O
br O
##ca O
##1 O
lo O
##cus O
even O
in O
some O
j O
##ew O
##ish O
mutation O
carriers O
, O
might O
suggest O
that O
the O
mutation O
arose O
independently O
. O
. O

crystal O
structure O
of O
the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
protein O
h O
##fe O
and O
characterization O
of O
its O
interaction O
with O
transfer O
##rin O
receptor O
. O

h O
##fe O
is O
an O
m O
##h O
##c O
- O
related O
protein O
that O
is O
m O
##uta O
##ted O
in O
the O
iron B-Disease
- I-Disease
over I-Disease
##load I-Disease
disease I-Disease
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
. O

h O
##fe O
binds O
to O
transfer O
##rin O
receptor O
( O
t O
##f O
##r O
) O
and O
reduces O
its O
affinity O
for O
iron O
- O
loaded O
transfer O
##rin O
, O
imp O
##lica O
##ting O
h O
##fe O
in O
iron O
metabolism O
. O

the O
2 O
. O

6 O
a O
crystal O
structure O
of O
h O
##fe O
reveals O
the O
locations O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
mutations O
and O
a O
patch O
of O
his O
##ti O
##dine O
##s O
that O
could O
be O
involved O
in O
p O
##h O
- O
dependent O
interactions O
. O

we O
also O
demonstrate O
that O
soluble O
t O
##f O
##r O
and O
h O
##fe O
bind O
tightly O
at O
the O
basic O
p O
##h O
of O
the O
cell O
surface O
, O
but O
not O
at O
the O
acidic O
p O
##h O
of O
in O
##tra O
##cellular O
ve O
##si O
##cles O
. O

t O
##f O
##r O
h O
##fe O
s O
##to O
##ichi O
##ome O
##try O
( O
2 O
1 O
) O
differs O
from O
t O
##f O
##r O
transfer O
##rin O
s O
##to O
##ichi O
##ome O
##try O
( O
2 O
2 O
) O
, O
implying O
a O
different O
mode O
of O
binding O
for O
h O
##fe O
and O
transfer O
##rin O
to O
t O
##f O
##r O
, O
consistent O
with O
our O
demonstration O
that O
h O
##fe O
, O
transfer O
##rin O
, O
and O
t O
##f O
##r O
form O
a O
te O
##rna O
##ry O
complex O
. O

identification O
of O
three O
novel O
mutations O
and O
a O
high O
frequency O
of O
the O
a O
##rg O
##7 O
##7 O
##8 O
##le O
##u O
mutation O
in O
k O
##ore O
##an O
patients O
with O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
. O

four O
mutations O
- O
- O
r O
##7 O
##7 O
##8 O
##l O
, O
a O
##8 O
##7 O
##4 O
##v O
, O
l O
##10 O
##8 O
##3 O
##f O
, O
and O
230 O
##4 O
##del O
##c O
- O
- O
in O
the O
copper O
- O
transporting O
enzyme O
, O
p O
- O
type O
at O
##pas O
##e O
( O
at O
##p O
##7 O
##b O
) O
, O
were O
identified O
in O
k O
##ore O
##an O
patients O
with O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
. O

a O
##rg O
##7 O
##7 O
##8 O
##le O
##u O
, O
the O
most O
frequently O
reported O
mutation O
of O
this O
enzyme O
, O
was O
found O
in O
six O
of O
eight O
unrelated O
patients O
studied O
, O
an O
all O
##ele O
frequency O
of O
37 O
. O

5 O
% O
, O
which O
is O
considerably O
higher O
than O
those O
in O
other O
as O
##ian O
populations O
. O

the O
novel O
single O
n O
##uc O
##leo O
##tide O
del O
##eti O
##on O
, O
230 O
##4 O
##del O
##c O
, O
was O
found O
in O
one O
patient O
. O

since O
a O
mutation O
at O
c O
##dn O
##a O
n O
##uc O
##leo O
##tide O
230 O
##2 O
( O
230 O
##2 O
##ins O
##c O
) O
had O
been O
previously O
described O
, O
this O
region O
of O
the O
at O
##p O
##7 O
##b O
gene O
may O
be O
susceptible O
to O
gene O
rear O
##rang O
##ement O
##s O
causing O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
. O

disruption O
of O
s O
##p O
##licing O
regulated O
by O
a O
cu O
##g O
- O
binding O
protein O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
caused O
by O
a O
c O
##t O
##g O
expansion O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
the O
d B-Disease
##m I-Disease
gene O
. O

one O
model O
of O
d B-Disease
##m I-Disease
path O
##ogen O
##esis O
suggests O
that O
r O
##nas O
from O
the O
expanded O
all O
##ele O
create O
a O
gain O
- O
of O
- O
function O
mutation O
by O
the O
inappropriate O
binding O
of O
proteins O
to O
the O
cu O
##g O
repeats O
. O

data O
presented O
here O
indicate O
that O
the O
conserved O
he O
##tero O
##gene O
##ous O
nuclear O
rib O
##on O
##uc O
##leo O
##p O
##rote O
##in O
, O
cu O
##g O
- O
binding O
protein O
( O
cu O
##g O
- O
b O
##p O
) O
, O
may O
media O
##te O
the O
trans O
- O
dominant O
effect O
of O
the O
r O
##na O
. O

cu O
##g O
- O
b O
##p O
was O
found O
to O
bind O
to O
the O
human O
cardiac O
t O
##rop O
##oni O
##n O
t O
( O
c O
##t O
##nt O
) O
pre O
- O
messenger O
r O
##na O
and O
regulate O
its O
alternative O
s O
##p O
##licing O
. O

s O
##p O
##licing O
of O
c O
##t O
##nt O
was O
disrupted O
in O
d B-Disease
##m I-Disease
s O
##tri O
##ated O
muscle O
and O
in O
normal O
cells O
expressing O
trans O
##cripts O
that O
contain O
cu O
##g O
repeats O
. O

altered O
expression O
of O
genes O
regulated O
post O
##tra O
##ns O
##cription O
##ally O
by O
cu O
##g O
- O
b O
##p O
therefore O
may O
contribute O
to O
d B-Disease
##m I-Disease
path O
##ogen O
##esis O
. O
. O

identification O
of O
a O
novel O
nonsense O
mutation O
and O
a O
miss O
##ense O
substitution O
in O
the O
v O
##as O
##op O
##ress O
##in O
- O
ne O
##uro O
##phy O
##sin O
ii O
gene O
in O
two O
span O
##ish O
kind O
##red O
##s O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
. O

f B-Disease
##ami I-Disease
##lial I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
( O
f B-Disease
##ndi I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disease I-Disease
caused O
by O
deficiency O
in O
the O
anti O
##di O
##ure O
##tic O
hormone O
a O
##rg O
##ini O
##ne O
v O
##as O
##op O
##ress O
##in O
( O
a O
##v O
##p O
) O
encoded O
by O
the O
a O
##v O
##p O
- O
ne O
##uro O
##phy O
##sin O
ii O
( O
a O
##v O
##p O
- O
n O
##pi O
##i O
) O
gene O
on O
chromosome O
20 O
##p O
##13 O
. O

in O
this O
study O
, O
we O
analyzed O
two O
families O
with O
f B-Disease
##ndi I-Disease
using O
direct O
automated O
fluorescent O
, O
solid O
phase O
, O
single O
- O
stranded O
d O
##na O
se O
##quencing O
of O
p O
##c O
##r O
- O
am O
##plified O
a O
##v O
##p O
- O
n O
##pi O
##i O
d O
##na O
. O

in O
one O
of O
the O
families O
, O
affected O
individuals O
presented O
a O
novel O
nonsense O
mutation O
in O
ex O
##on O
3 O
of O
the O
gene O
, O
consisting O
in O
a O
g O
to O
t O
transition O
at O
n O
##uc O
##leo O
##tide O
210 O
##1 O
, O
which O
produces O
a O
stop O
signal O
in O
co O
##don O
82 O
( O
g O
##lu O
) O
of O
n O
##pi O
##i O
. O

the O
premature O
termination O
eliminate O
##s O
part O
of O
the O
c O
- O
terminal O
domain O
of O
n O
##pi O
##i O
, O
including O
a O
c O
##ys O
##tein O
##e O
residue O
in O
position O
85 O
, O
which O
could O
be O
involved O
in O
the O
correct O
folding O
of O
the O
pro O
##hor O
##mon O
##e O
. O

in O
the O
second O
family O
, O
a O
g O
##27 O
##9 O
##a O
substitution O
at O
position O
- O
1 O
of O
the O
signal O
p O
##eptide O
was O
observed O
in O
all O
affected O
individuals O
. O

this O
miss O
##ense O
mutation O
, O
which O
replaces O
al O
##a O
with O
th O
##r O
, O
is O
frequent O
among O
f B-Disease
##ndi I-Disease
patients O
and O
is O
thought O
to O
reduce O
the O
efficiency O
of O
c O
##lea O
##vage O
by O
signal O
p O
##ept O
##idas O
##es O
. O
. O

genetic O
he O
##tero O
##gene O
##ity O
of O
sa B-Disease
##eth I-Disease
##re I-Disease
- I-Disease
ch I-Disease
##ot I-Disease
##zen I-Disease
syndrome I-Disease
, O
due O
to O
twist O
and O
f O
##g O
##f O
##r O
mutations O
. O

thirty O
- O
two O
unrelated O
patients O
with O
features O
of O
sa B-Disease
##eth I-Disease
##re I-Disease
- I-Disease
ch I-Disease
##ot I-Disease
##zen I-Disease
syndrome I-Disease
, O
a O
common O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
condition I-Disease
of O
c B-Disease
##rani I-Disease
##osy I-Disease
##nos I-Disease
##tosis I-Disease
and O
limb B-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
, O
were O
screened O
for O
mutations O
in O
twist O
, O
f O
##g O
##f O
##r O
##2 O
, O
and O
f O
##g O
##f O
##r O
##3 O
. O

nine O
novel O
and O
three O
re O
##current O
twist O
mutations O
were O
found O
in O
12 O
families O
. O

seven O
families O
were O
found O
to O
have O
the O
f O
##g O
##f O
##r O
##3 O
p O
##25 O
##0 O
##r O
mutation O
, O
and O
one O
individual O
was O
found O
to O
have O
an O
f O
##g O
##f O
##r O
##2 O
v O
##v O
##26 O
##9 O
- O
270 O
del O
##eti O
##on O
. O

to O
date O
, O
our O
detection O
rate O
for O
twist O
or O
f O
##g O
##f O
##r O
mutations O
is O
68 O
% O
in O
our O
sa B-Disease
##eth I-Disease
##re I-Disease
- I-Disease
ch I-Disease
##ot I-Disease
##zen I-Disease
syndrome I-Disease
patients O
, O
including O
our O
five O
patients O
elsewhere O
reported O
with O
twist O
mutations O
. O

more O
than O
35 O
different O
twist O
mutations O
are O
now O
known O
in O
the O
literature O
. O

the O
most O
common O
p O
##hen O
##otypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
twist O
mutations O
, O
are O
co B-Disease
##rona I-Disease
##l I-Disease
s I-Disease
##yn I-Disease
##ost I-Disease
##osis I-Disease
, O
bra B-Disease
##chy I-Disease
##ce I-Disease
##pha I-Disease
##ly I-Disease
, O
low B-Disease
frontal I-Disease
hair I-Disease
##line I-Disease
, O
facial B-Disease
as I-Disease
##ym I-Disease
##metry I-Disease
, O
p B-Disease
##tosis I-Disease
, O
h B-Disease
##yper I-Disease
##tel I-Disease
##oris I-Disease
##m I-Disease
, O
broad B-Disease
great I-Disease
toes I-Disease
, O
and O
c B-Disease
##lino I-Disease
##da I-Disease
##ct I-Disease
##yl I-Disease
##y I-Disease
. O

significant O
in O
##tra O
- O
and O
inter O
##fa O
##mi O
##lial O
p O
##hen O
##otypic O
var O
##iability O
is O
present O
for O
either O
twist O
mutations O
or O
f O
##g O
##f O
##r O
mutations O
. O

the O
overlap O
in O
clinical O
features O
and O
the O
presence O
, O
in O
the O
same O
genes O
, O
of O
mutations O
for O
more O
than O
one O
c B-Disease
##rani I-Disease
##osy I-Disease
##nos I-Disease
##to I-Disease
##tic I-Disease
condition I-Disease
- O
such O
as O
sa B-Disease
##eth I-Disease
##re I-Disease
- I-Disease
ch I-Disease
##ot I-Disease
##zen I-Disease
, I-Disease
c I-Disease
##rou I-Disease
##zon I-Disease
, I-Disease
and I-Disease
p I-Disease
##fe I-Disease
##iff I-Disease
##er I-Disease
syndrome I-Disease
##s I-Disease
- O
support O
the O
hypothesis O
that O
twist O
and O
f O
##g O
##f O
##rs O
are O
components O
of O
the O
same O
molecular O
pathway O
involved O
in O
the O
m O
##od O
##ulation O
of O
c O
##rani O
##of O
##ac O
##ial O
and O
limb O
development O
in O
humans O
. O
. O

mutation O
analysis O
of O
u O
##be O
##3 O
##a O
in O
angel B-Disease
##man I-Disease
syndrome I-Disease
patients O
. O

angel B-Disease
##man I-Disease
syndrome I-Disease
( O
as B-Disease
) O
is O
caused O
by O
chromosome O
15 O
##q O
##11 O
- O
q O
##13 O
del O
##eti O
##ons O
of O
maternal O
origin O
, O
by O
paternal O
un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
( O
up B-Disease
##d I-Disease
) O
15 O
, O
by O
imprint O
##ing O
defects O
, O
and O
by O
mutations O
in O
the O
u O
##be O
##3 O
##a O
gene O
. O

u O
##be O
##3 O
##a O
en O
##codes O
a O
u O
##bi O
##qui O
##tin O
- O
protein O
l O
##iga O
##se O
and O
shows O
brain O
- O
specific O
imprint O
##ing O
. O

here O
we O
describe O
u O
##be O
##3 O
##a O
coding O
- O
region O
mutations O
detected O
by O
s O
##s O
##c O
##p O
analysis O
in O
13 O
as B-Disease
individuals O
or O
families O
. O

two O
identical O
de O
no O
##vo O
5 O
- O
b O
##p O
du O
##plication O
##s O
in O
ex O
##on O
16 O
were O
found O
. O

among O
the O
other O
11 O
unique O
mutations O
, O
8 O
were O
small O
del O
##eti O
##ons O
or O
insertion O
##s O
predicted O
to O
cause O
frames O
##hi O
##fts O
, O
1 O
was O
a O
mutation O
to O
a O
stop O
co O
##don O
, O
1 O
was O
a O
miss O
##ense O
mutation O
, O
and O
1 O
was O
predicted O
to O
cause O
insertion O
of O
an O
is O
##ole O
##uc O
##ine O
in O
the O
he O
##ct O
domain O
of O
the O
u O
##be O
##3 O
##a O
protein O
, O
which O
functions O
in O
e O
##2 O
binding O
and O
u O
##bi O
##qui O
##tin O
transfer O
. O

eight O
of O
the O
cases O
were O
f O
##ami O
##lial O
, O
and O
five O
were O
s O
##poradic O
. O

in O
two O
f O
##ami O
##lial O
cases O
and O
one O
s O
##poradic O
case O
, O
mosaic O
##ism O
for O
u O
##be O
##3 O
##a O
mutations O
was O
detected O
in O
the O
mother O
of O
three O
as B-Disease
sons O
, O
in O
the O
maternal O
grandfather O
of O
two O
as B-Disease
first O
cousins O
, O
and O
in O
the O
mother O
of O
an O
as B-Disease
daughter O
. O

the O
frequencies O
with O
which O
we O
detected O
mutations O
were O
5 O
( O
14 O
% O
) O
of O
35 O
in O
s O
##poradic O
cases O
and O
8 O
( O
80 O
% O
) O
of O
10 O
in O
f O
##ami O
##lial O
cases O
. O
. O

the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
84 O
##5 O
g O
- O
- O
[UNK] O
a O
and O
187 O
c O
- O
- O
[UNK] O
g O
mutations O
: O
prevalence O
in O
non O
- O
ca O
##uca O
##sian O
populations O
. O

hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
, O
the O
inherited B-Disease
disorder I-Disease
of I-Disease
iron I-Disease
metabolism I-Disease
, O
leads O
, O
if O
un O
##tre O
##ated O
, O
to O
progressive O
iron B-Disease
over I-Disease
##load I-Disease
and O
premature B-Disease
death I-Disease
. O

the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
gene O
, O
h O
##fe O
, O
recently O
has O
been O
identified O
, O
and O
characterization O
of O
this O
gene O
has O
shown O
that O
it O
contains O
two O
mutations O
that O
result O
in O
amino O
acid O
substitution O
##s O
- O
c O
##dn O
##a O
n O
##uc O
##leo O
##tide O
##s O
84 O
##5 O
g O
- O
- O
[UNK] O
a O
( O
c O
##28 O
##2 O
##y O
) O
and O
187 O
c O
- O
- O
[UNK] O
g O
( O
h O
##6 O
##3 O
##d O
) O
. O

although O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
is O
common O
in O
ca O
##uca O
##sian O
##s O
, O
affecting O
[UNK] O
= O
1 O
/ O
300 O
individuals O
of O
northern O
euro O
##pe O
##an O
origin O
, O
it O
has O
not O
been O
recognized O
in O
other O
populations O
. O

the O
present O
study O
used O
p O
##c O
##r O
and O
restriction O
- O
enzyme O
dig O
##est O
##ion O
to O
analyze O
the O
frequency O
of O
the O
84 O
##5 O
g O
- O
- O
[UNK] O
a O
and O
187 O
c O
- O
- O
[UNK] O
g O
mutations O
in O
h O
##la O
- O
typed O
samples O
from O
non O
- O
ca O
##uca O
##sian O
populations O
, O
comprising O
au O
##stra O
##lian O
a O
##bor O
##igi O
##nal O
, O
chin O
##ese O
, O
and O
p O
##ac O
##ific O
island O
##ers O
. O

results O
showed O
that O
the O
84 O
##5 O
g O
- O
- O
[UNK] O
a O
mutation O
was O
present O
in O
these O
populations O
( O
all O
##ele O
frequency O
0 O
. O
32 O
% O
) O
, O
and O
, O
further O
##more O
, O
it O
was O
always O
seen O
in O
conjunction O
with O
h O
##la O
ha O
##p O
##lot O
##ype O
##s O
common O
in O
ca O
##uca O
##sian O
##s O
, O
suggesting O
that O
84 O
##5 O
g O
- O
- O
[UNK] O
a O
may O
have O
been O
introduced O
into O
these O
populations O
by O
ca O
##uca O
##sian O
ad O
##mi O
##x O
##ture O
. O

187 O
c O
- O
- O
[UNK] O
g O
was O
present O
at O
an O
all O
##ele O
frequency O
of O
2 O
. O

68 O
% O
in O
the O
two O
populations O
analyzed O
( O
au O
##stra O
##lian O
a O
##bor O
##igi O
##nal O
and O
chin O
##ese O
) O
. O

in O
the O
au O
##stra O
##lian O
a O
##bor O
##igi O
##nal O
samples O
, O
187 O
c O
- O
- O
[UNK] O
g O
was O
found O
to O
be O
associated O
with O
h O
##la O
ha O
##p O
##lot O
##ype O
##s O
common O
in O
ca O
##uca O
##sian O
##s O
, O
suggesting O
that O
it O
was O
introduced O
by O
recent O
ad O
##mi O
##x O
##ture O
. O

in O
the O
chin O
##ese O
samples O
analyzed O
, O
187 O
c O
- O
- O
[UNK] O
g O
was O
present O
in O
association O
with O
a O
wide O
variety O
of O
h O
##la O
ha O
##p O
##lot O
##ype O
##s O
, O
showing O
this O
mutation O
to O
be O
widespread O
and O
likely O
to O
pre O
##date O
the O
more O
genetically O
restricted O
84 O
##5 O
g O
- O
- O
[UNK] O
a O
mutation O
. O

g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
at B-Disease
##ten I-Disease
##uated I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
. O

g O
##er O
##m O
- O
line O
mutations O
of O
the O
tumor B-Disease
suppress O
##or O
a O
##p O
##c O
are O
implicated O
in O
at B-Disease
##ten I-Disease
##uated I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##ap I-Disease
##c I-Disease
) O
, O
a O
variant O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
. O

a B-Disease
##ap I-Disease
##c I-Disease
is O
recognized O
by O
the O
occurrence O
of O
[UNK] O
100 O
co B-Disease
##lon I-Disease
##ic I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
and O
a O
later O
onset O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
( O
age O
[UNK] O
40 O
years O
) O
. O

the O
aim O
of O
this O
study O
was O
to O
assess O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
a B-Disease
##ap I-Disease
##c I-Disease
families O
. O

by O
protein O
- O
t O
##run O
##cation O
test O
( O
p O
##tt O
) O
ass O
##ay O
, O
the O
entire O
coding O
region O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
was O
screened O
in O
affected O
individuals O
from O
11 O
a B-Disease
##ap I-Disease
##c I-Disease
kind O
##red O
##s O
, O
and O
their O
p O
##hen O
##otypic O
differences O
were O
examined O
. O

five O
novel O
g O
##er O
##m O
- O
line O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
were O
identified O
in O
seven O
kind O
##red O
##s O
. O

mutations O
were O
located O
in O
three O
different O
regions O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
( O
1 O
) O
at O
the O
5 O
end O
spanning O
ex O
##ons O
4 O
and O
5 O
, O
( O
2 O
) O
within O
ex O
##on O
9 O
, O
and O
( O
3 O
) O
at O
the O
3 O
di O
##stal O
end O
of O
the O
gene O
. O

var O
##iability O
in O
the O
number O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
was O
most O
apparent O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
and O
upper O
- O
gas O
##tro O
##int O
##est O
##inal O
manifest O
##ations O
were O
more O
severe O
in O
them O
. O

in O
individuals O
with O
mutations O
in O
either O
region O
2 O
or O
region O
3 O
, O
the O
average O
number O
of O
ad B-Disease
##eno I-Disease
##mas I-Disease
tended O
to O
be O
lower O
than O
those O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
although O
age O
at O
diagnosis O
was O
similar O
. O

in O
all O
a B-Disease
##ap I-Disease
##c I-Disease
kind O
##red O
##s O
, O
a O
pre O
##dom O
##ina O
##nce O
of O
right O
- O
sided O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
and O
re B-Disease
##ct I-Disease
##al I-Disease
p I-Disease
##oly I-Disease
##p I-Disease
spa O
##ring O
was O
observed O
. O

no O
des B-Disease
##mo I-Disease
##id I-Disease
tumors I-Disease
were O
found O
in O
these O
kind O
##red O
##s O
. O

our O
data O
suggest O
that O
, O
in O
a B-Disease
##ap I-Disease
##c I-Disease
families O
, O
the O
location O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
mutation O
may O
partially O
predict O
specific O
p O
##hen O
##otypic O
expression O
. O

this O
should O
help O
in O
the O
design O
of O
tailored O
clinical O
- O
management O
protocols O
in O
this O
subset O
of O
f B-Disease
##ap I-Disease
patients O
. O
. O

w B-Disease
##il I-Disease
##ms I-Disease
' I-Disease
tumor I-Disease
1 O
and O
da O
##x O
- O
1 O
m O
##od O
##ulate O
the O
orphan O
nuclear O
receptor O
s O
##f O
- O
1 O
in O
sex O
- O
specific O
gene O
expression O
. O

products O
of O
s O
##tero O
##ido O
##genic O
factor O
1 O
( O
s O
##f O
- O
1 O
) O
and O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
1 O
( O
w O
##t O
##1 O
) O
genes O
are O
essential O
for O
ma O
##mmal O
##ian O
go O
##nado O
##genesis O
prior O
to O
sexual O
differentiation O
. O

in O
males O
, O
s O
##f O
- O
1 O
participates O
in O
sexual O
development O
by O
regulating O
expression O
of O
the O
p O
##oly O
##pe O
##pt O
##ide O
hormone O
m O
##ull O
##eria O
##n O
in O
##hibit O
##ing O
substance O
( O
mi O
##s O
) O
. O

here O
, O
we O
show O
that O
w O
##t O
##1 O
- O
k O
##ts O
is O
##of O
##orms O
associate O
and O
s O
##yne O
##rg O
##ize O
with O
s O
##f O
- O
1 O
to O
promote O
mi O
##s O
expression O
. O

in O
contrast O
, O
w O
##t O
##1 O
miss O
##ense O
mutations O
, O
associated O
with O
male B-Disease
pseudo I-Disease
##her I-Disease
##ma I-Disease
##ph I-Disease
##rod I-Disease
##itis I-Disease
##m I-Disease
in O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
, O
fail O
to O
s O
##yne O
##rg O
##ize O
with O
s O
##f O
- O
1 O
. O

additionally O
, O
the O
x O
- O
linked O
, O
candidate O
dos O
##age O
- O
sensitive O
sex O
- O
reversal O
gene O
, O
da O
##x O
- O
1 O
, O
ant O
##agon O
##izes O
s O
##yne O
##rgy O
between O
s O
##f O
- O
1 O
and O
w O
##t O
##1 O
, O
most O
likely O
through O
a O
direct O
interaction O
with O
s O
##f O
- O
1 O
. O

we O
propose O
that O
w O
##t O
##1 O
and O
da O
##x O
- O
1 O
functional O
##ly O
oppose O
each O
other O
in O
test O
##is O
development O
by O
m O
##od O
##ulating O
s O
##f O
- O
1 O
- O
mediated O
trans O
##act O
##ivation O
. O
. O

a O
mouse O
model O
for O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
imprint O
##ing O
- O
centre O
mutations O
. O

imprint O
##ing O
in O
the O
15 O
##q O
##11 O
- O
q O
##13 O
region O
involves O
an O
imprint O
##ing O
centre O
( O
i O
##c O
) O
, O
mapping O
in O
part O
to O
the O
promoter O
and O
first O
ex O
##on O
of O
s O
##n O
##rp O
##n O
. O

del O
##eti O
##on O
of O
this O
i O
##c O
a O
##bol O
##ishes O
local O
paternal O
##ly O
derived O
gene O
expression O
and O
results O
in O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

we O
have O
created O
two O
del O
##eti O
##on O
mutations O
in O
mice O
to O
understand O
p B-Disease
##ws I-Disease
and O
the O
mechanism O
of O
this O
i O
##c O
. O

mice O
harbour O
##ing O
an O
in O
##tra O
##genic O
del O
##eti O
##on O
in O
s O
##n O
##rp O
##n O
are O
p O
##hen O
##otypic O
##ally O
normal O
, O
suggesting O
that O
mutations O
of O
s O
##n O
##rp O
##n O
are O
not O
sufficient O
to O
induce O
p B-Disease
##ws I-Disease
. O

mice O
with O
a O
larger O
del O
##eti O
##on O
involving O
both O
s O
##n O
##rp O
##n O
and O
the O
put O
##ative O
p O
##ws O
- O
i O
##c O
lack O
expression O
of O
the O
imprint O
##ed O
genes O
z O
##f O
##p O
##12 O
##7 O
( O
mouse O
ho O
##mo O
##logue O
of O
z O
##n O
##f O
##12 O
##7 O
) O
, O
n O
##dn O
and O
i O
##p O
##w O
, O
and O
manifest O
several O
p O
##hen O
##otype O
##s O
common O
to O
p B-Disease
##ws I-Disease
infants O
. O

these O
data O
demonstrate O
that O
both O
the O
position O
of O
the O
i O
##c O
and O
its O
role O
in O
the O
coordinate O
expression O
of O
genes O
is O
conserved O
between O
mouse O
and O
human O
, O
and O
indicate O
that O
the O
mouse O
is O
a O
suitable O
model O
system O
in O
which O
to O
investigate O
the O
molecular O
mechanisms O
of O
imprint O
##ing O
in O
this O
region O
of O
the O
genome O
. O
. O

mutations O
of O
the O
at O
##m O
gene O
detected O
in O
j O
##apa O
##nese O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
patients O
: O
possible O
pre O
##po O
##nder O
##ance O
of O
the O
two O
founder O
mutations O
46 O
##12 O
##del O
##16 O
##5 O
and O
78 O
##8 O
##3 O
##del O
##5 O
. O

the O
at O
##m O
( O
a O
- O
t O
, O
m O
##uta O
##ted O
) O
gene O
on O
human O
chromosome O
11 O
##q O
##22 O
. O

3 O
has O
recently O
been O
identified O
as O
the O
gene O
responsible O
for O
the O
human O
re B-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
. O

in O
order O
to O
define O
the O
types O
of O
disease O
- O
causing O
at O
##m O
mutations O
in O
j O
##apa O
##nese O
a B-Disease
- I-Disease
t I-Disease
patients O
as O
well O
as O
to O
look O
for O
possible O
mutation O
##al O
hot O
##sp O
##ots O
, O
reverse O
- O
trans O
##cribed O
r O
##na O
derived O
from O
ten O
patients O
belonging O
to O
eight O
unrelated O
j O
##apa O
##nese O
a B-Disease
- I-Disease
t I-Disease
families O
was O
analyzed O
for O
mutations O
by O
the O
restriction O
end O
##on O
##uc O
##lea O
##se O
finger O
##print O
##ing O
method O
. O

as O
has O
been O
reported O
by O
others O
, O
mutations O
that O
lead O
to O
ex O
##on O
skip O
##ping O
or O
premature O
protein O
t O
##run O
##cation O
were O
also O
predominant O
in O
our O
mutant O
##s O
. O

six O
different O
mutations O
were O
identified O
on O
12 O
of O
the O
16 O
all O
##ele O
##s O
examined O
. O

four O
were O
del O
##eti O
##ons O
involving O
a O
loss O
of O
a O
single O
ex O
##on O
ex O
##on O
7 O
, O
ex O
##on O
16 O
, O
ex O
##on O
33 O
or O
ex O
##on O
35 O
. O

the O
others O
were O
minute O
del O
##eti O
##ons O
, O
46 O
##4 O
##9 O
##dela O
in O
ex O
##on O
33 O
and O
78 O
##8 O
##3 O
##del O
##5 O
in O
ex O
##on O
55 O
. O

the O
mutations O
46 O
##12 O
##del O
##16 O
##5 O
and O
78 O
##8 O
##3 O
##del O
##5 O
were O
found O
in O
more O
than O
two O
unrelated O
families O
; O
44 O
% O
( O
7 O
of O
16 O
) O
of O
the O
mutant O
all O
##ele O
##s O
had O
one O
of O
the O
two O
mutations O
. O

the O
46 O
##12 O
##del O
##16 O
##5 O
mutations O
in O
three O
different O
families O
were O
all O
as O
##cribed O
to O
the O
same O
t O
- O
- O
[UNK] O
a O
substitution O
at O
the O
s O
##p O
##lice O
donor O
site O
in O
intro O
##n O
33 O
. O

micro O
##sat O
##elli O
##te O
g O
##eno O
##ty O
##ping O
around O
the O
at O
##m O
lo O
##cus O
also O
indicated O
that O
a O
common O
ha O
##p O
##lot O
##ype O
was O
shared O
by O
the O
mutant O
all O
##ele O
##s O
in O
both O
mutations O
. O

this O
suggests O
that O
these O
two O
founder O
mutations O
may O
be O
predominant O
among O
j O
##apa O
##nese O
at O
##m O
mutant O
all O
##ele O
##s O
. O

w O
##47 O
##4 O
##c O
amino O
acid O
substitution O
affects O
early O
processing O
of O
the O
alpha O
- O
subunit O
of O
beta O
- O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
and O
is O
associated O
with O
sub O
##ac O
##ute O
g B-Disease
( I-Disease
m I-Disease
##2 I-Disease
) I-Disease
gang I-Disease
##lio I-Disease
##si I-Disease
##dos I-Disease
##is I-Disease
. O

mutations O
in O
the O
he O
##xa O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
( O
he O
##x O
a O
) O
, O
that O
a O
##bol O
##ish O
he O
##x O
a O
enzyme O
activity O
cause O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
, O
the O
fatal O
infant B-Disease
##ile I-Disease
form I-Disease
of I-Disease
g I-Disease
( I-Disease
m I-Disease
##2 I-Disease
) I-Disease
gang I-Disease
##lio I-Disease
##si I-Disease
##dos I-Disease
##is I-Disease
, I-Disease
type I-Disease
1 I-Disease
. O

less O
severe O
, O
sub O
##ac O
##ute O
( O
juvenile O
- O
onset O
) O
and O
chronic O
( O
adult O
- O
onset O
) O
variants O
are O
characterized O
by O
a O
broad O
spectrum O
of O
clinical O
manifest O
##ations O
and O
are O
associated O
with O
residual O
levels O
of O
he O
##x O
a O
enzyme O
activity O
. O

we O
identified O
a O
142 O
##2 O
g O
- O
- O
[UNK] O
c O
( O
amino O
acid O
w O
##47 O
##4 O
##c O
) O
substitution O
in O
the O
first O
position O
of O
ex O
##on O
13 O
of O
he O
##xa O
of O
a O
non O
- O
j O
##ew O
##ish O
pro O
##band O
who O
manifest O
##ed O
a O
sub O
##ac O
##ute O
variant O
of O
g B-Disease
( I-Disease
m I-Disease
##2 I-Disease
) I-Disease
gang I-Disease
##lio I-Disease
##si I-Disease
##dos I-Disease
##is I-Disease
. O

on O
the O
second O
maternal O
##ly O
inherited O
all O
##ele O
, O
we O
identified O
the O
common O
infant O
##ile O
disease O
- O
causing O
4 O
- O
b O
##p O
insertion O
, O
+ O
ta O
##t O
##c O
127 O
##8 O
, O
in O
ex O
##on O
11 O
. O

pulse O
- O
chase O
analysis O
using O
pro O
##band O
fi O
##bro O
##blast O
##s O
revealed O
that O
the O
w O
##47 O
##4 O
##c O
- O
containing O
alpha O
- O
subunit O
precursor O
was O
normally O
synthesized O
, O
but O
not O
p O
##hos O
##ph O
##ory O
##lated O
or O
secret O
##ed O
, O
and O
the O
mature O
l O
##ys O
##oso O
##mal O
alpha O
- O
subunit O
was O
not O
detected O
. O

when O
the O
w O
##47 O
##4 O
##c O
- O
containing O
alpha O
- O
subunit O
was O
trans O
##ient O
##ly O
co O
- O
expressed O
with O
the O
beta O
- O
subunit O
to O
produce O
he O
##x O
a O
( O
alphabet O
##a O
) O
in O
co O
##s O
- O
7 O
cells O
, O
the O
mature O
alpha O
- O
subunit O
was O
present O
, O
but O
its O
level O
was O
much O
lower O
than O
that O
from O
normal O
alpha O
- O
subunit O
trans O
##fect O
##ions O
, O
although O
higher O
than O
in O
those O
cells O
trans O
##fected O
with O
an O
alpha O
- O
subunit O
associated O
with O
infant O
##ile O
t B-Disease
##s I-Disease
##d I-Disease
. O

further O
##more O
, O
the O
precursor O
level O
of O
the O
w O
##47 O
##4 O
##c O
alpha O
- O
subunit O
was O
found O
to O
a O
##cc O
##um O
##ulate O
in O
comparison O
to O
the O
normal O
alpha O
- O
subunit O
precursor O
levels O
. O

we O
conclude O
that O
the O
142 O
##2 O
g O
- O
- O
[UNK] O
c O
mutation O
is O
the O
cause O
of O
he B-Disease
##x I-Disease
a I-Disease
enzyme I-Disease
deficiency I-Disease
in O
the O
pro O
##band O
. O

the O
resulting O
w O
##47 O
##4 O
##c O
substitution O
clearly O
interfere O
##s O
with O
alpha O
- O
subunit O
processing O
, O
but O
because O
the O
base O
substitution O
falls O
at O
the O
first O
position O
of O
ex O
##on O
13 O
, O
a O
##ber O
##rant O
s O
##p O
##licing O
may O
also O
contribute O
to O
he B-Disease
##x I-Disease
a I-Disease
deficiency I-Disease
in O
this O
pro O
##band O
. O
. O

two O
frequent O
miss O
##ense O
mutations O
in O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
. O

pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
early O
childhood O
deaf B-Disease
##ness I-Disease
and O
go B-Disease
##iter I-Disease
. O

a O
century O
after O
its O
recognition O
as O
a O
syndrome O
by O
v O
##augh O
##an O
pen O
##dre O
##d O
, O
the O
disease O
gene O
( O
p O
##ds O
) O
was O
mapped O
to O
chromosome O
7 O
##q O
##22 O
- O
q O
##31 O
. O

1 O
and O
, O
recently O
, O
found O
to O
en O
##code O
a O
put O
##ative O
su O
##lf O
##ate O
transport O
##er O
. O

we O
performed O
mutation O
analysis O
of O
the O
p B-Disease
##ds I-Disease
gene O
in O
patients O
from O
14 O
pen B-Disease
##dre I-Disease
##d I-Disease
families O
originating O
from O
seven O
countries O
and O
identified O
all O
mutations O
. O

the O
mutations O
include O
three O
single O
base O
del O
##eti O
##ons O
, O
one O
s O
##p O
##lice O
site O
mutation O
and O
10 O
miss O
##ense O
mutations O
. O

one O
miss O
##ense O
mutation O
( O
l O
##23 O
##6 O
##p O
) O
was O
found O
in O
a O
ho O
##mo O
##zy O
##go O
##us O
state O
in O
two O
con O
##sang O
##uin O
##eous O
families O
and O
in O
a O
he O
##tero O
##zy O
##go O
##us O
state O
in O
five O
additional O
non O
- O
con O
##sang O
##uin O
##eous O
families O
. O

another O
miss O
##ense O
mutation O
( O
t O
##41 O
##6 O
##p O
) O
was O
found O
in O
a O
ho O
##mo O
##zy O
##go O
##us O
state O
in O
one O
family O
and O
in O
a O
he O
##tero O
##zy O
##go O
##us O
state O
in O
four O
families O
. O

pen B-Disease
##dre I-Disease
##d I-Disease
patients O
in O
three O
non O
- O
con O
##sang O
##uin O
##eous O
families O
were O
shown O
to O
be O
compound O
he O
##tero O
##zy O
##got O
##es O
for O
l O
##23 O
##6 O
##p O
and O
t O
##41 O
##6 O
##p O
. O

in O
total O
, O
one O
or O
both O
of O
these O
mutations O
were O
found O
in O
nine O
of O
the O
14 O
families O
analyzed O
. O

the O
identification O
of O
two O
frequent O
p B-Disease
##ds I-Disease
mutations O
will O
facilitate O
the O
molecular O
diagnosis O
of O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
. O

insertion O
##al O
mutation O
by O
trans O
##po O
##sable O
element O
, O
l O
##1 O
, O
in O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
results O
in O
x B-Disease
- I-Disease
linked I-Disease
di I-Disease
##lated I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
. O

x B-Disease
- I-Disease
linked I-Disease
di I-Disease
##lated I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
( O
x B-Disease
##ld I-Disease
##c I-Disease
##m I-Disease
) O
is O
a O
clinical O
p O
##hen O
##otype O
of O
d B-Disease
##ys I-Disease
##tro I-Disease
##phi I-Disease
##no I-Disease
##pathy I-Disease
which O
is O
characterized O
by O
prefer O
##ential O
my B-Disease
##oc I-Disease
##ard I-Disease
##ial I-Disease
involvement I-Disease
without O
any O
over O
##t O
clinical O
signs O
of O
skeletal B-Disease
my I-Disease
##op I-Disease
##athy I-Disease
. O

to O
date O
, O
several O
mutations O
in O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
, O
d O
##m O
##d O
, O
have O
been O
identified O
in O
patients O
with O
x B-Disease
##ld I-Disease
##c I-Disease
##m I-Disease
, O
but O
a O
path O
##ogenic O
correlation O
of O
these O
card O
##ios O
##pecific O
mutations O
in O
d O
##m O
##d O
with O
the O
x B-Disease
##ld I-Disease
##c I-Disease
##m I-Disease
p O
##hen O
##otype O
has O
remained O
to O
be O
el O
##uc O
##idated O
. O

we O
report O
here O
the O
identification O
of O
a O
unique O
de O
no O
##vo O
l O
##1 O
insertion O
in O
the O
muscle O
ex O
##on O
1 O
in O
d O
##m O
##d O
in O
three O
x B-Disease
##ld I-Disease
##c I-Disease
##m I-Disease
patients O
from O
two O
unrelated O
j O
##apa O
##nese O
families O
. O

the O
insertion O
was O
a O
5 O
- O
t O
##runcated O
form O
of O
human O
l O
##1 O
inverse O
##ly O
integrated O
in O
the O
5 O
- O
un O
##tra O
##ns O
##lated O
region O
in O
the O
muscle O
ex O
##on O
1 O
, O
which O
affected O
the O
transcription O
or O
the O
stability O
of O
the O
muscle O
form O
of O
d O
##ys O
##tro O
##phi O
##n O
trans O
##cripts O
but O
not O
that O
of O
the O
brain O
or O
pu O
##rkin O
##je O
cell O
form O
, O
probably O
due O
to O
its O
unique O
site O
of O
integration O
. O

we O
s O
##pec O
##ulate O
that O
this O
insertion O
of O
an O
l O
##1 O
sequence O
in O
d O
##m O
##d O
is O
responsible O
for O
some O
of O
the O
population O
of O
j O
##apa O
##nese O
patients O
with O
x B-Disease
##ld I-Disease
##c I-Disease
##m I-Disease
. O
. O

severe O
early O
- O
onset O
o B-Disease
##besity I-Disease
, O
ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
and O
red O
hair O
pig O
##mentation O
caused O
by O
p O
##om O
##c O
mutations O
in O
humans O
. O

se O
##quential O
c O
##lea O
##vage O
of O
the O
precursor O
protein O
pre O
- O
pro O
- O
op O
##io O
##mel O
##ano O
##cor O
##tin O
( O
p O
##om O
##c O
) O
generates O
the O
me O
##lan O
##oc O
##ort O
##in O
p O
##eptide O
##s O
ad O
##ren O
##oc O
##ort O
##ico O
##tro O
##phi O
##n O
( O
act O
##h O
) O
, O
me O
##lan O
##oc O
##yte O
- O
s O
##ti O
##mulating O
hormones O
( O
m O
##sh O
) O
alpha O
, O
beta O
and O
gamma O
as O
well O
as O
the O
op O
##io O
##id O
- O
receptor O
l O
##igan O
##d O
beta O
- O
end O
##or O
##phi O
##n O
. O

while O
a O
few O
cases O
of O
isolated O
act B-Disease
##h I-Disease
deficiency I-Disease
have O
been O
reported O
( O
o O
##mi O
##m O
2014 O
##00 O
) O
, O
an O
inherited O
p O
##om O
##c O
defect O
has O
not O
been O
described O
so O
far O
. O

recent O
studies O
in O
animal O
models O
el O
##uc O
##idated O
a O
central O
role O
of O
alpha O
- O
m O
##sh O
in O
the O
regulation O
of O
food O
intake O
by O
activation O
of O
the O
brain O
me O
##lan O
##oc O
##ort O
##in O
- O
4 O
- O
receptor O
( O
m O
##c O
##4 O
- O
r O
; O
re O
##fs O
3 O
- O
5 O
) O
and O
the O
link O
##age O
of O
human O
o B-Disease
##besity I-Disease
to O
chromosome O
2 O
in O
close O
proximity O
to O
the O
p O
##om O
##c O
lo O
##cus O
, O
led O
to O
the O
proposal O
of O
an O
association O
of O
p O
##om O
##c O
with O
human O
o B-Disease
##besity I-Disease
. O

the O
dual O
role O
of O
alpha O
- O
m O
##sh O
in O
regulating O
food O
intake O
and O
in O
##f O
##lue O
##ncing O
hair O
pig O
##mentation O
predict O
##s O
that O
the O
p O
##hen O
##otype O
associated O
with O
a O
defect O
in O
p O
##om O
##c O
function O
would O
include O
o B-Disease
##besity I-Disease
, O
alter O
##ation O
in O
pig O
##mentation O
and O
act B-Disease
##h I-Disease
deficiency I-Disease
. O

the O
observation O
of O
these O
symptoms O
in O
two O
pro O
##band O
##s O
prompted O
us O
to O
search O
for O
mutations O
within O
their O
p O
##om O
##c O
genes O
. O

patient O
1 O
was O
found O
to O
be O
a O
compound O
he O
##tero O
##zy O
##got O
##e O
for O
two O
mutations O
in O
ex O
##on O
3 O
( O
g O
##70 O
##13 O
##t O
, O
c O
##7 O
##13 O
##3 O
##del O
##ta O
) O
which O
interfere O
with O
appropriate O
synthesis O
of O
act O
##h O
and O
alpha O
- O
m O
##sh O
. O

patient O
2 O
was O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
mutation O
in O
ex O
##on O
2 O
( O
c O
##38 O
##0 O
##4 O
##a O
) O
which O
a O
##bol O
##ishes O
p O
##om O
##c O
translation O
. O

these O
findings O
represent O
the O
first O
examples O
of O
a O
genetic B-Disease
defect I-Disease
within O
the O
p O
##om O
##c O
gene O
and O
define O
a O
new O
mon B-Disease
##ogenic I-Disease
end I-Disease
##oc I-Disease
##rine I-Disease
disorder I-Disease
resulting O
in O
early O
- O
onset O
o B-Disease
##besity I-Disease
, O
ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
and O
red O
hair O
pig O
##mentation O
. O
. O

a O
euro O
##pe O
##an O
multi O
##cent O
##er O
study O
of O
p B-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
deficiency I-Disease
: O
classification O
of O
105 O
mutations O
and O
a O
general O
system O
for O
g O
##eno O
##type O
- O
based O
prediction O
of O
metabolic O
p O
##hen O
##otype O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
and O
mild B-Disease
h I-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
( O
m B-Disease
##hp I-Disease
) O
are O
all B-Disease
##eli I-Disease
##c I-Disease
disorders I-Disease
caused O
by O
mutations O
in O
the O
gene O
encoding O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
. O

previous O
studies O
have O
suggested O
that O
the O
highly O
variable O
metabolic O
p O
##hen O
##otype O
##s O
of O
p B-Disease
##ah I-Disease
deficiency I-Disease
co O
##rrel O
##ate O
with O
p O
##ah O
g O
##eno O
##type O
##s O
. O

we O
identified O
both O
ca O
##usa O
##tive O
mutations O
in O
68 O
##6 O
patients O
from O
seven O
euro O
##pe O
##an O
centers O
. O

on O
the O
basis O
of O
the O
p O
##hen O
##otypic O
characteristics O
of O
29 O
##7 O
functional O
##ly O
hem O
##iz O
##y O
##go O
##us O
patients O
, O
105 O
of O
the O
mutations O
were O
assigned O
to O
one O
of O
four O
arbitrary O
p O
##hen O
##otype O
categories O
. O

we O
proposed O
and O
tested O
a O
simple O
model O
for O
correlation O
between O
g O
##eno O
##type O
and O
p O
##hen O
##otypic O
outcome O
. O

the O
observed O
p O
##hen O
##otype O
matched O
the O
predicted O
p O
##hen O
##otype O
in O
79 O
% O
of O
the O
cases O
, O
and O
in O
only O
5 O
of O
184 O
patients O
was O
the O
observed O
p O
##hen O
##otype O
more O
than O
one O
category O
away O
from O
that O
expected O
. O

among O
the O
seven O
contributing O
centers O
, O
the O
proportion O
of O
patients O
for O
whom O
the O
observed O
p O
##hen O
##otype O
did O
not O
match O
the O
predicted O
p O
##hen O
##otype O
was O
4 O
% O
- O
23 O
% O
( O
p O
[UNK] O
. O
000 O
##1 O
) O
, O
suggesting O
that O
differences O
in O
methods O
used O
for O
mutation O
detection O
or O
p O
##hen O
##otype O
classification O
may O
account O
for O
a O
considerable O
proportion O
of O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
in O
##con O
##sist O
##encies O
. O

our O
data O
indicate O
that O
the O
p O
##ah O
- O
mutation O
g O
##eno O
##type O
is O
the O
main O
de O
##ter O
##mina O
##nt O
of O
metabolic O
p O
##hen O
##otype O
in O
most O
patients O
with O
p B-Disease
##ah I-Disease
deficiency I-Disease
. O

in O
the O
present O
study O
, O
the O
classification O
of O
105 O
p O
##ah O
mutations O
may O
allow O
the O
prediction O
of O
the O
bio O
##chemical O
p O
##hen O
##otype O
in O
[UNK] O
10 O
, O
000 O
g O
##eno O
##type O
##s O
, O
which O
may O
be O
useful O
for O
the O
management O
of O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
in O
newborn O
##s O
. O

so O
##matic O
instability O
of O
the O
c O
##t O
##g O
repeat O
in O
mice O
trans O
##genic O
for O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
region O
is O
age O
dependent O
but O
not O
correlated O
to O
the O
relative O
inter O
##tis O
##su O
##e O
transcription O
levels O
and O
pro O
##life O
##rative O
capacities O
. O

a O
( O
c O
##t O
##g O
) O
ne O
##x O
##pan O
##sion O
in O
the O
3 O
- O
un O
##tra O
##ns O
##lated O
region O
( O
u O
##tr O
) O
of O
the O
d O
##m O
protein O
kinase O
gene O
( O
d O
##mp O
##k O
) O
is O
responsible O
for O
causing O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
. O

major O
instability O
, O
with O
very O
large O
expansion O
##s O
between O
generations O
and O
high O
levels O
of O
so O
##matic O
mosaic O
##ism O
, O
is O
observed O
in O
patients O
. O

there O
is O
a O
good O
correlation O
between O
repeat O
size O
( O
at O
least O
in O
le O
##uc O
##ocytes O
) O
, O
clinical O
severity O
and O
age O
of O
onset O
. O

the O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
instability O
mechanisms O
involved O
in O
d B-Disease
##m I-Disease
and O
other O
human O
genetic B-Disease
diseases I-Disease
are O
unknown O
. O

we O
studied O
so O
##matic O
instability O
by O
measuring O
the O
c O
##t O
##g O
repeat O
length O
at O
several O
ages O
in O
various O
tissues O
of O
trans O
##genic O
mice O
carrying O
a O
( O
c O
##t O
##g O
) O
55 O
##ex O
##pan O
##sion O
surrounded O
by O
45 O
k O
##b O
of O
the O
human O
d B-Disease
##m I-Disease
region O
, O
using O
small O
- O
pool O
p O
##c O
##r O
. O

these O
mice O
have O
been O
shown O
to O
reproduce O
the O
inter O
##gene O
##ration O
##al O
and O
so O
##matic O
instability O
of O
the O
55 O
c O
##t O
##g O
repeat O
suggesting O
that O
surrounding O
sequences O
and O
the O
ch O
##roma O
##tin O
environment O
are O
involved O
in O
instability O
mechanisms O
. O

as O
observed O
in O
some O
of O
the O
tissues O
of O
d B-Disease
##m I-Disease
patients O
, O
there O
is O
a O
tendency O
for O
repeat O
length O
and O
so O
##matic O
mosaic O
##ism O
to O
increase O
with O
the O
age O
of O
the O
mouse O
. O

further O
##more O
, O
we O
observed O
no O
correlation O
between O
the O
so O
##matic O
mutation O
rate O
and O
tissue O
proliferation O
capacity O
. O

the O
so O
##matic O
mutation O
rates O
in O
different O
tissues O
were O
also O
not O
correlated O
to O
the O
relative O
inter O
- O
tissue O
difference O
in O
transcription O
##al O
levels O
of O
the O
three O
genes O
( O
d O
##mah O
##p O
, O
d O
##mp O
##k O
and O
59 O
) O
surrounding O
the O
repeat O
. O
. O

a O
novel O
miss O
##ense O
mutation O
in O
patients O
from O
a O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
p O
##ed O
##ig O
##ree O
showing O
only O
mild O
expression O
of O
the O
tumor B-Disease
p O
##hen O
##otype O
. O

we O
have O
used O
single O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
to O
study O
the O
27 O
ex O
##ons O
of O
the O
r O
##b O
##1 O
gene O
in O
individuals O
from O
a O
family O
showing O
mild O
expression O
of O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
p O
##hen O
##otype O
. O

in O
this O
family O
affected O
individuals O
developed O
un B-Disease
##ila I-Disease
##teral I-Disease
tumors I-Disease
and O
, O
as O
a O
result O
of O
link O
##age O
analysis O
, O
un O
##af O
##fected O
mutation O
carriers O
were O
also O
identified O
within O
the O
p O
##ed O
##ig O
##ree O
. O

a O
single O
band O
shift O
using O
s O
##s O
##c O
##p O
was O
identified O
in O
ex O
##on O
21 O
which O
resulted O
in O
a O
miss O
##ense O
mutation O
converting O
a O
c O
##ys O
- O
- O
[UNK] O
a O
##rg O
at O
n O
##uc O
##leo O
##tide O
position O
28 O
in O
the O
ex O
##on O
. O

the O
mutation O
destroyed O
an O
n O
##de O
##i O
restriction O
enzyme O
site O
. O

analysis O
of O
all O
family O
members O
demonstrated O
that O
the O
miss O
##ense O
mutation O
co O
- O
segregated O
with O
patients O
with O
tumors B-Disease
or O
who O
, O
as O
a O
result O
of O
link O
##age O
analysis O
had O
been O
predicted O
to O
carry O
the O
pre O
##dis O
##po O
##sing O
mutation O
. O

these O
observations O
point O
to O
another O
region O
of O
the O
r O
##b O
##1 O
gene O
where O
mutations O
only O
modify O
the O
function O
of O
the O
gene O
and O
raise O
important O
questions O
for O
genetic O
counseling O
in O
families O
with O
these O
distinctive O
p O
##hen O
##otype O
##s O
. O
. O

maternal B-Disease
di I-Disease
##so I-Disease
##my I-Disease
and O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
consistent O
with O
game O
##te O
complement O
##ation O
in O
a O
case O
of O
f O
##ami O
##lial O
trans O
##location O
( O
3 O
; O
15 O
) O
( O
p O
##25 O
; O
q O
##11 O
. O
2 O
) O
. O

maternal B-Disease
un I-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
( I-Disease
up I-Disease
##d I-Disease
) I-Disease
for I-Disease
chromosome I-Disease
15 I-Disease
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

we O
report O
on O
an O
unusual O
case O
of O
maternal B-Disease
di I-Disease
##so I-Disease
##my I-Disease
15 I-Disease
in O
p B-Disease
##ws I-Disease
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p O
##25 O
; O
q O
##11 O
. O
2 O
) O
with O
simultaneous O
maternal O
me O
##iot O
##ic O
non O
##dis O
##junct O
##ion O
for O
chromosome O
15 O
. O

the O
patient O
( O
j O
. O
b O
. O
) O
, O
a O
17 O
- O
year O
- O
old O
white O
male O
with O
p B-Disease
##ws I-Disease
, O
was O
found O
to O
have O
47 O
chromosome O
##s O
with O
a O
super O
##num O
##era O
##ry O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
pro O
##ximal O
long O
arm O
of O
chromosome O
15 O
, O
and O
di O
##stal O
chromosome O
arm O
3 O
##p O
. O

the O
t O
( O
3 O
; O
15 O
) O
was O
present O
in O
the O
balanced O
state O
in O
the O
patients O
father O
and O
a O
sister O
. O

fluorescent O
in O
sit O
##u O
hybrid O
##ization O
analysis O
demonstrated O
that O
the O
p B-Disease
##ws I-Disease
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
del O
##eti O
##on O
of O
the O
p B-Disease
##ws I-Disease
region O
on O
the O
normal O
pair O
of O
15 O
##s O
present O
in O
j O
. O

b O
. O

met O
##hyl O
##ation O
analysis O
at O
ex O
##on O
alpha O
of O
the O
small O
nuclear O
rib O
##on O
##uc O
##leo O
##p O
##rote O
##in O
- O
associated O
p O
##oly O
##pe O
##pt O
##ide O
n O
( O
s O
##n O
##rp O
##n O
) O
gene O
showed O
a O
pattern O
characteristic O
of O
only O
the O
maternal O
chromosome O
15 O
in O
j O
. O

b O
. O

maternal B-Disease
di I-Disease
##so I-Disease
##my I-Disease
was O
confirmed O
by O
polymer O
##ase O
chain O
reaction O
analysis O
of O
micro O
##sat O
##elli O
##te O
repeats O
at O
the O
gamma O
- O
amino O
##but O
##yric O
acid O
receptor O
beta O
##3 O
subunit O
( O
g O
##ab O
##rb O
##3 O
) O
lo O
##cus O
. O

a O
niece O
( O
b O
. O
b O
. O
) O
with O
45 O
chromosome O
##s O
and O
the O
derivative O
3 O
but O
without O
the O
der O
( O
15 O
) O
demonstrated O
a O
p O
##hen O
##otype O
consistent O
with O
that O
reported O
for O
ha O
##p O
##lo O
##ins O
##uff O
##iciency O
of O
di O
##stal O
3 O
p O
. O

un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
associated O
with O
un O
##bal O
##ance O
##d O
segregation O
of O
non O
- O
robe O
##rts O
##onia O
##n O
trans O
##location O
##s O
has O
been O
reported O
previously O
but O
has O
not O
, O
to O
our O
knowledge O
, O
been O
observed O
in O
a O
case O
of O
p B-Disease
##ws I-Disease
. O

further O
##more O
, O
our O
findings O
are O
best O
interpreted O
as O
true O
game O
##te O
complement O
##ation O
resulting O
in O
maternal B-Disease
up I-Disease
##d I-Disease
15 I-Disease
and O
p B-Disease
##ws I-Disease

s B-Disease
##ch I-Disease
##wart I-Disease
##z I-Disease
- I-Disease
jam I-Disease
##pel I-Disease
syndrome I-Disease
type I-Disease
2 I-Disease
and O
s B-Disease
##tu I-Disease
##ve I-Disease
- I-Disease
w I-Disease
##ied I-Disease
##emann I-Disease
syndrome I-Disease
: O
a O
case O
for O
" O
lump O
##ing O
" O
. O

recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
s B-Disease
##ch I-Disease
##wart I-Disease
##z I-Disease
- I-Disease
jam I-Disease
##pel I-Disease
syndrome I-Disease
( O
s B-Disease
##j I-Disease
##s I-Disease
) O
of O
my B-Disease
##oto I-Disease
##nia I-Disease
and O
skeletal B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
, O
which O
we O
called O
s B-Disease
##j I-Disease
##s I-Disease
type I-Disease
2 I-Disease
. O

this O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
s B-Disease
##tu I-Disease
##ve I-Disease
- I-Disease
w I-Disease
##ied I-Disease
##emann I-Disease
syndrome I-Disease
( O
s B-Disease
##ws I-Disease
) O
, O
which O
comprises O
camp B-Disease
##ome I-Disease
##lia I-Disease
at O
birth O
with O
skeletal B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
, O
contract B-Disease
##ures I-Disease
, O
and O
early B-Disease
death I-Disease
. O

to O
test O
for O
possible O
no O
##sol O
##og O
##ic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
s B-Disease
##j I-Disease
##s I-Disease
type I-Disease
2 I-Disease
at O
age O
10 O
years O
and O
another O
with O
s B-Disease
##ws I-Disease
at O
age O
7 O
years O
. O

patients O
reported O
as O
having O
either O
neon O
##ata O
##l O
s B-Disease
##j I-Disease
##s I-Disease
or O
s B-Disease
##ws I-Disease
presented O
a O
combination O
of O
a O
severe O
, O
pre O
##nat O
##al O
- O
onset O
ne B-Disease
##uro I-Disease
##mus I-Disease
##cular I-Disease
disorder I-Disease
( O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
joint I-Disease
contract I-Disease
##ures I-Disease
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
h B-Disease
##yper I-Disease
##ther I-Disease
##mia I-Disease
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
camp B-Disease
##ome I-Disease
##lic I-Disease
- I-Disease
meta I-Disease
##phy I-Disease
##sea I-Disease
##l I-Disease
skeletal I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

the O
similarity O
of O
the O
clinical O
and O
radio O
##graphic O
findings O
is O
so O
extensive O
that O
these O
disorders O
appear O
to O
be O
a O
single O
entity O
. O

the O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
in O
the O
two O
patients O
( O
one O
with O
s B-Disease
##j I-Disease
##s I-Disease
type I-Disease
2 I-Disease
, O
one O
with O
s B-Disease
##ws I-Disease
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

the O
hypothesis O
that O
s B-Disease
##ws I-Disease
and O
s B-Disease
##j I-Disease
##s I-Disease
type I-Disease
2 I-Disease
are O
the O
same O
disorder O
should O
be O
test O
##able O
by O
molecular O
methods O
. O
. O

a O
mouse O
model O
of O
severe O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
: O
defects O
in O
hem O
##ost O
##asis O
and O
th B-Disease
##rom I-Disease
##bos I-Disease
##is I-Disease
. O

von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor I-Disease
( I-Disease
v I-Disease
##w I-Disease
##f I-Disease
) I-Disease
deficiency I-Disease
causes O
severe O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
in O
humans O
. O

we O
generated O
a O
mouse O
model O
for O
this O
disease O
by O
using O
gene O
targeting O
. O

v B-Disease
##w I-Disease
##f I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mice O
appeared O
normal O
at O
birth O
; O
they O
were O
viable O
and O
fertile O
. O

neither O
v O
##w O
##f O
nor O
v O
##w O
##f O
prop O
##oly O
##pe O
##pt O
##ide O
( O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
anti O
##gen O
ii O
) O
were O
detect O
##able O
in O
plasma O
, O
plate O
##lets O
, O
or O
end O
##oth O
##eli O
##al O
cells O
of O
the O
ho O
##mo O
##zy O
##go O
##us O
mutant O
mice O
. O

the O
mutant O
mice O
exhibited O
defects O
in O
hem O
##ost O
##asis O
with O
a O
highly O
prolonged O
bleeding O
time O
and O
spontaneous O
bleeding O
events O
in O
approximately O
10 O
% O
of O
neon O
##ates O
. O

as O
in O
the O
human O
disease O
, O
the O
factor O
v O
##ii O
##i O
level O
in O
these O
mice O
was O
reduced O
strongly O
as O
a O
result O
of O
the O
lack O
of O
protection O
provided O
by O
v O
##w O
##f O
. O

defect O
##ive O
th B-Disease
##rom I-Disease
##bos I-Disease
##is I-Disease
in O
mutant O
mice O
was O
also O
evident O
in O
an O
in O
v O
##ivo O
model O
of O
vascular B-Disease
injury I-Disease
. O

in O
this O
model O
, O
the O
exterior O
##ized O
me O
##sent O
##ery O
was O
super O
##fused O
with O
f O
##er O
##ric O
chloride O
and O
the O
accumulation O
of O
fluorescent O
##ly O
labeled O
plate O
##lets O
was O
observed O
by O
in O
##tra O
##vi O
##tal O
micro O
##sco O
##py O
. O

we O
conclude O
that O
these O
mice O
very O
closely O
mimic O
severe O
human O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
and O
will O
be O
very O
useful O
for O
investigating O
the O
role O
of O
v O
##w O
##f O
in O
normal O
physiology O
and O
in O
disease O
models O
. O
. O

oral O
con O
##tra O
##ceptive O
##s O
and O
the O
risk O
of O
hereditary B-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

hereditary B-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
clinical O
study O
group O
. O

background O
women O
with O
mutations O
in O
either O
the O
br O
##ca O
##1 O
or O
the O
br O
##ca O
##2 O
gene O
have O
a O
high O
lifetime O
risk O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

oral O
con O
##tra O
##ceptive O
##s O
protect O
against O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
general O
, O
but O
it O
is O
not O
known O
whether O
they O
also O
protect O
against O
hereditary B-Disease
forms I-Disease
of I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

methods O
we O
enrolled O
207 O
women O
with O
hereditary B-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
and O
161 O
of O
their O
sisters O
as O
controls O
in O
a O
case O
- O
control O
study O
. O

all O
the O
patients O
carried O
a O
path O
##ogenic O
mutation O
in O
either O
br O
##ca O
##1 O
( O
179 O
women O
) O
or O
br O
##ca O
##2 O
( O
28 O
women O
) O
. O

the O
control O
women O
were O
enrolled O
regardless O
of O
whether O
or O
not O
they O
had O
either O
mutation O
. O

lifetime O
histories O
of O
oral O
- O
con O
##tra O
##ceptive O
use O
were O
obtained O
by O
interview O
or O
by O
written O
question O
##naire O
and O
were O
compared O
between O
patients O
and O
control O
women O
, O
after O
adjustment O
for O
year O
of O
birth O
and O
par O
##ity O
. O

results O
the O
adjusted O
odds O
ratio O
for O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
associated O
with O
any O
past O
use O
of O
oral O
con O
##tra O
##ceptive O
##s O
was O
0 O
. O

5 O
( O
95 O
percent O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
8 O
) O
. O

the O
risk O
decreased O
with O
increasing O
duration O
of O
use O
( O
p O
for O
trend O
, O
[UNK] O
0 O
. O
00 O
##1 O
) O
; O
use O
for O
six O
or O
more O
years O
was O
associated O
with O
a O
60 O
percent O
reduction O
in O
risk O
. O

oral O
- O
con O
##tra O
##ceptive O
use O
protected O
against O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
both O
for O
carriers O
of O
the O
br O
##ca O
##1 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
5 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
9 O
) O
and O
for O
carriers O
of O
the O
br O
##ca O
##2 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
4 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
2 O
to O
1 O
. O
1 O
) O
. O

conclusions O
oral O
- O
con O
##tra O
##ceptive O
use O
may O
reduce O
the O
risk O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
women O
with O
path O
##ogenic O
mutations O
in O
the O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
gene O

a O
j O
##apa O
##nese O
family O
with O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
with O
a O
co O
##don O
29 O
##1 O
del O
##eti O
##on O
: O
a O
clinical O
, O
bio O
##chemical O
, O
path O
##ological O
, O
and O
genetic O
report O
. O

we O
report O
a O
j O
##apa O
##nese O
family O
with O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
with O
a O
three O
base O
pair O
del O
##eti O
##on O
( O
del O
##ga O
##g O
29 O
##1 O
) O
in O
the O
al B-Disease
##d I-Disease
gene O
. O

a O
variety O
of O
p O
##hen O
##otype O
##s O
were O
observed O
within O
this O
family O
. O

while O
the O
pro O
##band O
( O
patient O
1 O
) O
was O
classified O
as O
having O
a O
rare O
intermediate O
type O
of O
adult O
cerebral O
and O
c O
##ere O
##bell O
##o O
- O
brain O
stem O
forms O
, O
his O
younger O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
childhood O
al B-Disease
##d I-Disease
type O
. O

another O
nephew O
( O
patient O
4 O
) O
of O
patient O
1 O
was O
classified O
as O
having O
an O
adolescent O
form O
. O

the O
ta O
##u O
level O
in O
the O
c O
##ere O
##bro O
##sp O
##inal O
fluid O
( O
c O
##s O
##f O
) O
in O
patient O
1 O
was O
as O
high O
as O
that O
of O
patients O
with O
al B-Disease
##z I-Disease
##heimer I-Disease
##s I-Disease
disease I-Disease
( O
ad B-Disease
) O
. O

his O
brain O
magnetic O
resonance O
image O
( O
m O
##ri O
) O
showed O
abnormal B-Disease
##ities I-Disease
in I-Disease
the I-Disease
bilateral I-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
hemisphere I-Disease
##s I-Disease
and O
brain O
stem O
, O
but O
not O
in O
the O
cerebral O
white O
matter O
, O
where O
marked O
reduction O
##s O
of O
the O
cerebral O
blood O
flow O
and O
oxygen O
metabolism O
were O
clearly O
demonstrated O
by O
p O
##os O
##it O
##ron O
emission O
to O
##mo O
##graphy O
( O
pet O
) O
. O

in O
patients O
2 O
and O
3 O
, O
the O
auto O
##psy O
findings O
showed O
massive O
dem B-Disease
##ye I-Disease
##lina I-Disease
##tion I-Disease
of I-Disease
the I-Disease
cerebral I-Disease
white I-Disease
matter I-Disease
with O
spa O
##ring O
of O
the O
u O
- O
fibers O
, O
compatible O
with O
the O
findings O
of O
childhood O
al B-Disease
##d I-Disease
. O

o O
##le O
##ic O
and O
er O
##uc O
##ic O
acids O
( O
lo O
##ren O
##zo O
##s O
oil O
) O
were O
administered O
to O
patients O
1 O
and O
4 O
, O
but O
sufficient O
effectiveness O
was O
not O
obtained O
. O

the O
findings O
in O
this O
family O
suggest O
that O
del O
##ga O
##g O
##29 O
##1 O
is O
part O
of O
the O
cause O
of O
j O
##apa O
##nese O
al B-Disease
##d I-Disease
with O
p O
##hen O
##otypic O
variations O
. O

more O
##over O
, O
although O
the O
scale O
of O
the O
study O
is O
limited O
, O
there O
is O
a O
possibility O
that O
pet O
can O
detect O
an O
ins B-Disease
##id I-Disease
##ious I-Disease
les I-Disease
##ion I-Disease
which O
is O
und O
##ete O
##ct O
##able O
by O
com O
##puted O
to O
##mo O
##gram O
( O
c O
##t O
) O
or O
m O
##ri O
analysis O
, O
and O
that O
the O
higher O
level O
of O
ta O
##u O
reflects O
the O
process O
of O
ne B-Disease
##uron I-Disease
##al I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
in O
al B-Disease
##d I-Disease
. O

lo O
##ren O
##zo O
##s O
oil O
should O
be O
given O
in O
the O
early O
stage O
. O
. O

nonsense O
mutation O
in O
ex O
##on O
4 O
of O
human O
complement O
c O
##9 O
gene O
is O
the O
major O
cause O
of O
j O
##apa O
##nese O
complement B-Disease
c I-Disease
##9 I-Disease
deficiency I-Disease
. O

deficiency B-Disease
of I-Disease
the I-Disease
ninth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c O
##9 O
) O
is O
the O
most O
common O
complement B-Disease
deficiency I-Disease
in O
j O
##apa O
##n O
but O
is O
rare O
in O
other O
countries O
. O

we O
studied O
the O
molecular O
basis O
of O
c B-Disease
##9 I-Disease
deficiency I-Disease
in O
four O
j O
##apa O
##nese O
c B-Disease
##9 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
patients O
who O
had O
suffered O
from O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
. O

direct O
se O
##quencing O
of O
am O
##plified O
c O
##9 O
c O
##dn O
##a O
and O
d O
##na O
revealed O
a O
nonsense O
substitution O
( O
c O
##ga O
- O
- O
[UNK] O
t O
##ga O
) O
at O
co O
##don O
95 O
in O
ex O
##on O
4 O
in O
the O
four O
c B-Disease
##9 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
individuals O
. O

an O
all O
##ele O
- O
specific O
polymer O
##ase O
chain O
reaction O
system O
designed O
to O
detect O
exclusively O
only O
one O
of O
the O
normal O
and O
mutant O
all O
##ele O
##s O
indicated O
that O
all O
the O
four O
patients O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
mutation O
in O
ex O
##on O
4 O
and O
that O
the O
parents O
of O
patient O
2 O
were O
he O
##tero O
##zy O
##go O
##us O
. O

the O
common O
mutation O
at O
co O
##don O
95 O
in O
ex O
##on O
4 O
might O
be O
responsible O
for O
most O
j O
##apa O
##nese O
c B-Disease
##9 I-Disease
deficiency I-Disease
. O
. O

br O
##ca O
##1 O
required O
for O
transcription O
- O
coupled O
repair O
of O
o O
##xi O
##da O
##tive O
d O
##na O
damage O
. O

the O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
br O
##ca O
##1 O
en O
##codes O
a O
zinc O
finger O
protein O
of O
unknown O
function O
. O

association O
of O
the O
br O
##ca O
##1 O
protein O
with O
the O
d O
##na O
repair O
protein O
r O
##ad O
##51 O
and O
changes O
in O
the O
p O
##hos O
##ph O
##ory O
##lation O
and O
cellular O
local O
##ization O
of O
the O
protein O
after O
exposure O
to O
d O
##na O
- O
damaging O
agents O
are O
consistent O
with O
a O
role O
for O
br O
##ca O
##1 O
in O
d O
##na O
repair O
. O

here O
, O
it O
is O
shown O
that O
mouse O
em O
##b O
##ryo O
##nic O
stem O
cells O
def B-Disease
##icient I-Disease
in I-Disease
br I-Disease
##ca I-Disease
##1 I-Disease
are O
defect O
##ive O
in O
the O
ability O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
o O
##xi O
##da O
##tive O
d O
##na O
damage O
, O
and O
are O
h O
##yper O
##sen O
##sitive O
to O
ion O
##izing O
radiation O
and O
hydrogen O
per O
##oxide O
. O

these O
results O
suggest O
that O
br O
##ca O
##1 O
participates O
, O
directly O
or O
indirectly O
, O
in O
transcription O
- O
coupled O
repair O
of O
o O
##xi O
##da O
##tive O
d O
##na O
damage O
. O
. O

t O
##run O
##cation O
mutations O
in O
the O
trans O
##act O
##ivation O
region O
of O
p O
##ax O
##6 O
result O
in O
dominant O
- O
negative O
mutant O
##s O
. O

p O
##ax O
##6 O
is O
a O
transcription O
factor O
with O
two O
d O
##na O
- O
binding O
domains O
( O
paired O
box O
and O
home O
##ob O
##ox O
) O
and O
a O
pro O
##line O
- O
se O
##rine O
- O
th O
##re O
##oni O
##ne O
( O
ps O
##t O
) O
- O
rich O
trans O
##act O
##ivation O
domain O
. O

p O
##ax O
##6 O
regulate O
##s O
eye O
development O
in O
animals O
ranging O
from O
j O
##elly O
##fish O
to O
d O
##ros O
##op O
##hil O
##a O
to O
humans O
. O

he O
##tero O
##zy O
##go O
##us O
mutations O
in O
the O
human O
p O
##ax O
##6 O
gene O
result O
in O
various O
p O
##hen O
##otype O
##s O
, O
including O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
, O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
k I-Disease
##era I-Disease
##titis I-Disease
, O
and O
f B-Disease
##ami I-Disease
##lial I-Disease
f I-Disease
##ove I-Disease
##al I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

it O
is O
believed O
that O
the O
m O
##uta O
##ted O
all O
##ele O
of O
p O
##ax O
##6 O
produces O
an O
inactive O
protein O
and O
an B-Disease
##iri I-Disease
##dia I-Disease
is O
caused O
due O
to O
genetic O
ha O
##p O
##lo O
##ins O
##uff O
##iciency O
. O

however O
, O
several O
t O
##run O
##cation O
mutations O
have O
been O
found O
to O
occur O
in O
the O
c O
- O
terminal O
half O
of O
p O
##ax O
##6 O
in O
patients O
with O
an B-Disease
##iri I-Disease
##dia I-Disease
resulting O
in O
mutant O
proteins O
that O
retain O
the O
d O
##na O
- O
binding O
domains O
but O
have O
lost O
most O
of O
the O
trans O
##act O
##ivation O
domain O
. O

it O
is O
not O
clear O
whether O
such O
mutant O
##s O
really O
behave O
as O
loss O
- O
of O
- O
function O
mutant O
##s O
as O
predicted O
by O
ha O
##p O
##lo O
##ins O
##uff O
##iciency O
. O

contrary O
to O
this O
theory O
, O
our O
data O
showed O
that O
these O
mutant O
##s O
are O
dominant O
- O
negative O
in O
trans O
##ient O
trans O
##fect O
##ion O
ass O
##ays O
when O
they O
are O
co O
##ex O
##pressed O
with O
wild O
- O
type O
p O
##ax O
##6 O
. O

we O
found O
that O
the O
dominant O
- O
negative O
effects O
result O
from O
the O
enhanced O
d O
##na O
binding O
ability O
of O
these O
mutant O
##s O
. O

kinetic O
studies O
of O
binding O
and O
di O
##sso O
##ciation O
revealed O
that O
various O
t O
##run O
##cation O
mutant O
##s O
have O
3 O
- O
5 O
- O
fold O
higher O
affinity O
to O
various O
d O
##na O
- O
binding O
sites O
when O
compared O
with O
the O
wild O
- O
type O
p O
##ax O
##6 O
. O

these O
results O
provide O
a O
new O
insight O
into O
the O
role O
of O
mutant O
p O
##ax O
##6 O
in O
causing O
an B-Disease
##iri I-Disease
##dia I-Disease
. O
. O

reversal O
of O
severe O
h B-Disease
##yper I-Disease
##tro I-Disease
##phic I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
and O
excellent O
ne O
##uro O
##psy O
##cho O
##log O
##ic O
outcome O
in O
very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
a I-Disease
##cy I-Disease
##l I-Disease
- I-Disease
co I-Disease
##en I-Disease
##zy I-Disease
##me I-Disease
a I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
. O

very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
a I-Disease
##cy I-Disease
##l I-Disease
- I-Disease
co I-Disease
##en I-Disease
##zy I-Disease
##me I-Disease
a I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
v I-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
is O
a O
disorder O
of O
fatty O
acid O
beta O
oxidation O
that O
reportedly O
has O
high O
rates O
of O
m O
##or O
##bid O
##ity O
and O
mortality O
. O

we O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
h B-Disease
##yper I-Disease
##tro I-Disease
##phic I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
, O
he B-Disease
##pa I-Disease
##tom I-Disease
##eg I-Disease
##aly I-Disease
, O
en B-Disease
##ce I-Disease
##pha I-Disease
##lop I-Disease
##athy I-Disease
, O
and O
h B-Disease
##y I-Disease
##pot I-Disease
##onia I-Disease
. O

bio O
##chemical O
studies O
indicated O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
caused O
by O
a O
stable O
yet O
inactive O
enzyme O
. O

molecular O
genetic O
analysis O
of O
her O
v O
##l O
##ca O
##d O
gene O
revealed O
a O
t O
##13 O
##7 O
##2 O
##c O
( O
f O
##45 O
##8 O
##l O
) O
miss O
##ense O
mutation O
and O
a O
166 O
##8 O
a O
##ca O
##g O
166 O
##9 O
s O
##p O
##lice O
site O
mutation O
. O

after O
initial O
treatment O
with O
in O
##tra O
##ven O
##ous O
glucose O
and O
car O
##ni O
##tine O
, O
the O
patient O
has O
th O
##rive O
##d O
on O
a O
low O
- O
fat O
diet O
supplemented O
with O
medium O
- O
chain O
t O
##rig O
##ly O
##cer O
##ide O
oil O
and O
car O
##ni O
##tine O
and O
avoid O
##ance O
of O
fast O
##ing O
. O

her O
vent O
##ric O
##ular O
h O
##yper O
##tro O
##phy O
resolved O
significantly O
over O
1 O
year O
, O
and O
cognitive O
##ly O
, O
she O
is O
in O
the O
superior O
range O
for O
age O
. O

clinical O
recognition O
of O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
is O
important O
because O
it O
is O
one O
of O
the O
few O
directly O
treat O
##able O
causes O
of O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
in O
children O
. O
. O

c O
##lon O
##ing O
of O
a O
novel O
member O
of O
the O
low O
- O
density O
lip O
##op O
##rote O
##in O
receptor O
family O
. O

a O
gene O
encoding O
a O
novel O
trans O
##me O
##mb O
##rane O
protein O
was O
identified O
by O
d O
##na O
sequence O
analysis O
within O
the O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
( O
id B-Disease
##d I-Disease
##m I-Disease
) O
lo O
##cus O
id O
##d O
##m O
##4 O
on O
chromosome O
11 O
##q O
##13 O
. O

based O
on O
its O
ch O
##rom O
##oso O
##mal O
position O
, O
this O
gene O
is O
a O
candidate O
for O
con O
##fer O
##ring O
su O
##s O
##ce O
##pt O
##ibility O
to O
diabetes B-Disease
. O

the O
gene O
, O
termed O
low O
- O
density O
lip O
##op O
##rote O
##in O
receptor O
related O
protein O
5 O
( O
l O
##rp O
##5 O
) O
, O
en O
##codes O
a O
protein O
of O
161 O
##5 O
amino O
acids O
that O
contains O
conserved O
modules O
which O
are O
characteristic O
of O
the O
low O
- O
density O
lip O
##op O
##rote O
##in O
( O
l O
##dl O
) O
receptor O
family O
. O

these O
modules O
include O
a O
put O
##ative O
signal O
p O
##eptide O
for O
protein O
export O
, O
four O
e O
##pid O
##er O
##mal O
growth O
factor O
( O
e O
##g O
##f O
) O
repeats O
with O
associated O
space O
##r O
domains O
, O
three O
l O
##dl O
- O
receptor O
( O
l O
##dl O
##r O
) O
repeats O
, O
a O
single O
trans O
##me O
##mb O
##rane O
spanning O
domain O
, O
and O
a O
c O
##yt O
##op O
##las O
##mic O
domain O
. O

the O
encoded O
protein O
has O
a O
unique O
organization O
of O
e O
##g O
##f O
and O
l O
##dl O
##r O
repeats O
; O
therefore O
, O
l O
##rp O
##5 O
likely O
represents O
a O
new O
category O
of O
the O
l O
##dl O
##r O
family O
. O

both O
human O
and O
mouse O
l O
##rp O
##5 O
c O
##dn O
##as O
have O
been O
isolated O
and O
the O
encoded O
mature O
proteins O
are O
95 O
% O
identical O
, O
indicating O
a O
high O
degree O
of O
evolutionary O
conservation O
. O
. O

the O
a B-Disease
##p I-Disease
##c I-Disease
variants O
i O
##13 O
##0 O
##7 O
##k O
and O
e O
##13 O
##17 O
##q O
are O
associated O
with O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
, O
but O
not O
always O
with O
a O
family O
history O
. O

classical O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
is O
a O
high O
- O
pen O
##et O
##rance O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disease I-Disease
that O
pre O
##dis O
##pose O
##s O
to O
hundreds O
or O
thousands O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
and I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
that O
results O
from O
t O
##run O
##cating O
mutations O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

a O
variant O
of O
f B-Disease
##ap I-Disease
is O
at B-Disease
##ten I-Disease
##uated I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
, O
which O
results O
from O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

at B-Disease
##ten I-Disease
##uated I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
patients O
have O
" O
multiple O
" O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
( O
typically O
fewer O
than O
100 O
) O
without O
the O
fl O
##ori O
##d O
p O
##hen O
##otype O
of O
classical O
f B-Disease
##ap I-Disease
. O

another O
group O
of O
patients O
with O
multiple O
ad B-Disease
##eno I-Disease
##mas I-Disease
has O
no O
mutations O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
, O
and O
their O
p O
##hen O
##otype O
probably O
results O
from O
variation O
at O
a O
lo O
##cus O
, O
or O
lo O
##ci O
, O
elsewhere O
in O
the O
genome O
. O

recently O
, O
however O
, O
a O
miss O
##ense O
variant O
of O
a B-Disease
##p I-Disease
##c I-Disease
( O
i O
##13 O
##0 O
##7 O
##k O
) O
was O
described O
that O
con O
##fers O
an O
increased O
risk O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
, O
including O
multiple O
ad B-Disease
##eno I-Disease
##mas I-Disease
, O
in O
ash O
##ken O
##azi O
##m O
. O

we O
have O
studied O
a O
set O
of O
164 O
patients O
with O
multiple O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
and I-Disease
/ I-Disease
or I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
analyzed O
co O
##don O
##s O
126 O
##3 O
- O
137 O
##7 O
( O
ex O
##on O
15 O
##g O
) O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
for O
g O
##er O
##m O
- O
line O
variants O
. O

three O
patients O
with O
the O
i O
##13 O
##0 O
##7 O
##k O
all O
##ele O
were O
detected O
, O
each O
of O
ash O
##ken O
##azi O
descent O
. O

four O
patients O
had O
a O
g O
##er O
##m O
- O
line O
e O
##13 O
##17 O
##q O
miss O
##ense O
variant O
of O
a O
##p O
##c O
that O
was O
not O
present O
in O
controls O
; O
one O
of O
these O
individuals O
had O
an O
unusually O
large O
number O
of O
meta B-Disease
##p I-Disease
##lastic I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
of I-Disease
the I-Disease
color I-Disease
##ec I-Disease
##tum I-Disease
. O

there O
is O
increasing O
evidence O
that O
there O
exist O
g O
##er O
##m O
- O
line O
variants O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
that O
pre O
##dis O
##pose O
to O
the O
development O
of O
multiple O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
and I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
, O
but O
without O
the O
fl O
##ori O
##d O
p O
##hen O
##otype O
of O
classical O
f B-Disease
##ap I-Disease
, O
and O
possibly O
with O
importance O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
risk O
in O
the O
general O
population O
. O
. O

g O
##eno O
##mic O
structure O
of O
the O
human O
con B-Disease
##gen I-Disease
##ital I-Disease
chloride I-Disease
di I-Disease
##ar I-Disease
##r I-Disease
##hea I-Disease
( O
c B-Disease
##ld I-Disease
) O
gene O
. O

con B-Disease
##gen I-Disease
##ital I-Disease
chloride I-Disease
di I-Disease
##ar I-Disease
##r I-Disease
##hea I-Disease
( O
c B-Disease
##ld I-Disease
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
en O
##codes O
an O
in O
##test O
##inal O
an O
##ion O
transport O
##er O
. O

we O
report O
here O
the O
complete O
g O
##eno O
##mic O
organization O
of O
the O
human O
c B-Disease
##ld I-Disease
gene O
which O
spans O
approximately O
39 O
##k O
##b O
, O
and O
comprises O
21 O
ex O
##ons O
. O

all O
ex O
##on O
/ O
intro O
##n O
boundaries O
conform O
to O
the O
g O
##t O
/ O
a O
##g O
rule O
. O

an O
analysis O
of O
the O
put O
##ative O
promoter O
region O
sequence O
shows O
a O
put O
##ative O
ta O
##ta O
box O
and O
predict O
##s O
multiple O
transcription O
factor O
binding O
sites O
. O

the O
g O
##eno O
##mic O
structure O
was O
determined O
using O
d O
##na O
from O
several O
sources O
including O
multiple O
large O
- O
insert O
l O
##iba O
##ries O
and O
g O
##eno O
##mic O
d O
##na O
from O
fin O
##nish O
c B-Disease
##ld I-Disease
patients O
and O
controls O
. O

ex O
##on O
- O
specific O
prime O
##rs O
developed O
in O
this O
study O
will O
facilitate O
mutation O
screening O
studies O
of O
patients O
with O
the O
disease O
. O

g O
##eno O
##mic O
se O
##quencing O
of O
a O
b O
##ac O
clone O
h O
_ O
r O
##g O
##36 O
##4 O
##p O
##16 O
revealed O
the O
presence O
of O
another O
, O
highly O
ho O
##mo O
##log O
##ous O
gene O
3 O
of O
the O
c B-Disease
##ld I-Disease
gene O
, O
with O
a O
similar O
g O
##eno O
##mic O
structure O
, O
recently O
identified O
as O
the O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
gene O
( O
p B-Disease
##ds I-Disease
) O
. O
. O

the O
a O
##p O
##ci O
##13 O
##0 O
##7 O
##k O
all O
##ele O
and O
cancer B-Disease
risk O
in O
a O
community O
- O
based O
study O
of O
ash O
##ken O
##azi O
j O
##ews O
. O

mutations O
in O
a O
##p O
##c O
are O
classical O
##ly O
associated O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
, O
a O
highly O
pen O
##et O
##rant O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disorder I-Disease
characterized O
by O
multiple O
in O
##test O
##inal O
p B-Disease
##oly I-Disease
##ps I-Disease
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
( O
c B-Disease
##rc I-Disease
) O
. O

a B-Disease
##p I-Disease
##c I-Disease
is O
a O
t O
##umour O
- O
suppress O
##or O
gene O
, O
and O
so O
##matic O
loss O
occurs O
in O
t B-Disease
##umour I-Disease
##s I-Disease
. O

the O
g O
##er O
##m O
##line O
t O
- O
to O
- O
a O
trans O
##version O
responsible O
for O
the O
a O
##p O
##c O
i O
##13 O
##0 O
##7 O
##k O
all O
##ele O
converts O
the O
wild O
- O
type O
sequence O
to O
a O
ho O
##mo O
##pol O
##yme O
##r O
tract O
( O
a O
##8 O
) O
that O
is O
genetically O
unstable O
and O
prone O
to O
so O
##matic O
mutation O
. O

the O
i O
##13 O
##0 O
##7 O
##k O
all O
##ele O
was O
found O
in O
6 O
. O

1 O
% O
of O
un O
##sel O
##ec O
##ted O
ash O
##ken O
##azi O
j O
##ews O
and O
higher O
proportions O
of O
ash O
##ken O
##azi O
##m O
with O
family O
or O
personal O
histories O
of O
c B-Disease
##rc I-Disease
( O
re O
##f O
. O
2 O
) O
. O

to O
evaluate O
the O
role O
of O
i O
##13 O
##0 O
##7 O
##k O
in O
cancer B-Disease
, O
we O
g O
##eno O
##type O
##d O
5 O
, O
08 O
##1 O
ash O
##ken O
##azi O
volunteers O
in O
a O
community O
survey O
. O

risk O
of O
developing O
color B-Disease
##ec I-Disease
##tal I-Disease
, I-Disease
breast I-Disease
and I-Disease
other I-Disease
cancer I-Disease
##s I-Disease
were O
compared O
between O
g O
##eno O
##type O
##d O
i O
##13 O
##0 O
##7 O
##k O
carriers O
and O
non O
- O
carriers O
and O
their O
first O
- O
degree O
relatives O
. O

sperm O
d O
##na O
analysis O
in O
a O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
pre O
##mu O
##tation O
carrier O
suggests O
both O
me O
##iot O
##ic O
and O
mit O
##otic O
expansion O
in O
the O
f B-Disease
##rda I-Disease
gene O
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
is O
usually O
caused O
by O
an O
expansion O
of O
a O
g O
##aa O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
intro O
##n O
1 O
of O
the O
f B-Disease
##rda I-Disease
gene O
. O

occasionally O
, O
a O
fully O
expanded O
all O
##ele O
has O
been O
found O
to O
arise O
from O
a O
pre O
##mu O
##tation O
of O
100 O
or O
less O
triple O
##t O
repeats O
. O

we O
have O
examined O
the O
sperm O
d O
##na O
of O
a O
pre O
##mu O
##tation O
carrier O
. O

this O
man O
##s O
le O
##uc O
##oc O
##yte O
d O
##na O
showed O
one O
normal O
all O
##ele O
and O
one O
all O
##ele O
of O
approximately O
100 O
repeats O
. O

his O
sperm O
showed O
an O
expanded O
all O
##ele O
in O
a O
tight O
range O
center O
##ing O
on O
a O
size O
of O
approximately O
320 O
t O
##rin O
##uc O
##leo O
##tide O
repeats O
. O

his O
affected O
son O
has O
repeat O
sizes O
of O
104 O
##0 O
and O
540 O
. O

these O
data O
suggest O
that O
expansion O
occurs O
in O
two O
stages O
, O
the O
first O
during O
me O
##ios O
##is O
followed O
by O
a O
second O
mit O
##otic O
expansion O
. O

we O
also O
show O
that O
in O
all O
inform O
##ative O
carrier O
father O
to O
affected O
child O
transmissions O
, O
with O
the O
notable O
exception O
of O
the O
pre O
##mu O
##tation O
carrier O
, O
the O
expansion O
size O
decreases O
. O
. O

the O
r O
##4 O
##9 O
##6 O
##h O
mutation O
of O
a O
##ryl O
##sul O
##fa O
##tase O
a O
does O
not O
cause O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

deficiency B-Disease
of I-Disease
a I-Disease
##ryl I-Disease
##sul I-Disease
##fa I-Disease
##tase I-Disease
a I-Disease
( O
a O
##rsa O
) O
enzyme O
activity O
causes O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
. O

a O
number O
of O
a O
##rsa O
gene O
mutations O
responsible O
for O
m B-Disease
##ld I-Disease
have O
been O
identified O
. O

recently O
, O
the O
r O
##4 O
##9 O
##6 O
##h O
mutation O
of O
a O
##rsa O
was O
proposed O
to O
be O
a O
cause O
of O
m B-Disease
##ld I-Disease
( O
drag O
##hia O
et O
al O
. O
, O
1997 O
) O
. O

we O
have O
investigated O
the O
r O
##4 O
##9 O
##6 O
##h O
mutation O
and O
found O
this O
mutation O
at O
a O
relatively O
high O
frequency O
in O
an O
a O
##f O
##rica O
##n O
am O
##eric O
##an O
population O
( O
f O
= O
0 O
. O
09 O
, O
n O
= O
61 O
subjects O
) O
. O

the O
a O
##rsa O
enzyme O
activity O
in O
subjects O
with O
and O
without O
the O
r O
##4 O
##9 O
##6 O
##h O
mutation O
was O
determined O
and O
found O
to O
be O
normal O
. O

it O
is O
therefore O
concluded O
that O
the O
r O
##4 O
##9 O
##6 O
##h O
mutation O
of O
a O
##rsa O
does O
not O
negatively O
influence O
the O
activity O
of O
a O
##rsa O
and O
is O
not O
a O
cause O
of O
m B-Disease
##ld I-Disease

down O
- O
regulation O
of O
trans O
##me O
##mb O
##rane O
carbon O
##ic O
an O
##hy O
##dra O
##ses O
in O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
cell O
lines O
by O
wild O
- O
type O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
trans O
##gene O
##s O
. O

to O
discover O
genes O
involved O
in O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( O
v B-Disease
##hl I-Disease
) O
- O
mediated O
car O
##cin O
##ogen O
##esis O
, O
we O
used O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
cell O
lines O
stab O
##ly O
trans O
##fected O
with O
wild O
- O
type O
v O
##hl O
- O
expressing O
trans O
##gene O
##s O
. O

large O
- O
scale O
r O
##na O
differential O
display O
technology O
applied O
to O
these O
cell O
lines O
identified O
several O
differential O
##ly O
expressed O
genes O
, O
including O
an O
alpha O
carbon O
##ic O
an O
##hy O
##dra O
##se O
gene O
, O
termed O
ca O
##12 O
. O

the O
de O
##duced O
protein O
sequence O
was O
classified O
as O
a O
one O
- O
pass O
trans O
##me O
##mb O
##rane O
ca O
possessing O
an O
apparently O
intact O
cat O
##alytic O
domain O
in O
the O
extra O
##cellular O
ca O
module O
. O

re O
##int O
##roduced O
wild O
- O
type O
v B-Disease
##hl I-Disease
strongly O
in O
##hibit O
##ed O
the O
over O
##ex O
##press O
##ion O
of O
the O
ca O
##12 O
gene O
in O
the O
parental O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
cell O
lines O
. O

similar O
results O
were O
obtained O
with O
ca O
##9 O
, O
encoding O
another O
trans O
##me O
##mb O
##rane O
ca O
with O
an O
intact O
cat O
##alytic O
domain O
. O

although O
both O
domains O
of O
the O
v B-Disease
##hl I-Disease
protein O
contribute O
to O
regulation O
of O
ca O
##12 O
expression O
, O
the O
el O
##ong O
##in O
binding O
domain O
alone O
could O
effectively O
regulate O
ca O
##9 O
expression O
. O

we O
mapped O
ca O
##12 O
and O
ca O
##9 O
lo O
##ci O
to O
chromosome O
bands O
15 O
##q O
##22 O
and O
17 O
##q O
##21 O
. O

2 O
respectively O
, O
regions O
prone O
to O
am O
##p O
##lification O
in O
some O
human O
cancer B-Disease
##s I-Disease
. O

additional O
experiments O
are O
needed O
to O
define O
the O
role O
of O
ca O
i O
##x O
and O
ca O
x O
##ii O
enzymes O
in O
the O
regulation O
of O
p O
##h O
in O
the O
extra O
##cellular O
micro O
##en O
##vir O
##on O
##ment O
and O
its O
potential O
impact O
on O
cancer B-Disease
cell O
growth O
. O

a O
gene O
encoding O
a O
trans O
##me O
##mb O
##rane O
protein O
is O
m O
##uta O
##ted O
in O
patients O
with O
diabetes B-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
and O
op B-Disease
##tic I-Disease
at I-Disease
##rop I-Disease
##hy I-Disease
( O
wolf B-Disease
##ram I-Disease
syndrome I-Disease
) O
. O

wolf B-Disease
##ram I-Disease
syndrome I-Disease
( O
w B-Disease
##fs I-Disease
; O
o O
##mi O
##m O
222 O
##30 O
##0 O
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
ne I-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disorder I-Disease
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
and O
progressive O
op B-Disease
##tic I-Disease
at I-Disease
##rop I-Disease
##hy I-Disease
. O

link O
##age O
to O
markers O
on O
chromosome O
4 O
##p O
was O
confirmed O
in O
five O
families O
. O

on O
the O
basis O
of O
me O
##iot O
##ic O
re O
##comb O
##ina O
##nts O
and O
disease O
- O
associated O
ha O
##p O
##lot O
##ype O
##s O
, O
the O
w B-Disease
##fs I-Disease
gene O
was O
localized O
to O
a O
b O
##ac O
/ O
p O
##1 O
con O
##ti O
##g O
of O
less O
than O
250 O
k O
##b O
. O

mutations O
in O
a O
novel O
gene O
( O
w O
##fs O
##1 O
) O
encoding O
a O
put O
##ative O
trans O
##me O
##mb O
##rane O
protein O
were O
found O
in O
all O
affected O
individuals O
in O
six O
w B-Disease
##fs I-Disease
families O
, O
and O
these O
mutations O
were O
associated O
with O
the O
disease O
p O
##hen O
##otype O
. O

w O
##fs O
##1 O
appears O
to O
function O
in O
survival O
of O
is O
##let O
beta O
- O
cells O
and O
neurons O
. O
. O

stable O
interaction O
between O
the O
products O
of O
the O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
tumor B-Disease
suppress O
##or O
genes O
in O
mit O
##otic O
and O
me O
##iot O
##ic O
cells O
. O

br O
##ca O
##1 O
and O
br O
##ca O
##2 O
account O
for O
most O
cases O
of O
f O
##ami O
##lial O
, O
early O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
and O
en O
##code O
products O
that O
each O
interact O
with O
h O
##rad O
##51 O
. O

results O
presented O
here O
show O
that O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
co O
##ex O
##ist O
in O
a O
bio O
##chemical O
complex O
and O
co O
##loc O
##ali O
##ze O
in O
sub O
##nu O
##cle O
##ar O
f O
##oc O
##i O
in O
so O
##matic O
cells O
and O
on O
the O
a O
##xial O
elements O
of O
developing O
s O
##yna O
##pton O
##ema O
##l O
complexes O
. O

like O
br O
##ca O
##1 O
and O
r O
##ad O
##51 O
, O
br O
##ca O
##2 O
relocate O
##s O
to O
p O
##c O
##na O
+ O
replication O
sites O
following O
exposure O
of O
s O
phase O
cells O
to O
h O
##ydro O
##xy O
##ure O
##a O
or O
u O
##v O
i O
##rra O
##diation O
. O

thus O
, O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
participate O
, O
together O
, O
in O
a O
pathway O
( O
s O
) O
associated O
with O
the O
activation O
of O
double O
- O
strand O
break O
repair O
and O
/ O
or O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
. O

d O
##ys O
##function O
of O
this O
pathway O
may O
be O
a O
general O
phenomenon O
in O
the O
majority O
of O
cases O
of O
hereditary B-Disease
breast I-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O
. O

a O
novel O
a O
##rg O
##36 O
##2 O
##ser O
mutation O
in O
the O
s O
##tero O
##l O
27 O
- O
h O
##ydro O
##xy O
##lase O
gene O
( O
c O
##y O
##p O
##27 O
) O
: O
its O
effects O
on O
pre O
- O
m O
##rna O
s O
##p O
##licing O
and O
enzyme O
activity O
. O

a O
novel O
c O
to O
a O
mutation O
in O
the O
s O
##tero O
##l O
27 O
- O
h O
##ydro O
##xy O
##lase O
gene O
( O
c O
##y O
##p O
##27 O
) O
was O
identified O
by O
se O
##quencing O
am O
##plified O
c O
##y O
##p O
##27 O
gene O
products O
from O
a O
patient O
with O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
( O
c B-Disease
##t I-Disease
##x I-Disease
) O
. O

the O
mutation O
changed O
the O
ad O
##ren O
##od O
##ox O
##in O
co O
##fa O
##ctor O
binding O
residue O
36 O
##2 O
##ar O
##g O
to O
36 O
##2 O
##ser O
( O
c O
##gt O
36 O
##2 O
##ar O
##g O
to O
a O
##gt O
36 O
##2 O
##ser O
) O
, O
and O
was O
responsible O
for O
deficiency O
in O
the O
s O
##tero O
##l O
27 O
- O
h O
##ydro O
##xy O
##lase O
activity O
, O
as O
confirmed O
by O
expression O
of O
mutant O
c O
##dn O
##a O
into O
co O
##s O
- O
1 O
cells O
. O

quantitative O
analysis O
showed O
that O
the O
expression O
of O
c O
##y O
##p O
##27 O
gene O
m O
##rna O
in O
the O
patient O
represented O
52 O
. O

5 O
% O
of O
the O
normal O
level O
. O

as O
the O
mutation O
occurred O
at O
the O
pen O
##ult O
##imate O
n O
##uc O
##leo O
##tide O
of O
ex O
##on O
6 O
( O
- O
2 O
position O
of O
ex O
##on O
6 O
- O
intro O
##n O
6 O
s O
##p O
##lice O
site O
) O
of O
the O
gene O
, O
we O
h O
##y O
##pot O
##hes O
##ized O
that O
the O
mutation O
may O
partially O
affect O
the O
normal O
s O
##p O
##licing O
efficiency O
in O
ex O
##on O
6 O
and O
cause O
alternative O
s O
##p O
##licing O
elsewhere O
, O
which O
resulted O
in O
decreased O
trans O
##cript O
in O
the O
patient O
. O

trans O
##fect O
##ion O
of O
constructed O
mini O
##gene O
##s O
, O
with O
or O
without O
the O
mutation O
, O
into O
co O
##s O
- O
1 O
cells O
confirmed O
that O
the O
mutant O
mini O
##gene O
was O
responsible O
for O
a O
m O
##rna O
species O
alternatively O
s O
##p O
##lice O
##d O
at O
an O
activated O
cry O
##ptic O
5 O
s O
##p O
##lice O
site O
88 O
b O
##p O
upstream O
from O
the O
3 O
end O
of O
ex O
##on O
6 O
. O

our O
data O
suggest O
that O
the O
c O
to O
a O
mutation O
at O
the O
pen O
##ult O
##imate O
n O
##uc O
##leo O
##tide O
of O
ex O
##on O
6 O
of O
the O
c O
##y O
##p O
##27 O
gene O
not O
only O
causes O
the O
deficiency B-Disease
in I-Disease
the I-Disease
s I-Disease
##tero I-Disease
##l I-Disease
27 I-Disease
- I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
activity I-Disease
, O
but O
also O
partially O
leads O
to O
alternative O
pre O
- O
m O
##rna O
s O
##p O
##licing O
of O
the O
gene O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
regarding O
effects O
on O
pre O
- O
m O
##rna O
s O
##p O
##licing O
of O
a O
mutation O
at O
the O
- O
2 O
position O
of O
a O
5 O
s O
##p O
##lice O
site O
. O

at O
##m O
g O
##er O
##m O
##line O
mutations O
in O
classical O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
patients O
in O
the O
du O
##tch O
population O
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
at O
##m O
gene O
are O
responsible O
for O
the O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
. O

in O
our O
study O
, O
we O
have O
determined O
the O
at O
##m O
mutation O
spectrum O
in O
19 O
classical O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
including O
some O
immigrant O
populations O
, O
as O
well O
as O
12 O
of O
du O
##tch O
ethnic O
origin O
. O

both O
the O
protein O
t O
##run O
##cation O
test O
( O
p O
##tt O
) O
and O
the O
restriction O
end O
##on O
##uc O
##lea O
##se O
finger O
##print O
##ing O
( O
re O
##f O
) O
method O
were O
used O
and O
compared O
for O
their O
detection O
efficiency O
, O
identifying O
76 O
% O
and O
60 O
% O
of O
the O
mutations O
, O
respectively O
. O

most O
patients O
were O
found O
to O
be O
compound O
he O
##tero O
##zy O
##got O
##e O
. O

seventeen O
mutations O
were O
distinct O
, O
of O
which O
10 O
were O
not O
reported O
previously O
. O

mutations O
are O
small O
del O
##eti O
##ons O
or O
point O
mutations O
frequently O
affecting O
s O
##p O
##lice O
sites O
. O

more O
##over O
, O
a O
16 O
. O

7 O
- O
k O
##b O
g O
##eno O
##mic O
del O
##eti O
##on O
of O
the O
3 O
end O
of O
the O
gene O
, O
most O
likely O
a O
result O
of O
re O
##comb O
##ination O
between O
two O
line O
elements O
, O
was O
identified O
. O

the O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
t O
##ur O
##kis O
##h O
a B-Disease
- I-Disease
t I-Disease
individuals O
, O
was O
previously O
described O
to O
be O
a O
t O
##ur O
##kis O
##h O
a B-Disease
- I-Disease
t I-Disease
founder O
mutation O
. O

the O
presence O
of O
a O
founder O
mutation O
among O
relatively O
small O
ethnic O
population O
groups O
in O
western O
euro O
##pe O
could O
indicate O
a O
high O
carrier O
frequency O
in O
such O
communities O
. O

in O
patients O
of O
du O
##tch O
ethnic O
origin O
, O
however O
, O
no O
significant O
founder O
effect O
could O
be O
identified O
. O

the O
observed O
genetic O
he O
##tero O
##gene O
##ity O
including O
the O
relative O
high O
percentage O
of O
s O
##p O
##lice O
- O
site O
mutations O
had O
no O
reflection O
on O
the O
p O
##hen O
##otype O
. O

all O
patients O
manifest O
##ed O
classical O
a B-Disease
- I-Disease
t I-Disease
and O
increased O
cellular O
radio O
##res O
##istan O
##t O
d O
##na O
synthesis O
. O

determination O
of O
the O
g O
##eno O
##mic O
structure O
of O
the O
co O
##l O
##4 O
##a O
##4 O
gene O
and O
of O
novel O
mutations O
causing O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
al I-Disease
##port I-Disease
syndrome I-Disease
. O

auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
al I-Disease
##port I-Disease
syndrome I-Disease
is O
a O
progressive O
hem B-Disease
##at I-Disease
##uri I-Disease
##c I-Disease
g I-Disease
##lo I-Disease
##mer I-Disease
##ulon I-Disease
##ep I-Disease
##hr I-Disease
##itis I-Disease
characterized O
by O
g B-Disease
##lo I-Disease
##mer I-Disease
##ular I-Disease
basement I-Disease
membrane I-Disease
abnormal I-Disease
##ities I-Disease
and O
associated O
with O
mutations O
in O
either O
the O
co O
##l O
##4 O
##a O
##3 O
or O
the O
co O
##l O
##4 O
##a O
##4 O
gene O
, O
which O
en O
##code O
the O
alpha O
##3 O
and O
alpha O
##4 O
type O
i O
##v O
co O
##lla O
##gen O
chains O
, O
respectively O
. O

to O
date O
, O
mutation O
screening O
in O
the O
two O
genes O
has O
been O
hampered O
by O
the O
lack O
of O
g O
##eno O
##mic O
structure O
information O
. O

we O
report O
here O
the O
complete O
characterization O
of O
the O
48 O
ex O
##ons O
of O
the O
co O
##l O
##4 O
##a O
##4 O
gene O
, O
a O
comprehensive O
gene O
screen O
, O
and O
the O
subsequent O
detection O
of O
10 O
novel O
mutations O
in O
eight O
patients O
diagnosed O
with O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
al I-Disease
##port I-Disease
syndrome I-Disease
. O

further O
##more O
, O
we O
identified O
a O
g O
##ly O
##cine O
to O
al O
##ani O
##ne O
substitution O
in O
the O
co O
##lla O
##gen O
##ous O
domain O
that O
is O
apparently O
silent O
in O
the O
he O
##tero O
##zy O
##go O
##us O
carriers O
, O
in O
11 O
. O

5 O
% O
of O
all O
control O
individuals O
, O
and O
in O
one O
control O
individual O
ho O
##mo O
##zy O
##go O
##us O
for O
this O
g O
##ly O
##cine O
substitution O
. O

there O
has O
been O
no O
previous O
finding O
of O
a O
g O
##ly O
##cine O
substitution O
that O
is O
not O
associated O
with O
any O
obvious O
p O
##hen O
##otype O
in O
ho O
##mo O
##zy O
##go O
##us O
individuals O
. O

founder O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
mutations O
in O
f O
##rench O
can O
##adia O
##n O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

we O
have O
identified O
four O
mutations O
in O
each O
of O
the O
breast B-Disease
cancer I-Disease
- O
su O
##s O
##ce O
##pt O
##ibility O
genes O
, O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
, O
in O
f O
##rench O
can O
##adia O
##n O
breast B-Disease
cancer I-Disease
and O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
from O
que O
##be O
##c O
. O

to O
identify O
founder O
effects O
, O
we O
examined O
independently O
as O
##cer O
##tain O
##ed O
f O
##rench O
can O
##adia O
##n O
cancer B-Disease
families O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O

mutations O
were O
found O
in O
41 O
of O
97 O
families O
. O

six O
of O
eight O
mutations O
were O
observed O
at O
least O
twice O
. O

the O
br O
##ca O
##1 O
c O
##44 O
##46 O
##t O
mutation O
was O
the O
most O
common O
mutation O
found O
, O
followed O
by O
the O
br O
##ca O
##2 O
87 O
##65 O
##dela O
##g O
mutation O
. O

together O
, O
these O
mutations O
were O
found O
in O
28 O
of O
41 O
families O
identified O
to O
have O
a O
mutation O
. O

the O
odds O
of O
detection O
of O
any O
of O
the O
four O
br O
##ca O
##1 O
mutations O
was O
18 O
. O

7 O
##x O
greater O
if O
one O
or O
more O
cases O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
were O
also O
present O
in O
the O
family O
. O

the O
odds O
of O
detection O
of O
any O
of O
the O
four O
br O
##ca O
##2 O
mutations O
was O
5 O
. O

3 O
##x O
greater O
if O
there O
were O
at O
least O
five O
cases O
of O
breast B-Disease
cancer I-Disease
in O
the O
family O
. O

interesting O
##ly O
, O
the O
presence O
of O
a O
breast B-Disease
cancer I-Disease
case O
[UNK] O
36 O
years O
of O
age O
was O
strongly O
predict O
##ive O
of O
the O
presence O
of O
any O
of O
the O
eight O
mutations O
screened O
. O

carriers O
of O
the O
same O
mutation O
, O
from O
different O
families O
, O
shared O
similar O
ha O
##p O
##lot O
##ype O
##s O
, O
indicating O
that O
the O
mutant O
all O
##ele O
##s O
were O
likely O
to O
be O
identical O
by O
descent O
for O
a O
mutation O
in O
the O
founder O
population O
. O

the O
identification O
of O
common O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
mutations O
will O
facilitate O
carrier O
detection O
in O
f O
##rench O
can O
##adia O
##n O
breast B-Disease
cancer I-Disease
and O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

are O
d O
##p O
##7 O
##1 O
and O
d O
##p O
##14 O
##0 O
brain O
d O
##ys O
##tro O
##phi O
##n O
is O
##of O
##orms O
related O
to O
cognitive B-Disease
imp I-Disease
##air I-Disease
##ment I-Disease
in O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
? O

molecular O
study O
and O
ne O
##uro O
##psy O
##cho O
##logical O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B-Disease
imp I-Disease
##air I-Disease
##ment I-Disease
observed O
in O
most O
d B-Disease
##m I-Disease
##d I-Disease
patients O
. O

complete O
analysis O
of O
the O
d O
##ys O
##tro O
##phi O
##n O
gene O
was O
performed O
to O
define O
the O
local O
##ization O
of O
del O
##eti O
##ons O
and O
du O
##plication O
##s O
in O
relation O
to O
the O
different O
d B-Disease
##m I-Disease
##d I-Disease
promoter O
##s O
. O

q O
##ual O
##itative O
analysis O
of O
the O
d O
##p O
##7 O
##1 O
trans O
##cript O
and O
testing O
for O
the O
specific O
first O
ex O
##on O
of O
d O
##p O
##14 O
##0 O
were O
also O
carried O
out O
. O

ne O
##uro O
##psy O
##cho O
##logical O
analysis O
assessed O
verbal O
and O
v O
##is O
##uo O
##sp O
##ati O
##al O
intelligence O
, O
verbal O
memory O
, O
and O
reading O
skills O
. O

comparison O
of O
molecular O
and O
ps O
##ych O
##ometric O
findings O
demonstrated O
that O
del O
##eti O
##ons O
and O
du O
##plication O
##s O
that O
were O
localized O
in O
the O
di O
##stal O
part O
of O
the O
gene O
seemed O
to O
be O
prefer O
##ential O
##ly O
associated O
with O
cognitive B-Disease
imp I-Disease
##air I-Disease
##ment I-Disease
. O

two O
altered O
d O
##p O
##7 O
##1 O
trans O
##cripts O
and O
two O
deleted O
d O
##p O
##14 O
##0 O
d O
##na O
sequences O
were O
found O
in O
four O
patients O
with O
severe O
cerebral B-Disease
d I-Disease
##ys I-Disease
##function I-Disease
. O

these O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
di O
##stal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
d B-Disease
##m I-Disease
##d I-Disease
is O
##of O
##orms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B-Disease
imp I-Disease
##air I-Disease
##ment I-Disease
associated O
with O
d B-Disease
##m I-Disease
##d I-Disease
. O
. O

i O
##13 O
##0 O
##7 O
##k O
a O
##p O
##c O
and O
h O
##m O
##l O
##h O
##1 O
mutations O
in O
a O
non O
- O
j O
##ew O
##ish O
family O
with O
hereditary B-Disease
non I-Disease
- I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

we O
describe O
a O
f O
##rench O
can O
##adia O
##n O
hereditary B-Disease
non I-Disease
- I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
( O
h B-Disease
##n I-Disease
##p I-Disease
##cc I-Disease
) O
kind O
##red O
which O
carries O
a O
novel O
t O
##run O
##cating O
mutation O
in O
h O
##m O
##l O
##h O
##1 O
. O

interesting O
##ly O
, O
the O
i O
##13 O
##0 O
##7 O
##k O
a O
##p O
##c O
p O
##oly O
##mor O
##phism O
, O
associated O
with O
an O
increased O
risk O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
, O
is O
also O
present O
in O
this O
family O
. O

the O
i O
##13 O
##0 O
##7 O
##k O
p O
##oly O
##mor O
##phism O
has O
previously O
only O
been O
identified O
in O
individuals O
of O
self O
- O
reported O
ash O
##ken O
##azi O
j O
##ew O
##ish O
origins O
. O

in O
addition O
, O
in O
this O
family O
, O
there O
appears O
to O
be O
no O
relationship O
between O
the O
i O
##13 O
##0 O
##7 O
##k O
p O
##oly O
##mor O
##phism O
and O
the O
presence O
or O
absence O
of O
cancer B-Disease
. O
. O

identification O
of O
a O
novel O
mutation O
of O
the O
c O
##po O
gene O
in O
a O
j O
##apa O
##nese O
hereditary B-Disease
cop I-Disease
##rop I-Disease
##or I-Disease
##phy I-Disease
##ria I-Disease
family O
. O

hereditary B-Disease
cop I-Disease
##rop I-Disease
##or I-Disease
##phy I-Disease
##ria I-Disease
( O
h B-Disease
##c I-Disease
##p I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disease I-Disease
characterized O
by O
a O
deficiency B-Disease
of I-Disease
cop I-Disease
##rop I-Disease
##or I-Disease
##phy I-Disease
##rino I-Disease
##gen I-Disease
o I-Disease
##xi I-Disease
##das I-Disease
##e I-Disease
( O
c O
##po O
) O
caused O
by O
a O
mutation O
in O
the O
c O
##po O
gene O
. O

only O
11 O
mutations O
of O
the O
gene O
have O
been O
reported O
in O
h B-Disease
##c I-Disease
##p I-Disease
patients O
. O

we O
report O
another O
mutation O
in O
a O
j O
##apa O
##nese O
family O
. O

polymer O
##ase O
chain O
reaction O
- O
single O
strand O
conform O
##ational O
p O
##oly O
##mor O
##phism O
and O
direct O
sequence O
analyses O
demonstrated O
a O
c O
to O
t O
substitution O
in O
ex O
##on O
1 O
of O
the O
c O
##po O
gene O
at O
n O
##uc O
##leo O
##tide O
position O
85 O
, O
which O
lies O
in O
the O
put O
##ative O
pre O
##se O
##quence O
for O
targeting O
to O
mit O
##och O
##ond O
##ria O
. O

this O
mutation O
changes O
the O
co O
##don O
for O
g O
##lut O
##amine O
to O
a O
termination O
co O
##don O
at O
amino O
acid O
position O
29 O
. O

ma O
##ei O
restriction O
analysis O
showed O
two O
other O
carriers O
in O
the O
family O
. O

the O
c O
- O
t O
mutation O
is O
located O
within O
a O
recently O
proposed O
put O
##ative O
alternative O
translation O
initiation O
co O
##don O
( O
t O
##ic O
- O
1 O
) O
, O
supporting O
that O
t O
##ic O
- O
1 O
is O
the O
real O
t O
##ic O
rather O
than O
t O
##ic O
- O
2 O
. O
. O

human B-Disease
complement I-Disease
factor I-Disease
h I-Disease
deficiency I-Disease
associated O
with O
hem B-Disease
##oly I-Disease
##tic I-Disease
u I-Disease
##rem I-Disease
##ic I-Disease
syndrome I-Disease
. O

this O
study O
reports O
on O
six O
cases O
of O
deficiency B-Disease
in I-Disease
the I-Disease
human I-Disease
complement I-Disease
regulatory I-Disease
protein I-Disease
factor I-Disease
h I-Disease
( O
f O
##h O
) O
in O
the O
context O
of O
an O
acute B-Disease
re I-Disease
##nal I-Disease
disease I-Disease
. O

five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
id O
##io O
##pathic O
hem B-Disease
##oly I-Disease
##tic I-Disease
u I-Disease
##rem I-Disease
##ic I-Disease
syndrome I-Disease
( O
h B-Disease
##us I-Disease
) O
. O

two O
of O
the O
children O
exhibited O
a O
ho O
##mo O
##zy O
##go O
##us O
deficiency O
characterized O
by O
the O
absence O
of O
the O
150 O
- O
k O
##d O
form O
of O
factor O
h O
and O
the O
presence O
, O
upon O
im O
##mu O
##nob O
##lot O
##ting O
, O
of O
the O
42 O
- O
k O
##d O
factor O
h O
- O
like O
protein O
1 O
( O
f O
##hl O
- O
1 O
) O
and O
other O
f O
##h O
- O
related O
protein O
( O
f O
##hr O
) O
bands O
. O

southern O
b O
##lot O
and O
p O
##c O
##r O
analysis O
of O
d O
##na O
of O
one O
patient O
with O
ho O
##mo O
##zy O
##go O
##us O
deficiency O
ruled O
out O
the O
presence O
of O
a O
large O
del O
##eti O
##on O
of O
the O
f O
##h O
gene O
as O
the O
underlying O
defect O
for O
the O
deficiency O
. O

the O
other O
four O
children O
presented O
with O
he O
##tero O
##zy O
##go O
##us O
deficiency O
and O
exhibited O
a O
normal O
im O
##mu O
##nob O
##lot O
##ting O
pattern O
of O
proteins O
of O
the O
f O
##h O
family O
. O

factor B-Disease
h I-Disease
deficiency I-Disease
is O
the O
only O
complement B-Disease
deficiency I-Disease
associated O
with O
h B-Disease
##us I-Disease
. O

these O
observations O
suggest O
a O
role O
for O
f O
##h O
and O
/ O
or O
f O
##h O
receptors O
in O
the O
path O
##ogen O
##esis O
of O
id O
##io O
##pathic O
h B-Disease
##us I-Disease
. O
. O

further O
evidence O
for O
a O
major O
ancient O
mutation O
underlying O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
from O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
studies O
in O
the O
j O
##apa O
##nese O
population O
. O

the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
mutation O
is O
an O
unstable O
( O
c O
##t O
##g O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosome O
##s O
but O
am O
##plified O
to O
50 O
- O
3000 O
copies O
on O
d B-Disease
##m I-Disease
chromosome O
##s O
. O

previous O
findings O
in O
ca O
##uca O
##sian O
populations O
of O
a O
d B-Disease
##m I-Disease
founder O
chromosome O
raise O
a O
question O
about O
the O
molecular O
events O
involved O
in O
the O
expansion O
mutation O
. O

to O
investigate O
whether O
a O
founder O
chromosome O
for O
the O
d B-Disease
##m I-Disease
mutation O
exists O
in O
the O
j O
##apa O
##nese O
population O
, O
we O
g O
##eno O
##type O
##d O
families O
using O
p O
##oly O
##morphic O
markers O
near O
the O
( O
c O
##t O
##g O
) O
n O
repeat O
region O
and O
constructed O
ha O
##p O
##lot O
##ype O
##s O
. O

six O
different O
ha O
##p O
##lot O
##ype O
##s O
were O
found O
and O
d B-Disease
##m I-Disease
all O
##ele O
##s O
were O
always O
ha O
##p O
##lot O
##ype O
a O
. O

to O
find O
an O
origin O
of O
the O
( O
c O
##t O
##g O
) O
n O
repeat O
mutation O
and O
to O
investigate O
the O
mechanism O
of O
the O
expansion O
mutation O
in O
the O
j O
##apa O
##nese O
population O
we O
have O
studied O
90 O
j O
##apa O
##nese O
d B-Disease
##m I-Disease
families O
comprising O
190 O
affected O
and O
130 O
un O
##af O
##fected O
members O
. O

the O
results O
suggest O
that O
a O
few O
common O
ancestral O
mutations O
in O
both O
ca O
##uca O
##sian O
and O
j O
##apa O
##nese O
populations O
have O
originated O
by O
expansion O
of O
an O
ancestral O
n O
= O
5 O
repeat O
to O
n O
= O
19 O
- O
37 O
copies O
. O

these O
data O
support O
multi O
##ste O
##p O
models O
of O
triple O
##t O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
d B-Disease
##m I-Disease
and O
fried B-Disease
##re I-Disease
##ich I-Disease
##s I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O
. O

the O
molecular O
basis O
of O
c B-Disease
##6 I-Disease
deficiency I-Disease
in O
the O
western O
cape O
, O
south O
a O
##f O
##rica O
. O

deficiency B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c O
##6 O
) O
has O
been O
reported O
in O
a O
number O
of O
families O
from O
the O
western O
cape O
, O
south O
a O
##f O
##rica O
. O

men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
disease I-Disease
is O
endemic O
in O
the O
cape O
and O
almost O
all O
p O
##ed O
##ig O
##ree O
##s O
of O
total O
c B-Disease
##6 I-Disease
deficiency I-Disease
( O
c O
##6 O
##q O
##0 O
) O
have O
been O
as O
##cer O
##tain O
##ed O
because O
of O
re O
##current O
disease O
. O

we O
have O
sequence O
##d O
the O
expressed O
ex O
##ons O
of O
the O
c O
##6 O
gene O
from O
selected O
cases O
and O
have O
found O
three O
molecular O
defects O
leading O
to O
total O
deficiency O
87 O
##9 O
##del O
##g O
, O
which O
is O
the O
common O
defect O
in O
the O
cape O
and O
hit O
##her O
##to O
un O
##re O
##port O
##ed O
, O
and O
119 O
##5 O
##del O
##c O
and O
1936 O
##del O
##g O
, O
which O
have O
been O
previously O
reported O
in O
a O
##f O
##rica O
##n O
- O
am O
##eric O
##ans O
. O

we O
also O
show O
that O
the O
87 O
##9 O
##del O
##g O
and O
119 O
##5 O
##del O
##c O
defects O
are O
associated O
with O
characteristic O
c O
##6 O
/ O
c O
##7 O
region O
d O
##na O
marker O
ha O
##p O
##lot O
##ype O
##s O
, O
although O
small O
variations O
were O
observed O
. O

the O
1936 O
##del O
##g O
defect O
was O
observed O
only O
once O
in O
the O
cape O
, O
but O
its O
associated O
ha O
##p O
##lot O
##ype O
could O
be O
de O
##duced O
. O

the O
data O
from O
the O
ha O
##p O
##lot O
##ype O
##s O
indicate O
that O
these O
three O
molecular O
defects O
account O
for O
the O
defects O
in O
all O
the O
38 O
unrelated O
c O
##6 O
##q O
##0 O
individuals O
we O
have O
studied O
from O
the O
cape O
. O

we O
have O
also O
observed O
the O
87 O
##9 O
##del O
##g O
defect O
in O
two O
du O
##tch O
c B-Disease
##6 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
kind O
##red O
##s O
, O
but O
the O
87 O
##9 O
##del O
##g O
defect O
in O
the O
cape O
probably O
did O
not O
come O
from O
the O
net O
##her O
##lands O
. O
. O

complement B-Disease
c I-Disease
##7 I-Disease
deficiency I-Disease
: O
seven O
further O
molecular O
defects O
and O
their O
associated O
marker O
ha O
##p O
##lot O
##ype O
##s O
. O

seven O
further O
molecular O
bases O
of O
c B-Disease
##7 I-Disease
deficiency I-Disease
are O
described O
. O

all O
these O
new O
molecular O
defects O
involve O
single O
- O
n O
##uc O
##leo O
##tide O
events O
, O
del O
##eti O
##ons O
and O
substitution O
##s O
, O
some O
of O
which O
alter O
s O
##p O
##lice O
sites O
, O
and O
others O
co O
##don O
##s O
. O

they O
are O
distributed O
along O
the O
c O
##7 O
gene O
, O
but O
predominantly O
towards O
the O
3 O
end O
. O

all O
were O
found O
in O
compound O
he O
##tero O
##zy O
##go O
##us O
individuals O
. O

the O
c O
##6 O
/ O
c O
##7 O
marker O
ha O
##p O
##lot O
##ype O
##s O
associated O
with O
most O
c B-Disease
##7 I-Disease
defects I-Disease
are O
ta O
##bula O
##ted O
. O
. O

a O
genome O
- O
wide O
search O
for O
ch O
##rom O
##oso O
##mal O
lo O
##ci O
linked O
to O
mental O
health O
well O
##ness O
in O
relatives O
at O
high O
risk O
for O
bi B-Disease
##pol I-Disease
##ar I-Disease
affect I-Disease
##ive I-Disease
disorder I-Disease
among O
the O
old O
order O
am O
##ish O
. O

bi B-Disease
##pol I-Disease
##ar I-Disease
affect I-Disease
##ive I-Disease
disorder I-Disease
( O
b B-Disease
##pad I-Disease
; O
man B-Disease
##ic I-Disease
- I-Disease
de I-Disease
##pressive I-Disease
illness I-Disease
) O
is O
characterized O
by O
episodes O
of O
man B-Disease
##ia I-Disease
and O
/ O
or O
h B-Disease
##y I-Disease
##po I-Disease
##mani I-Disease
##a I-Disease
inter O
##spersed O
with O
periods O
of O
depression B-Disease
. O

compelling O
evidence O
supports O
a O
significant O
genetic O
component O
in O
the O
su O
##s O
##ce O
##pt O
##ibility O
to O
develop O
b B-Disease
##pad I-Disease
. O

to O
date O
, O
however O
, O
link O
##age O
studies O
have O
attempted O
only O
to O
identify O
ch O
##rom O
##oso O
##mal O
lo O
##ci O
that O
cause O
or O
increase O
the O
risk O
of O
developing O
b B-Disease
##pad I-Disease
. O

to O
determine O
whether O
there O
could O
be O
protective O
all O
##ele O
##s O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
b B-Disease
##pad I-Disease
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B-Disease
disorders I-Disease
, O
we O
used O
mental O
health O
well O
##ness O
( O
absence O
of O
any O
psychiatric B-Disease
disorder I-Disease
) O
as O
the O
p O
##hen O
##otype O
in O
our O
genome O
- O
wide O
link O
##age O
scan O
of O
several O
large O
multi O
##gene O
##ration O
old O
order O
am O
##ish O
p O
##ed O
##ig O
##ree O
##s O
exhibiting O
an O
extremely O
high O
incidence O
of O
b B-Disease
##pad I-Disease
. O

we O
have O
found O
strong O
evidence O
for O
a O
lo O
##cus O
on O
chromosome O
4 O
##p O
at O
d O
##4 O
##s O
##29 O
##4 O
##9 O
( O
maximum O
gene O
##hun O
##ter O
- O
plus O
non O
##par O
##ame O
##tric O
link O
##age O
score O
= O
4 O
. O
05 O
, O
p O
= O
5 O
. O
22 O
x O
10 O
( O
- O
4 O
) O
; O
si O
##b O
##pal O
p O
##em O
##pi O
##rical O
value O
[UNK] O
3 O
x O
10 O
( O
- O
5 O
) O
) O
and O
suggest O
##ive O
evidence O
for O
a O
lo O
##cus O
on O
chromosome O
4 O
##q O
at O
d O
##4 O
##s O
##39 O
##7 O
( O
maximum O
gene O
##hun O
##ter O
- O
plus O
non O
##par O
##ame O
##tric O
link O
##age O
score O
= O
3 O
. O
29 O
, O
p O
= O
2 O
. O
57 O
x O
10 O
( O
- O
3 O
) O
; O
si O
##b O
##pal O
p O
##em O
##pi O
##rical O
value O
[UNK] O
1 O
x O
10 O
( O
- O
3 O
) O
) O
that O
are O
linked O
to O
mental O
health O
well O
##ness O
. O

these O
findings O
are O
consistent O
with O
the O
hypothesis O
that O
certain O
all O
##ele O
##s O
could O
prevent O
or O
modify O
the O
clinical O
manifest O
##ations O
of O
b B-Disease
##pad I-Disease
and O
perhaps O
other O
related O
affect B-Disease
##ive I-Disease
disorders I-Disease
. O

segregation O
distortion O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disease I-Disease
which O
, O
in O
the O
typical O
p O
##ed O
##ig O
##ree O
, O
shows O
a O
three O
generation O
anticipation O
ca O
##sca O
##de O
. O

this O
results O
in O
in B-Disease
##fer I-Disease
##tility I-Disease
and O
con B-Disease
##gen I-Disease
##ital I-Disease
my I-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
c B-Disease
##d I-Disease
##m I-Disease
) O
with O
the O
disappearance O
of O
d B-Disease
##m I-Disease
in O
that O
p O
##ed O
##ig O
##ree O
. O

the O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
prefer O
##ential O
transmission O
of O
the O
larger O
all O
##ele O
at O
the O
d B-Disease
##m I-Disease
lo O
##cus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
d B-Disease
##m I-Disease
in O
the O
population O
. O

in O
a O
survey O
of O
d B-Disease
##m I-Disease
in O
northern O
i O
##rel O
##and O
, O
59 O
p O
##ed O
##ig O
##ree O
##s O
were O
as O
##cer O
##tain O
##ed O
. O

si O
##bs O
##hips O
where O
the O
status O
of O
all O
the O
members O
had O
been O
identified O
were O
examined O
to O
determine O
the O
transmission O
of O
the O
d B-Disease
##m I-Disease
expansion O
from O
affected O
parents O
to O
their O
offspring O
. O

where O
the O
transmitting O
parent O
was O
male O
, O
58 O
. O

3 O
% O
of O
the O
offspring O
were O
affected O
, O
and O
in O
the O
case O
of O
a O
female O
transmitting O
parent O
, O
68 O
. O

7 O
% O
were O
affected O
. O

studies O
on O
me O
##iot O
##ic O
drive O
in O
d B-Disease
##m I-Disease
have O
shown O
increased O
transmission O
of O
the O
larger O
all O
##ele O
at O
the O
d B-Disease
##m I-Disease
lo O
##cus O
in O
non O
- O
d O
##m O
he O
##tero O
##zy O
##got O
##es O
for O
c O
##t O
##gn O
. O

this O
study O
provides O
further O
evidence O
that O
the O
d B-Disease
##m I-Disease
expansion O
tends O
to O
be O
transmitted O
prefer O
##ential O
##ly O
. O

diagnosis O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
. O

if O
un O
##tre O
##ated O
, O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
can O
cause O
serious O
illness O
and O
early B-Disease
death I-Disease
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
diagnosed O
. O

the O
corners O
##tone O
of O
screening O
and O
case O
detection O
is O
the O
measurement O
of O
serum O
transfer O
##rin O
sat O
##uration O
and O
the O
serum O
f O
##er O
##rit O
##in O
level O
. O

once O
the O
diagnosis O
is O
suspected O
, O
physicians O
must O
use O
serum O
f O
##er O
##rit O
##in O
levels O
and O
he O
##pa O
##tic O
iron O
stores O
on O
liver O
bio O
##psy O
specimens O
to O
assess O
patients O
for O
the O
presence O
of O
iron B-Disease
over I-Disease
##load I-Disease
. O

liver O
bio O
##psy O
is O
also O
used O
to O
establish O
the O
presence O
or O
absence O
of O
c B-Disease
##ir I-Disease
##r I-Disease
##hos I-Disease
##is I-Disease
, O
which O
can O
affect O
pro O
##gno O
##sis O
and O
management O
. O

a O
d O
##na O
- O
based O
test O
for O
the O
h O
##fe O
gene O
is O
commercially O
available O
, O
but O
its O
place O
in O
the O
diagnosis O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
is O
still O
being O
evaluated O
. O

currently O
, O
the O
most O
useful O
role O
for O
this O
test O
is O
in O
the O
detection O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
in O
the O
family O
members O
of O
patients O
with O
a O
proven O
case O
of O
the O
disease O
. O

it O
is O
crucial O
to O
di O
##ag O
##nose O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
before O
he B-Disease
##pa I-Disease
##tic I-Disease
c I-Disease
##ir I-Disease
##r I-Disease
##hos I-Disease
##is I-Disease
develops O
because O
p O
##hl O
##eb O
##oto O
##my O
therapy O
can O
a O
##vert O
serious O
chronic O
disease O
and O
can O
even O
lead O
to O
normal O
life O
expect O
##ancy O
. O
. O

prevalence O
of O
the O
i O
##13 O
##0 O
##7 O
##k O
a B-Disease
##p I-Disease
##c I-Disease
gene O
variant O
in O
is O
##rae O
##li O
j O
##ews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

background O
[UNK] O
aims O
is O
##rae O
##li O
j O
##ews O
of O
euro O
##pe O
##an O
birth O
, O
i O
. O
e O
. O
, O
ash O
##ken O
##azi O
##m O
, O
have O
the O
highest O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
incidence O
of O
any O
is O
##rae O
##li O
ethnic O
group O
. O

the O
i O
##13 O
##0 O
##7 O
##k O
a B-Disease
##p I-Disease
##c I-Disease
gene O
variant O
was O
found O
in O
6 O
. O

1 O
% O
of O
am O
##eric O
##an O
j O
##ews O
, O
28 O
% O
of O
their O
f O
##ami O
##lial O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
cases O
, O
but O
not O
in O
non O
- O
j O
##ews O
. O

we O
assessed O
the O
i O
##13 O
##0 O
##7 O
##k O
prevalence O
in O
is O
##rae O
##li O
j O
##ews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

methods O
d O
##na O
samples O
from O
500 O
unrelated O
j O
##ews O
of O
euro O
##pe O
##an O
or O
non O
- O
euro O
##pe O
##an O
origin O
, O
with O
or O
without O
a O
personal O
and O
/ O
or O
family O
history O
of O
neo B-Disease
##p I-Disease
##lasia I-Disease
, O
were O
examined O
for O
the O
i O
##13 O
##0 O
##7 O
##k O
variant O
by O
the O
all O
##ele O
- O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
( O
as O
##o O
) O
method O
. O

results O
in O
persons O
at O
average O
risk O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
, O
i O
##13 O
##0 O
##7 O
##k O
was O
found O
in O
5 O
. O

0 O
% O
of O
120 O
euro O
##pe O
##an O
and O
1 O
. O

6 O
% O
of O
188 O
non O
- O
euro O
##pe O
##an O
j O
##ews O
( O
p O
= O
0 O
. O
08 O
) O
. O

it O
occurred O
in O
15 O
. O

4 O
% O
of O
52 O
ash O
##ken O
##azi O
is O
##rae O
##lis O
with O
f O
##ami O
##lial O
cancer B-Disease
( O
p O
= O
0 O
. O
02 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
euro O
##pe O
##an O
j O
##ews O
at O
increased O
cancer B-Disease
risk O
. O

color B-Disease
##ec I-Disease
##tal I-Disease
neo I-Disease
##p I-Disease
##lasia I-Disease
occurred O
personally O
or O
in O
the O
families O
of O
13 O
of O
20 O
ash O
##ken O
##azi O
i O
##13 O
##0 O
##7 O
##k O
carriers O
, O
8 O
of O
whom O
also O
had O
a O
personal O
or O
family O
history O
of O
non O
##co O
##lon O
##ic O
neo B-Disease
##p I-Disease
##lasia I-Disease
. O

conclusions O
the O
i O
##13 O
##0 O
##7 O
##k O
a O
##p O
##c O
variant O
may O
represent O
a O
su O
##s O
##ce O
##pt O
##ibility O
gene O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
, I-Disease
or I-Disease
other I-Disease
, I-Disease
cancer I-Disease
##s I-Disease
in O
ash O
##ken O
##azi O
j O
##ews O
, O
and O
partially O
explains O
the O
higher O
incidence O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
in O
euro O
##pe O
##an O
is O
##rae O
##lis O
. O

systematic O
analysis O
of O
cop O
##rop O
##or O
##phy O
##rino O
##gen O
o O
##xi O
##das O
##e O
gene O
defects O
in O
hereditary B-Disease
cop I-Disease
##rop I-Disease
##or I-Disease
##phy I-Disease
##ria I-Disease
and O
mutation O
update O
. O

hereditary B-Disease
cop I-Disease
##rop I-Disease
##or I-Disease
##phy I-Disease
##ria I-Disease
( O
h B-Disease
##c I-Disease
) O
is O
an O
acute O
he B-Disease
##pa I-Disease
##tic I-Disease
p I-Disease
##or I-Disease
##phy I-Disease
##ria I-Disease
with O
auto O
##so O
##mal O
dominant O
inheritance O
caused O
by O
def B-Disease
##icient I-Disease
activity I-Disease
of I-Disease
cop I-Disease
##rop I-Disease
##or I-Disease
##phy I-Disease
##rino I-Disease
##gen I-Disease
ii I-Disease
##i I-Disease
o I-Disease
##xi I-Disease
##das I-Disease
##e I-Disease
( O
c O
##po O
) O
. O

clinical O
manifest O
##ations O
of O
the O
disease O
are O
characterized O
by O
acute O
attacks O
of O
ne B-Disease
##uro I-Disease
##logical I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
often O
pre O
##ci O
##pit O
##ated O
by O
drugs O
, O
fast O
##ing O
, O
c O
##yclic O
##al O
ho O
##rmon O
##al O
changes O
, O
or O
infectious B-Disease
diseases I-Disease
. O

skin O
photos O
##ens O
##iti O
##vity O
may O
also O
be O
present O
. O

the O
seven O
ex O
##ons O
, O
the O
ex O
##on O
/ O
intro O
##n O
boundaries O
and O
part O
of O
3 O
non O
##co O
##ding O
sequence O
of O
the O
c O
##po O
gene O
were O
systematically O
analyzed O
by O
an O
ex O
##on O
- O
by O
- O
ex O
##on O
den O
##at O
##uring O
gradient O
gel O
electro O
##ph O
##ores O
##is O
( O
d O
##gg O
##e O
) O
strategy O
followed O
by O
direct O
se O
##quencing O
in O
seven O
unrelated O
he O
##tero O
##zy O
##go O
##us O
h B-Disease
##c I-Disease
patients O
from O
f O
##rance O
, O
ho O
##lland O
, O
and O
c O
##ze O
##ch O
republic O
. O

seven O
novel O
mutations O
and O
two O
new O
p O
##oly O
##mor O
##phism O
##s O
were O
detected O
. O

among O
these O
mutations O
two O
are O
miss O
##ense O
( O
g O
##19 O
##7 O
##w O
, O
w O
##42 O
##7 O
##r O
) O
, O
two O
are O
nonsense O
( O
q O
##30 O
##6 O
##x O
, O
q O
##38 O
##5 O
##x O
) O
, O
two O
are O
small O
del O
##eti O
##ons O
( O
66 O
##2 O
##de O
##14 O
##b O
##p O
; O
116 O
##8 O
##del O
##3 O
##b O
##p O
removing O
a O
g O
##ly O
##cine O
at O
position O
390 O
) O
, O
and O
one O
is O
a O
s O
##p O
##licing O
mutation O
( O
i O
##v O
##s O
##1 O
- O
15 O
##c O
- O
- O
[UNK] O
g O
) O
which O
creates O
a O
new O
accept O
##or O
s O
##p O
##lice O
site O
. O

the O
path O
##ological O
significance O
of O
the O
point O
mutations O
g O
##19 O
##7 O
##w O
, O
w O
##42 O
##7 O
##r O
, O
and O
the O
in O
- O
frame O
del O
##eti O
##on O
390 O
##del O
##gly O
were O
assessed O
by O
their O
respective O
expression O
in O
a O
pro O
##kar O
##yo O
##tic O
system O
using O
site O
- O
directed O
m O
##uta O
##genesis O
. O

these O
mutations O
resulted O
in O
the O
absence O
or O
a O
dramatic O
decrease O
of O
c O
##po O
activity O
. O

the O
two O
p O
##oly O
##mor O
##phism O
##s O
were O
localized O
in O
non O
##co O
##ding O
part O
of O
the O
gene O
1 O
) O
a O
c O
/ O
g O
p O
##oly O
##mor O
##phism O
in O
the O
pro O
##moto O
##r O
region O
, O
142 O
b O
##p O
upstream O
from O
the O
transcription O
##al O
initiation O
site O
( O
- O
142 O
##c O
/ O
g O
) O
, O
and O
2 O
) O
a O
6 O
b O
##p O
del O
##eti O
##on O
p O
##oly O
##mor O
##phism O
in O
the O
3 O
non O
##co O
##ding O
part O
of O
the O
c O
##po O
gene O
, O
57 O
##4 O
b O
##p O
downstream O
of O
the O
last O
base O
of O
the O
normal O
termination O
co O
##don O
( O
+ O
57 O
##4 O
del O
##att O
##ct O
##t O
) O
. O

five O
in O
##tra O
##genic O
dim O
##or O
##phism O
##s O
are O
now O
well O
characterized O
and O
the O
high O
degree O
of O
all O
##eli O
##c O
he O
##tero O
##gene O
##ity O
in O
h B-Disease
##c I-Disease
is O
demonstrated O
with O
seven O
new O
different O
mutations O
making O
a O
total O
of O
nineteen O
c O
##po O
gene B-Disease
defects I-Disease
reported O
so O
far O
. O
. O

coincidence O
of O
two O
novel O
a O
##ryl O
##sul O
##fa O
##tase O
a O
all O
##ele O
##s O
and O
mutation O
45 O
##9 O
+ O
1 O
##g O
[UNK] O
a O
within O
a O
family O
with O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
: O
molecular O
basis O
of O
p O
##hen O
##otypic O
he O
##tero O
##gene O
##ity O
. O

in O
a O
family O
with O
three O
siblings O
, O
one O
developed O
classical O
late O
infant O
##ile O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
def O
##icient O
a O
##ryl O
##sul O
##fa O
##tase O
a O
( O
a O
##rsa O
) O
activity O
and O
increased O
gal O
##act O
##osy O
##ls O
##ulf O
##ati O
##de O
( O
g O
##s O
) O
ex O
##cre O
##tion O
. O

the O
two O
other O
siblings O
, O
apparently O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
respectively O
, O
and O
their O
father O
, O
apparently O
healthy O
as O
well O
, O
presented O
a O
##rsa O
and O
g O
##s O
values O
within O
the O
range O
of O
m B-Disease
##ld I-Disease
patients O
. O

mutation O
screening O
and O
sequence O
analysis O
disclosed O
the O
involvement O
of O
three O
different O
a O
##rsa O
mutations O
being O
the O
molecular O
basis O
of O
in O
##tra O
##fa O
##mi O
##lial O
p O
##hen O
##otypic O
he O
##tero O
##gene O
##ity O
. O

the O
late O
infant O
##ile O
patient O
inherited O
from O
his O
mother O
the O
frequent O
0 O
- O
type O
mutation O
45 O
##9 O
+ O
1 O
##g O
[UNK] O
a O
, O
and O
from O
his O
father O
a O
novel O
, O
single O
base O
##pair O
micro O
##del O
##eti O
##on O
of O
g O
##uan O
##ine O
at O
n O
##uc O
##leo O
##tide O
7 O
in O
ex O
##on O
1 O
( O
7 O
##del O
##g O
) O
. O

the O
two O
clinical O
##ly O
un O
##af O
##fected O
siblings O
carried O
the O
maternal O
mutation O
45 O
##9 O
+ O
1 O
##g O
[UNK] O
a O
and O
, O
on O
their O
paternal O
all O
##ele O
, O
a O
novel O
c O
##yt O
##os O
##ine O
to O
thy O
##mi O
##dine O
transition O
at O
n O
##uc O
##leo O
##tide O
243 O
##5 O
in O
ex O
##on O
8 O
, O
resulting O
in O
substitution O
of O
al O
##ani O
##ne O
46 O
##4 O
by O
v O
##ali O
##ne O
( O
a O
##46 O
##4 O
##v O
) O
. O

the O
fathers O
g O
##eno O
##type O
thus O
was O
7 O
##del O
##g O
/ O
a O
##46 O
##4 O
##v O
. O

mutation O
a O
##46 O
##4 O
##v O
was O
not O
found O
in O
18 O
unrelated O
m B-Disease
##ld I-Disease
patients O
and O
50 O
controls O
. O

a O
##46 O
##4 O
##v O
, O
although O
clearly O
modify O
##ing O
a O
##rsa O
and O
g O
##s O
levels O
, O
apparently O
bears O
little O
significance O
for O
clinical O
manifest O
##ation O
of O
m B-Disease
##ld I-Disease
, O
mimic O
##king O
the O
frequent O
a O
##rsa O
pseudo O
##de O
##ficiency O
all O
##ele O
. O

our O
results O
demonstrate O
that O
in O
certain O
genetic O
conditions O
m B-Disease
##ld I-Disease
- O
like O
a O
##rsa O
and O
g O
##s O
values O
need O
not O
be O
parallel O
##ed O
by O
clinical O
disease O
, O
a O
finding O
with O
serious O
diagnostic O
and O
pro O
##gno O
##stic O
implications O
. O

more O
##over O
, O
further O
a O
##rsa O
all O
##ele O
##s O
functional O
##ly O
similar O
to O
a O
##46 O
##4 O
##v O
might O
exist O
which O
, O
together O
with O
0 O
- O
type O
mutations O
, O
may O
cause O
path O
##ological O
a O
##rsa O
and O
g O
##s O
levels O
, O
but O
not O
clinical O
outbreak O
of O
the O
disease O
. O
. O

human O
m O
##l O
##h O
##1 O
deficiency O
pre O
##dis O
##pose O
##s O
to O
hem B-Disease
##ato I-Disease
##logical I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncy I-Disease
and O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##mat I-Disease
##osis I-Disease
type I-Disease
1 I-Disease
. O

he O
##tero O
##zy O
##go O
##us O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
d O
##na O
mi O
##sma O
##tch O
repair O
genes O
lead O
to O
hereditary B-Disease
non I-Disease
##pol I-Disease
##y I-Disease
##po I-Disease
##sis I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

the O
disease O
su O
##s O
##ce O
##pt O
##ibility O
of O
individuals O
who O
constitutional O
##ly O
lack O
both O
wild O
- O
type O
all O
##ele O
##s O
is O
unknown O
. O

we O
have O
identified O
three O
offspring O
in O
a O
hereditary B-Disease
non I-Disease
##pol I-Disease
##y I-Disease
##po I-Disease
##sis I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
family O
who O
developed O
hem B-Disease
##ato I-Disease
##logical I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncy I-Disease
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##mat I-Disease
##osis I-Disease
type I-Disease
1 I-Disease
( O
n B-Disease
##f I-Disease
##1 I-Disease
) O
. O

d O
##na O
sequence O
analysis O
and O
all O
##ele O
- O
specific O
am O
##p O
##lification O
in O
two O
siblings O
revealed O
a O
ho O
##mo O
##zy O
##go O
##us O
m O
##l O
##h O
##1 O
mutation O
( O
c O
##6 O
##7 O
##6 O
##t O
- O
- O
[UNK] O
a O
##rg O
##22 O
##6 O
##stop O
) O
. O

thus O
, O
a O
ho O
##mo O
##zy O
##go O
##us O
g O
##er O
##m O
- O
line O
m O
##l O
##h O
##1 O
mutation O
and O
con O
##se O
##quent O
mi O
##sma O
##tch O
repair O
deficiency O
results O
in O
a O
m O
##uta O
##tor O
p O
##hen O
##otype O
characterized O
by O
le B-Disease
##uke I-Disease
##mia I-Disease
and O
/ O
or O
l B-Disease
##ymph I-Disease
##oma I-Disease
associated O
with O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##mat I-Disease
##osis I-Disease
type I-Disease
1 I-Disease
. O
. O

miss O
##ense O
mutations O
in O
the O
most O
ancient O
residues O
of O
the O
p O
##ax O
##6 O
paired O
domain O
under O
##lie O
a O
spectrum O
of O
human O
con B-Disease
##gen I-Disease
##ital I-Disease
eye I-Disease
ma I-Disease
##lf I-Disease
##orm I-Disease
##ations I-Disease
. O

mutations O
of O
the O
human O
p O
##ax O
##6 O
gene O
under O
##lie O
an B-Disease
##iri I-Disease
##dia I-Disease
( O
con B-Disease
##gen I-Disease
##ital I-Disease
absence I-Disease
of I-Disease
the I-Disease
i I-Disease
##ris I-Disease
) O
, O
a O
rare O
dominant O
ma B-Disease
##lf I-Disease
##orm I-Disease
##ation I-Disease
of I-Disease
the I-Disease
eye I-Disease
. O

the O
spectrum O
of O
p O
##ax O
##6 O
mutations O
in O
an B-Disease
##iri I-Disease
##dia I-Disease
patients O
is O
highly O
bias O
##ed O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
leading O
to O
premature O
t O
##run O
##cation O
of O
the O
protein O
( O
nonsense O
, O
s O
##p O
##licing O
, O
insertion O
##s O
and O
del O
##eti O
##ons O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
another O
( O
miss O
##ense O
) O
. O

the O
extraordinary O
conservation O
of O
the O
p O
##ax O
##6 O
protein O
at O
the O
amino O
acid O
level O
amongst O
ve O
##rte O
##bra O
##tes O
predict O
##s O
that O
path O
##ological O
miss O
##ense O
mutations O
should O
in O
fact O
be O
common O
even O
though O
they O
are O
hardly O
ever O
seen O
in O
an B-Disease
##iri I-Disease
##dia I-Disease
patients O
. O

this O
indicates O
that O
there O
is O
a O
heavy O
as O
##cer O
##tain O
##ment O
bias O
in O
the O
selection O
of O
patients O
for O
p O
##ax O
##6 O
mutation O
analysis O
and O
that O
the O
missing O
p O
##ax O
##6 O
miss O
##ense O
mutations O
frequently O
may O
under O
##lie O
p O
##hen O
##otype O
##s O
distinct O
from O
textbook O
an B-Disease
##iri I-Disease
##dia I-Disease
. O

here O
we O
present O
four O
novel O
p O
##ax O
##6 O
miss O
##ense O
mutations O
, O
two O
in O
association O
with O
at O
##y O
##pical O
p O
##hen O
##otype O
##s O
e B-Disease
##ct I-Disease
##op I-Disease
##ia I-Disease
pupil I-Disease
##la I-Disease
##e I-Disease
( O
displaced B-Disease
pupils I-Disease
) O
and O
con B-Disease
##gen I-Disease
##ital I-Disease
n I-Disease
##ys I-Disease
##tag I-Disease
##mus I-Disease
( O
searching B-Disease
gaze I-Disease
) O
, O
and O
two O
in O
association O
with O
more O
recognizable O
an B-Disease
##iri I-Disease
##dia I-Disease
p O
##hen O
##otype O
##s O
. O

striking O
##ly O
, O
all O
four O
mutations O
are O
located O
within O
the O
p O
##ax O
##6 O
paired O
domain O
and O
affect O
amino O
acids O
which O
are O
highly O
conserved O
in O
all O
known O
paired O
domain O
proteins O
. O

our O
results O
support O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
miss O
##ense O
mutations O
is O
caused O
by O
as O
##cer O
##tain O
##ment O
bias O
and O
suggest O
that O
a O
substantial O
burden O
of O
p B-Disease
##ax I-Disease
##6 I-Disease
- I-Disease
related I-Disease
disease I-Disease
remains O
to O
be O
uncovered O
. O
. O

the O
ch O
##rom O
##oso O
##mal O
order O
of O
genes O
controlling O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
complex O
, O
proper O
##din O
factor O
b O
, O
and O
deficiency B-Disease
of I-Disease
the I-Disease
second I-Disease
component I-Disease
of I-Disease
complement I-Disease
. O

the O
relationship O
of O
the O
genes O
coding O
for O
h O
##la O
to O
those O
coding O
for O
proper O
##din O
factor O
b O
all O
##otype O
##s O
and O
for O
deficiency B-Disease
of I-Disease
the I-Disease
second I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##2 O
) O
was O
studied O
in O
families O
of O
patients O
with O
connect O
##ive O
tissue O
disorders O
. O

patients O
were O
selected O
because O
they O
were O
he O
##tero O
##zy O
##go O
##us O
or O
ho O
##mo O
##zy O
##go O
##us O
for O
c B-Disease
##2 I-Disease
deficiency I-Disease
. O

12 O
families O
with O
15 O
mating O
##s O
inform O
##ative O
for O
c B-Disease
##2 I-Disease
deficiency I-Disease
were O
found O
. O

of O
57 O
inform O
##ative O
me O
##ios O
##es O
, O
two O
crossover O
##s O
were O
noted O
between O
the O
c B-Disease
##2 I-Disease
deficiency I-Disease
gene O
and O
the O
h O
##la O
- O
b O
gene O
, O
with O
a O
re O
##comb O
##ina O
##nt O
fraction O
of O
0 O
. O

03 O
##5 O
. O

a O
lo O
##d O
score O
of O
13 O
was O
calculated O
for O
link O
##age O
between O
c B-Disease
##2 I-Disease
deficiency I-Disease
and O
h O
##la O
- O
b O
at O
a O
maximum O
likelihood O
value O
of O
the O
re O
##comb O
##ina O
##nt O
fraction O
of O
0 O
. O

04 O
. O

18 O
families O
with O
21 O
inform O
##ative O
mating O
##s O
for O
both O
proper O
##din O
factor O
b O
all O
##otype O
and O
h O
##la O
- O
b O
were O
found O
. O

of O
72 O
inform O
##ative O
me O
##ios O
##es O
, O
three O
re O
##comb O
##ina O
##nts O
were O
found O
, O
giving O
a O
re O
##comb O
##ina O
##nt O
fraction O
of O
0 O
. O

04 O
##2 O
. O

a O
lo O
##d O
score O
of O
16 O
between O
h O
##la O
- O
b O
and O
factor O
b O
all O
##otype O
##s O
was O
calculated O
at O
a O
maximum O
likelihood O
value O
of O
the O
re O
##comb O
##ina O
##nt O
fraction O
of O
0 O
. O

04 O
. O

a O
crossover O
was O
shown O
to O
have O
occurred O
between O
genes O
for O
factor O
b O
and O
h O
##la O
- O
d O
, O
in O
which O
h O
##la O
- O
d O
se O
##g O
##re O
##gar O
##ed O
with O
h O
##la O
- O
a O
and O
b O
. O

these O
studies O
suggest O
that O
the O
genes O
for O
factor O
b O
and O
c B-Disease
##2 I-Disease
deficiency I-Disease
are O
located O
outside O
those O
for O
h O
##la O
, O
that O
the O
order O
of O
genes O
##e O
is O
h O
##la O
- O
a O
, O
- O
b O
, O
- O
d O
, O
factor O
b O
all O
##otype O
, O
c B-Disease
##2 I-Disease
deficiency I-Disease
, O
that O
the O
genes O
coding O
for O
c B-Disease
##2 I-Disease
deficiency I-Disease
and O
factor O
b O
all O
##otype O
##s O
are O
approximately O
3 O
- O
- O
5 O
cent O
##imo O
##rgan O
##s O
from O
the O
h O
##la O
- O
a O
and O
h O
##la O
- O
b O
lo O
##ci O
, O
and O
that O
the O
apparent O
lack O
of O
re O
##comb O
##ina O
##nts O
between O
the O
factor O
b O
gene O
and O
c B-Disease
##2 I-Disease
deficiency I-Disease
gene O
suggests O
that O
these O
two O
genes O
lie O
in O
close O
proximity O
to O
one O
another O
. O

distribution O
of O
em O
##eri O
##n O
and O
la O
##mins O
in O
the O
heart O
and O
implications O
for O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

em O
##eri O
##n O
is O
a O
nuclear O
membrane O
protein O
which O
is O
missing O
or O
defect O
##ive O
in O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
ed B-Disease
##m I-Disease
##d I-Disease
) O
. O

it O
is O
one O
member O
of O
a O
family O
of O
la O
##mina O
- O
associated O
proteins O
which O
includes O
lap O
##1 O
, O
lap O
##2 O
and O
la O
##min O
b O
receptor O
( O
lb O
##r O
) O
. O

a O
panel O
of O
16 O
mon O
##oc O
##lon O
##al O
antibodies O
( O
ma O
##bs O
) O
has O
been O
mapped O
to O
six O
specific O
sites O
throughout O
the O
em O
##eri O
##n O
molecule O
using O
p O
##hage O
- O
displayed O
p O
##eptide O
libraries O
and O
has O
been O
used O
to O
local O
##ize O
em O
##eri O
##n O
in O
human O
and O
rabbit O
heart O
. O

several O
ma O
##bs O
against O
different O
em O
##eri O
##n O
e O
##pit O
##ope O
##s O
did O
not O
recognize O
inter O
##calated O
discs O
in O
the O
heart O
, O
though O
they O
recognized O
card O
##io O
##my O
##oc O
##yte O
nuclei O
strongly O
, O
both O
at O
the O
rim O
and O
in O
in O
##tra O
##nu O
##cle O
##ar O
spots O
or O
channels O
. O

a O
p O
##oly O
##c O
##lon O
##al O
rabbit O
anti O
##ser O
##um O
against O
em O
##eri O
##n O
did O
recognize O
both O
nuclear O
membrane O
and O
inter O
##calated O
discs O
but O
, O
after O
affinity O
pu O
##rification O
against O
a O
pure O
- O
em O
##eri O
##n O
band O
on O
a O
western O
b O
##lot O
, O
it O
stained O
only O
the O
nuclear O
membrane O
. O

these O
results O
would O
not O
be O
expected O
if O
im O
##mu O
##nos O
##taining O
at O
inter O
##calated O
discs O
were O
due O
to O
a O
product O
of O
the O
em O
##eri O
##n O
gene O
and O
, O
therefore O
, O
cast O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B-Disease
defects I-Disease
in O
ed B-Disease
##m I-Disease
##d I-Disease
are O
caused O
by O
absence O
of O
em O
##eri O
##n O
from O
inter O
##calated O
discs O
. O

although O
em O
##eri O
##n O
was O
abundant O
in O
the O
membrane O
##s O
of O
card O
##io O
##my O
##oc O
##yte O
nuclei O
, O
it O
was O
absent O
from O
many O
non O
- O
my O
##oc O
##yte O
cells O
in O
the O
heart O
. O

this O
distribution O
of O
em O
##eri O
##n O
was O
similar O
to O
that O
of O
la O
##min O
a O
, O
a O
candidate O
gene O
for O
an O
auto O
##so O
##mal O
form O
of O
ed B-Disease
##m I-Disease
##d I-Disease
. O

in O
contrast O
, O
la O
##min O
b O
##1 O
was O
absent O
from O
card O
##io O
##my O
##oc O
##yte O
nuclei O
, O
showing O
that O
la O
##min O
b O
##1 O
is O
not O
essential O
for O
local O
##ization O
of O
em O
##eri O
##n O
to O
the O
nuclear O
la O
##mina O
. O

la O
##min O
b O
##1 O
is O
also O
almost O
completely O
absent O
from O
skeletal O
muscle O
nuclei O
. O

in O
ed B-Disease
##m I-Disease
##d I-Disease
, O
the O
additional O
absence O
of O
la O
##min O
b O
##1 O
from O
heart O
and O
skeletal O
muscle O
nuclei O
which O
already O
lack O
em O
##eri O
##n O
may O
offer O
an O
alternative O
explanation O
of O
why O
these O
tissues O
are O
particularly O
affected O
. O
. O

genetic O
mapping O
of O
the O
copper B-Disease
toxic I-Disease
##osis I-Disease
lo O
##cus O
in O
bed O
##lington O
te O
##rrier O
##s O
to O
dog O
chromosome O
10 O
, O
in O
a O
region O
s O
##yn O
##ten O
##ic O
to O
human O
chromosome O
region O
2 O
##p O
##13 O
- O
p O
##16 O
. O

abnormal O
he B-Disease
##pa I-Disease
##tic I-Disease
copper I-Disease
accumulation I-Disease
is O
recognized O
as O
an O
inherited B-Disease
disorder I-Disease
in O
man O
, O
mouse O
, O
rat O
and O
dog O
. O

the O
major O
cause O
of O
he B-Disease
##pa I-Disease
##tic I-Disease
copper I-Disease
accumulation I-Disease
in O
man O
is O
a O
d O
##ys O
##function O
##al O
at O
##p O
##7 O
##b O
gene O
, O
causing O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
( O
w B-Disease
##d I-Disease
) O
. O

mutations O
in O
the O
at O
##p O
##7 O
##b O
genes O
have O
also O
been O
demonstrated O
in O
mouse O
and O
rat O
. O

the O
at O
##p O
##7 O
##b O
gene O
has O
been O
excluded O
in O
the O
much O
rare O
##r O
human O
copper B-Disease
over I-Disease
##load I-Disease
disease O
non B-Disease
- I-Disease
in I-Disease
##dian I-Disease
childhood I-Disease
c I-Disease
##ir I-Disease
##r I-Disease
##hos I-Disease
##is I-Disease
, O
indicating O
genetic O
he O
##tero O
##gene O
##ity O
. O

by O
investigating O
the O
common O
auto O
##so O
##mal O
re O
##cess O
##ive O
copper B-Disease
toxic I-Disease
##osis I-Disease
( O
c B-Disease
##t I-Disease
) O
in O
bed O
##lington O
te O
##rrier O
##s O
, O
we O
have O
identified O
a O
new O
lo O
##cus O
involved O
in O
progressive O
liver B-Disease
disease I-Disease
. O

we O
examined O
whether O
the O
w B-Disease
##d I-Disease
gene O
at O
##p O
##7 O
##b O
was O
also O
ca O
##usa O
##tive O
for O
c B-Disease
##t I-Disease
by O
investigating O
the O
ch O
##rom O
##oso O
##mal O
co O
- O
local O
##ization O
of O
at O
##p O
##7 O
##b O
and O
c O
##0 O
##41 O
##0 O
##7 O
, O
using O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
( O
fish O
) O
. O

c O
##0 O
##41 O
##0 O
##7 O
is O
an O
anonymous O
micro O
##sat O
##elli O
##te O
marker O
closely O
linked O
to O
c B-Disease
##t I-Disease
. O

however O
, O
b O
##ac O
clone O
##s O
containing O
at O
##p O
##7 O
##b O
and O
c O
##0 O
##41 O
##0 O
##7 O
mapped O
to O
the O
can O
##ine O
chromosome O
regions O
c O
##fa O
##22 O
##q O
##11 O
and O
c O
##fa O
##10 O
##q O
##26 O
, O
respectively O
, O
demonstrating O
that O
w B-Disease
##d I-Disease
cannot O
be O
ho O
##mo O
##log O
##ous O
to O
c B-Disease
##t I-Disease
. O

the O
copper O
transport O
genes O
c O
##tr O
##1 O
and O
c O
##tr O
##2 O
were O
also O
excluded O
as O
candidate O
genes O
for O
c B-Disease
##t I-Disease
since O
they O
both O
mapped O
to O
can O
##ine O
chromosome O
region O
c O
##fa O
##11 O
##q O
##22 O
. O

2 O
- O
22 O
. O

5 O
. O

a O
trans O
##cribed O
sequence O
identified O
from O
the O
c O
##0 O
##41 O
##0 O
##7 O
- O
containing O
b O
##ac O
was O
found O
to O
be O
ho O
##mo O
##log O
##ous O
to O
a O
gene O
expressed O
from O
human O
chromosome O
2 O
##p O
##13 O
- O
p O
##16 O
, O
a O
region O
devoid O
of O
any O
position O
##al O
candidate O
genes O
. O

molecular O
analysis O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
in O
205 O
families O
: O
extended O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
f B-Disease
##ap I-Disease
and O
evidence O
for O
the O
role O
of O
a B-Disease
##p I-Disease
##c I-Disease
amino O
acid O
changes O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
pre O
##dis O
##position O
. O

background O
/ O
aims O
the O
development O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
and O
a O
variable O
range O
of O
extra O
##co O
##lon O
##ic O
manifest O
##ations O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
mutations O
. O

in O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
was O
performed O
to O
determine O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
for O
nine O
extra O
##co O
##lon O
##ic O
manifest O
##ations O
and O
to O
investigate O
the O
incidence O
of O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
in O
non O
- O
f O
##ap O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

methods O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
was O
anal O
##ys O
##ed O
in O
190 O
unrelated O
f B-Disease
##ap I-Disease
and O
15 O
non O
- O
f O
##ap O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
patients O
using O
den O
##at O
##uring O
gradient O
gel O
electro O
##ph O
##ores O
##is O
, O
the O
protein O
t O
##run O
##cation O
test O
, O
and O
direct O
se O
##quencing O
. O

results O
chain O
terminating O
signals O
were O
only O
identified O
in O
patients O
belonging O
to O
the O
f B-Disease
##ap I-Disease
group O
( O
105 O
patients O
) O
. O

amino O
acid O
changes O
were O
identified O
in O
four O
patients O
, O
three O
of O
whom O
belonged O
to O
the O
non O
- O
f O
##ap O
group O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
patients O
. O

g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
identified O
significant O
differences O
in O
the O
nature O
of O
certain O
extra O
##co O
##lon O
##ic O
manifest O
##ations O
in O
f B-Disease
##ap I-Disease
patients O
belonging O
to O
three O
mutation O
subgroup O
##s O
. O

conclusions O
extended O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
made O
in O
this O
study O
may O
have O
the O
potential O
to O
determine O
the O
most O
appropriate O
surveillance O
and O
prop O
##hyl O
##actic O
treatment O
regime O
##ns O
for O
those O
patients O
with O
mutations O
associated O
with O
life O
threatening O
conditions O
. O

this O
study O
also O
provided O
evidence O
for O
the O
path O
##ological O
nature O
of O
amino O
acid O
changes O
in O
a O
##p O
##c O
associated O
with O
both O
f B-Disease
##ap I-Disease
and O
non O
- O
f O
##ap O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
patients O
. O
. O

inherited B-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
and O
cancer B-Disease
risk O
of O
the O
a O
##p O
##c O
i O
##13 O
##0 O
##7 O
##k O
p O
##oly O
##mor O
##phism O
. O

g O
##er O
##m O
- O
line O
and O
so O
##matic O
t O
##run O
##cating O
mutations O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
are O
thought O
to O
initiate O
color B-Disease
##ec I-Disease
##tal I-Disease
tumor I-Disease
formation O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
syndrome I-Disease
and O
s O
##poradic O
color O
##ec O
##tal O
car O
##cin O
##ogen O
##esis O
, O
respectively O
. O

recently O
, O
an O
is O
##ole O
##uc O
##ine O
- O
- O
[UNK] O
l O
##ys O
##ine O
p O
##oly O
##mor O
##phism O
at O
co O
##don O
130 O
##7 O
( O
i O
##13 O
##0 O
##7 O
##k O
) O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
ash O
##ken O
##azi O
j O
##ew O
##ish O
population O
. O

to O
assess O
the O
risk O
of O
this O
common O
a B-Disease
##p I-Disease
##c I-Disease
all O
##eli O
##c O
variant O
in O
color O
##ec O
##tal O
car O
##cin O
##ogen O
##esis O
, O
we O
have O
analyzed O
a O
large O
co O
##hor O
##t O
of O
un O
##sel O
##ec O
##ted O
ash O
##ken O
##azi O
j O
##ew O
##ish O
subjects O
with O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
and O
. O
or O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
, I-Disease
for O
the O
a O
##p O
##c O
i O
##13 O
##0 O
##7 O
##k O
p O
##oly O
##mor O
##phism O
. O

the O
a O
##p O
##c O
i O
##13 O
##0 O
##7 O
##k O
all O
##ele O
was O
identified O
in O
48 O
( O
10 O
. O
1 O
% O
) O
of O
47 O
##6 O
patients O
. O

compared O
with O
the O
frequency O
in O
two O
separate O
population O
control O
groups O
, O
the O
a O
##p O
##c O
i O
##13 O
##0 O
##7 O
##k O
all O
##ele O
is O
associated O
with O
an O
estimated O
relative O
risk O
of O
1 O
. O

5 O
- O
1 O
. O

7 O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
neo I-Disease
##p I-Disease
##lasia I-Disease
( O
both O
p O
= O
. O
01 O
) O
. O

further O
##more O
, O
compared O
with O
non O
##car O
##rier O
##s O
, O
a O
##p O
##c O
i O
##13 O
##0 O
##7 O
##k O
carriers O
had O
increased O
numbers O
of O
ad B-Disease
##eno I-Disease
##mas I-Disease
and O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
per O
patient O
( O
p O
= O
. O
03 O
) O
, O
as O
well O
as O
a O
younger O
age O
at O
diagnosis O
. O

we O
conclude O
that O
the O
a O
##p O
##c O
i O
##13 O
##0 O
##7 O
##k O
variant O
leads O
to O
increased O
ad B-Disease
##eno I-Disease
##ma I-Disease
formation O
and O
directly O
contributes O
to O
3 O
% O
- O
4 O
% O
of O
all O
ash O
##ken O
##azi O
j O
##ew O
##ish O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

the O
estimated O
relative O
risk O
for O
carriers O
may O
justify O
specific O
clinical O
screening O
for O
the O
360 O
, O
000 O
am O
##eric O
##ans O
expected O
to O
harbor O
this O
all O
##ele O
, O
and O
genetic O
testing O
in O
the O
setting O
of O
long O
- O
term O
- O
outcome O
studies O
may O
impact O
significantly O
on O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
prevention O
in O
this O
population O
. O

local O
##ization O
of O
human O
br O
##ca O
##1 O
and O
its O
loss O
in O
high O
- O
grade O
, O
non B-Disease
- I-Disease
inherited I-Disease
breast I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

although O
the O
link O
between O
the O
br O
##ca O
##1 O
t B-Disease
##umour I-Disease
- O
suppress O
##or O
gene O
and O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
br O
##ca O
##1 O
in O
non B-Disease
- I-Disease
f I-Disease
##ami I-Disease
##lial I-Disease
cancer I-Disease
##s I-Disease
is O
unclear O
. O

br O
##ca O
##1 O
mutations O
are O
rare O
in O
s B-Disease
##poradic I-Disease
cancer I-Disease
##s I-Disease
, O
but O
loss O
of O
br O
##ca O
##1 O
resulting O
from O
reduced O
expression O
or O
incorrect O
sub O
##cellular O
local O
##ization O
is O
post O
##ulated O
to O
be O
important O
in O
non B-Disease
- I-Disease
f I-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

e O
##pi O
##gene O
##tic O
loss O
, O
however O
, O
has O
not O
received O
general O
acceptance O
due O
to O
controversy O
regarding O
the O
sub O
##cellular O
local O
##ization O
of O
br O
##ca O
##1 O
proteins O
, O
reports O
of O
which O
have O
ranged O
from O
exclusively O
nuclear O
, O
to O
conditional O
##ly O
nuclear O
, O
to O
the O
er O
/ O
go O
##l O
##gi O
, O
to O
c O
##yt O
##op O
##las O
##mic O
in O
##va O
##gin O
##ations O
into O
the O
nucleus O
. O

in O
an O
attempt O
to O
resolve O
this O
issue O
, O
we O
have O
comprehensive O
##ly O
characterized O
19 O
anti O
- O
br O
##ca O
##1 O
antibodies O
. O

these O
re O
##age O
##nts O
detect O
a O
220 O
- O
k O
##d O
protein O
localized O
in O
discrete O
nuclear O
f O
##oc O
##i O
in O
all O
e O
##pit O
##hel O
##ial O
cell O
lines O
, O
including O
those O
derived O
from O
breast B-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncies I-Disease
. O

im O
##mu O
##no O
##his O
##to O
##chemical O
stain O
##ing O
of O
human O
breast O
specimens O
also O
revealed O
br O
##ca O
##1 O
nuclear O
f O
##oc O
##i O
in O
ben O
##ign O
breast O
, O
invasive B-Disease
lo I-Disease
##bula I-Disease
##r I-Disease
cancer I-Disease
##s I-Disease
and O
low B-Disease
- I-Disease
grade I-Disease
duct I-Disease
##al I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

con O
##verse O
##ly O
, O
br O
##ca O
##1 O
expression O
was O
reduced O
or O
und O
##ete O
##ct O
##able O
in O
the O
majority O
of O
high O
- O
grade O
, O
duct B-Disease
##al I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
, O
suggesting O
that O
absence O
of O
br O
##ca O
##1 O
may O
contribute O
to O
the O
path O
##ogen O
##esis O
of O
a O
significant O
percentage O
of O
s B-Disease
##poradic I-Disease
breast I-Disease
cancer I-Disease
##s I-Disease
. O
. O

